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ABSTRACT 
 
 The purpose of this study was to retrospectively determine the influence of genetic 
profiling on diet type and exercise for weight loss, body composition, and biomarkers of 
metabolic health in previously sedentary women. SNPs in obesity candidate genes ADRB2-
79, ADRB2-46, PPARγ2, FABP2, and ADRB3 were evaluated to predict health outcomes. 
Eighty-six women (age 37.5±13.4 yrs; ht 163.7±6.9 cm; wt 82.0±16.8 kg; 40.8±5.1% body 
fat) were randomized to the control (CTRL), American Heart Association (AHA), Curves 
Complete-I (CC-I), or Curves Complete-II (CC-II) program for 24-wks (N=86). Participants 
in the diet groups followed a 1,400 kcal/d diet for 1 wk; 1,500 kcal/d diet for 23 wks (AHA 
55%:15% CHO:PRO, CC-I 25%:45% CHO:PRO, CC-II 15%:45% CHO:PRO), while 
participating in supervised resistance circuit (3x/wk) and Zumba exercise (1x/wk). 
Remaining subjects in the CTRL had no diet or exercise intervention. Body composition, 
anthropometrics, resting energy expenditure (REE), physical activity, and psychosocial 
assessments were measured at 0, 4, 8, 12, 16, 20 and 24 weeks. VO2max capacity, upper and 
lower body isotonic strength and endurance, and lipid biomarkers were assessed at 0, 12, and 
24 weeks. Data were analyzed using multivariate analysis of variance for repeated measures. 
MANOVA of body composition data revealed time x diet interaction (Wilks’ Lambda 
p=0.05) with no difference observed among diet groups (p=0.86), as all diet groups 
significantly improved these variables and CTRL had no deviation from baseline after 24 
wks. MANOVA of body composition (body weight, fat mass, lean mass, fat-free mass, and 
body fat %) revealed an overall time effect (Wilks’ Lambda p<0.001), but no time x match 
interaction (p=0.99) when analyzed as a genetically True (T) or False (F) match to diet. Both 
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T and F participants matched to diet revealed similar weight loss (F -4.25±0.93; T -4.63±0.85 
kg, p=0.61). Results indicate that women following a controlled diet and exercise program 
experience similarly favorable changes in body composition, cardiovascular fitness, and 
biomarkers of health. However, diets designed for weight loss based on SNP profiles elicits 
further research, as no time x genetic match interactions in body weight or composition were 
observed in T and F matches to diets. 
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CHAPTER I 
INTRODUCTION AND RATIONALE 
 
Background 
 The prevalence of obesity among adults in the United States in 2011-2012 was an 
estimated 34.9%, with no significant statistical change since 2003-2004 [1]. Despite the 
efforts of healthcare professionals, this epidemic is ongoing, as the causative factors of 
obesity are continuously shown to be as metabolically diverse and interactive. The most 
obvious external and environmental contributor to weight gain is excessive caloric intake 
concurrent with limited physical activity (PA), resulting in a state of positive energy balance. 
Chronic exposure to this homeostatic disruption eventually alters nutrient sensitivity and 
decreases phenotype flexibility. Physiological and molecular mechanisms that regulate 
metabolic activity become impaired, and the consequential cascade alters the normative 
responsiveness to glucose, triglyceride, and protein consumption [2]. Well established, 
identifiable risk factors that indicate metabolic functional dysregulation and subsequent 
morbidity include dyslipidemia, elevated low density lipoprotein (LDL), hypertension, and 
insulin resistance [2, 3]. Not surprisingly, this decline in cellular regulation extends to a 
decline in mechanical function, and further incites weight gain.  
While much attention has been given to dietary strategies for optimizing weight loss 
results, these efforts have not been consistently successful as long-term solutions [4-7, 9, 10]. 
An array of well-designed clinical trials have been exhaustively examined - ranging from 
very low energy diets (VLED <800 kcal/day) [11-14], ketogenic diets [15-18, 24], low fat 
[18-24], and very high protein diets (>2g/kg) [25-27]. Research has shown that caloric 
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restrictive interventions elicit weight loss and improve body composition acutely, although 
most follow up measures after one year or more indicate weight regain with only a 
diminutive decrease from the initial baseline. The addition of physical activity (PA) tends to 
improve long term weight loss maintenance in several meta-analyses [4-7], yet sustained PA 
with an emphasis on an exercise training (ET) regimen may be necessary to maintain health 
outcomes, regardless of initial weight loss [8]. Even still, weight maintenance remains a 
challenge despite the method or intensity of the initial treatment. Recent data from the 
National Institute of Health (NIH) demonstrated that contestants participating in a popular 
weight loss television show experienced an initial significant decrease in resting energy 
expenditure (REE) and dramatic slowing of metabolism which may have biologically in part, 
contributed to most contestant’s weight regain 6-years post-intervention. Weight loss at the 
end of the competition was (mean±SD) 58.3±24.9 kg (p< 0.001), and REE decreased by 
610±483 kcal/day (p= 0.004). After 6 years, 41.0±31.3 kg of the lost weight was regained 
(p< 0.001), while REE was 704±427 kcal/day below baseline (p< 0.001) and metabolic 
adaptation was -499±207 kcal/day (p< 0.001) [28]. Additional clinical trial results reveal as 
few as ~10% maintain significant continuation of weight loss from baseline after 3 to 5 years 
[9,10]. Considering the relatively low success rate of these investigations and the high 
variability of individual responsiveness, a body of growing research is directing attention to 
genetic factors and their potential interaction with hypocaloric intake, specific 
macronutrients, and/or exercise activity.  
For example, Bouchard et al. investigated the variability between pairs of identical 
twins, as well as the correlation within the pairs in response to a controlled exercise 
3 
intervention [29]. Seven pairs of adult, sedentary males completed the 93-day trial, in which 
subjects expended ~4.2MJ (1,000 kcal) during exercise 2x/day on a cycle ergometer every 9 
out of 10 days. Although all participants experienced significant reductions in body 
composition measurements and biochemical markers of lipid oxidation (body weight, body 
mass index ([BMI], fat mass [FM], visceral adipose tissue [VAT]), fasting triglycerides 
[TAG], and cholesterol [CHL]), significant variability existed between groups (i.e.: set of 
twins) denoted by the F-Ratio on each of these measurements (p≤0.05). Intraclass 
coefficients (ICC) were also significant within group response on each parameter (p≤0.05). 
All subjects underwent the same relative exercise and dietary composition protocol for three 
months in a clinically controlled environment. These results attribute to the contention that 
individuals may oxidize preferentially more lipids relative to carbohydrates, and that the high 
or low lipid oxidization phenotypes are influenced by, as of yet, undefined genes. 
Hainer et al. [30] later conducted an experiment with a similar examination of 
metabolic response in twin pairs; however, her aim was to investigate metabolic response to 
diet induced weight loss versus exercise induced. 14 pairs of obese female identical twins 
(age = 39±1.7 years) underwent a 40-day inpatient protocol of a very low caloric deficit 
(VLCD) of 1.6 MJ/day for 4 weeks. Body composition measurements were obtained via 
hydrodensitometry and metabolic rate via indirect calorimetry, verbatim to Bouchard’s [29] 
previous method of data acquisition on exercise response in twin pairs. Hainer obtained 
similar results in significant losses in body composition parameters (p≤0.001), but not resting 
metabolic rate (RMR). Additionally, all body composition ICC were significant within 
groups (p≤0.002), yet high variability existed between pairs. For example, body weight loss 
ranged from 5.9 kg and 12.4 kg (ICC=0.85; F=12.8, [p≤0.001]). Fat mass reduction range 
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was between 3.1 kg and 12.4 kg (ICC=0.88; F=17.0 [p≤0.001]). The high correlation 
between twin pair members (r=0.778, p<0.001) in response to therapeutic weight loss 
suggests a strong genetic contribution to metabolic efficiency denoted by the residual of the 
measured energy deficit regressed on the estimated energy deficit. 
In addition to the non-inherited environmental factors such as caloric 
overconsumption and lack of physical activity, the aforementioned studies conducted by 
Bouchard et al. and Hainer et al. reveal inherited DNA genotypes and epigenetic factors can 
determine a phenotypical adaptation to a particular stimulus. As such, when assessing 
obesity-related etiology, consideration has to be given to the variations of metabolic 
candidate or “susceptibility” genes as plausible mediators involving lipid oxidation, glucose 
metabolism, thermogenic effects of food, and oxidative status [31]. To date, over 547 
candidate genes have been linked to obesity-related phenotypes [32].  
Nutrigenetics 
This relatively new approach targeting gene-diet interaction is known as 
nutrigenetics. Specifically, nutrigenetics investigates the modifying effects of qualitative 
(single nucleotide polymorphisms [SNPs], small deletions, duplications, or insertions) or 
quantitative (large duplications or deletions) gene variants in response to a dietary protocol. 
Qualitative variants can alter the regulatory region of a gene (i.e., the promoter region) or 
coding/noncoding sequences; whereas quantitative changes directly affect the level of 
expression [33]. SNPs are the most common sequence variations in the human genome, with 
over 10 million identified to date from genome wide association studies (GWAS) [34]. SNPs 
are base pair substitutions that alter the allele pattern as homozygous or heterozygous at 
specific chromosome loci. When a nucleotide of a gene is modified (e.g. adenine to thymine 
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[AA to AT], guanine to cytosine [GG to GC] or any variation thereof) at a coding or 
promoter region, an amino acid substitution takes place altering the protein’s binding affinity 
and possible functionality. Depending on the number SNPs of in the gene, and whether any 
of them have known functional effects, analyses can be conducted using individual SNPs or 
combinations of SNPs, such as haplotypes [35]. These polymorphisms may contribute to 
individual nutrient sensitivity; thereby presenting a valid and novel approach to personalized 
nutrition for weight loss, maintenance, and optimal health. 
The implication of metabolic effects of SNPs arose from studies examining the 
effects of components found in coffee on cardiovascular disease (CVD), with 
contraindicative results on plausible risk factors [36-41]. Weggemans et al. [42] was the first 
to report that a polymorphism in the apolipoprotein E (APOE) gene resulted in elevated LDL 
cholesterol in response to cafestol, a dipertene molecule present in primarily unfiltered 
coffee. In a follow up study, individuals with the ApoA1 83 CC genotype had greater 
elevations in LDL cholesterol in response to cafestol compared to those with the ApoA1 83 
CT genotype [43]. The identification of SNPs in candidate genes to examine the association 
between coffee and coronary heart disease (CHD) has been beneficial in the association of 
CHD and causal risk factor components in coffee. This was further demonstrated by Cornelis 
et al. [44], who was the first to incorporate a genetic modifier of caffeine metabolism in the 
analysis of coffee and risk of myocardial infarction. Cytochrome P450 (CYP)1A2 accounts 
for over 95% of caffeine clearance from the plasma. With typical amounts of caffeine 
consumption from dietary sources, the large variability in the enzyme activity of cytochrome 
P450 (CYP)1A2– mediated metabolism has been targeted for the inter-individual variability 
in caffeine metabolism [45-47]. The -163C>A polymorphism in the CYP1A2 gene has been 
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associated with reduced caffeine metabolism as a result of decreased enzyme inducibility 
[44, 48]. These findings suggest an increased risk of myocardial infarction associated with 
coffee consumption, but only among individuals who were carriers of the -163C allele, 
corresponding to the genotype associated with a slower rate of caffeine metabolism. 
With the novel identification of SNPs in candidate genes now known to be associated 
with metabolism of dietary components and CHD, scientists have been optimistic in 
identifying additional SNPs responsible for phenotypical differences in obesity, body 
composition, and health risk factor components. Indeed, a plethora of cohort investigations 
such as the ongoing Quebec Family Study conducted between 1979 – 2002 have identified 
significant familial aggregation and several genetic influences associated with BMI, 
adiposity, leptin, fat free mass (FFM), subcutaneous, abdominal and visceral fat distributions, 
physical activity levels, metabolic rates and additional behavioral characteristics [49-54]. 
These large scale associative cohort studies have led to the development of investigating 
candidate genes within the scope of a dietary and/or exercise intervention. Though 
intervention trials are relatively scarce in the developmental stages, nutrigenetics has already 
become a sought out implication as a marketable solution for weight loss based on metabolic 
genotypes. However, the findings within the literature of controlled trials examining the 
influence of metabolic candidate gene SNPs have yet to be elucidated.  
Although a standardized weight loss intervention is immediately effective for most 
individuals, high variability still exists in regards to response and maintenance of controlled 
behavioral change. In addition to behavioral modifications, it is probable that SNPs in 
candidate metabolic genes modulate intracellular processes at selected sequence coding 
regions. Previous research [55, 56] has determined that allele variants in adrenergic receptors 
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(ADRB2-79, ADRB2-46, ADRB3), peroxisome proliferator activated receptor (PPARγ2), 
and fatty acid binding protein (FABP2), may influence responsiveness to dietary 
macronutrient distribution. However, these findings have yet to be followed up with a 
concurrent exercise protocol. Examining the efficacy of exercise with dietary intervention 
based on metabolic genotype will help develop predictable models for optimal weight loss 
strategies.  
Statement of the Problem 
Does a metabolic genetic profile influence results in individuals participating in a 
fitness and weight loss program when assigned to a specified diet? 
Purpose 
The purpose of this study was to: 
1. Retrospectively determine the influence of genetic profiling by diet type and exercise
for weight loss, body composition, and biomarkers of metabolic health
2. Assess whether a high CHO (55% kcal) or high PRO (45% kcal) macronutrient
distribution may have more favorable results for weight loss, body composition,
fitness measurements, and biomarkers of metabolic health in previously sedentary
women during a six-month weight loss trial
General Study Overview 
This study was a 24-week weight loss intervention trial in women aged 18-60 years. 
To ensure homogeneity among groups, participants were randomized based on age, BMI, and 
baseline body fat percentage, and assigned to one of four groups: CC-I (30% CHO kcal, 45% 
PRO kcal, 25% FAT kcal), CC-II (20% CHO, 45% PRO, 35% FAT), AHA (55% CHO kcal, 
15% PRO, 30% FAT), or control (CTRL). Except the CTRL group, all participants in a 
treatment group (CC-I, CC-II, AHA) adhered to a diet consisting of 1500 total kcal/day, and 
exercise was performed on a hydraulic resistance circuit for 30 min/day, 4x/week. 
Additionally, participants in the treatment groups were instructed to walk 10,000 steps on 
non-resistance exercise days. Buccal cheek swabs were obtained at baseline to determine 
individual SNPs in the candidate genes FABP2 (rs1799883), PPARγ2 (rs1801282), ADRB3 
(rs4994), ADRB2, (rs1042713) and (rs1042714). Body composition (fat mass [FM], Fat-free 
mass [FFM], percent body fat) by DEXA scan, anthropometric measurements (body weight, 
waist circumference, hip circumference), resting energy expenditure (REE) via indirect 
calorimetry, complete blood counts, dietary intake and weekly physical activity, and 
psychosocial quality of life were assessed at 0, 4, 8, 12, 16, 20, and 24 weeks. Maximal 
cardiopulmonary exercise capacity (VO2max) and upper and lower body single repetition 
max isotonic strength (1 RM), fasting glucose, lipid panels, insulin concentrations, were 
assessed at 0, 12, and 24 weeks. 
Hypotheses 
H1: Significant differences in body composition, measures of fitness, and 
biochemical markers of health will be observed in participants assigned to the treatment 
groups (AHA, CC-I, and CC-II) in comparison to the CTRL group.
H2: Participants matched to a True (T) diet that favors their metabolic genetic profile 
will experience significantly greater weight loss and improvements in body composition 
than the False (F) unmatched participants. 
H3: Participants matched to a True (T) diet that favors their metabolic genetic profile 
will experience significant improvement in biochemical markers of health than the False (F) 
unmatched participants. 
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Limitations 
The study was conducted within the following parameters: 
1. 86 sedentary overweight, female participants (BMI > 25) between the ages of 18-50
years were recruited to participate in the study.
2. Participants were recruited with flyers posted on campus, electronic communication
via the Texas A&M University general information system, and advertisements in the
local newspaper.
3. Participants were recruited from the Texas A&M University and the Bryan/College
Station community from those who respond to advertisements for the study. Thus, the
selection process was not truly random. This may have affected the conclusions that
can be applied to the general population.
4. Familiarization and testing sessions were conducted in the Exercise and Sport
Nutrition Laboratory (ESNL) at Texas A&M University.
5. Participants were matched for age and BMI and randomly assigned to one of three
treatment groups or a control group.
6. Participants had not consumed any nutritional supplements that may affect muscle
mass or metabolism for at least three months prior to the start of the study.
7. Participants had not participated in an aerobic and/or anaerobic training program for
three months prior to the start of the study.
8. Participants had no known disease or health contraindication to exercise, or otherwise
obtained physician clearance prior to the start of the study.
9. Participants were not pregnant or lactating prior to and throughout the duration of the
study.
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10. Participants in the CC-I, CC-II, and AHA groups were required to adhere to the
fitness program consisting of 3 regular circuit workouts and one Zumba workout each
week throughout the trial.
11. Participants in the CC-I and CC-II groups were required to participate in one weekly
nutritional coaching session throughout the investigation.
12. Participants in the CTRL group were requested not to make lifestyle modifications
throughout the investigation.
13. Participants in the treatment groups were required to follow the CC-I, CC-II, or AHA
diet within a free-living environment.
14. Treatment participants were assigned absolute caloric intakes without consideration
of relative body mass and composition.
15. There were innate limitations of the laboratory equipment that were used for data
collection and analysis.
16. There were innate limitations in the sensitivity of the technologies and protocols
utilized to identify quantifiable changes in the criterion variables.
17. Participant daily schedules and inherent circadian rhythms that exist for all humans
due to slightly different testing times, stresses, etc., may have affected results.
Assumptions 
1. Participants accurately answered the entrance criteria screening questions and the
health and activity history forms.
2. Participants followed the CC-I, CC-II, or the AHA diet protocol as specified
according to dietary recall records.
3. Participants were direct in completing questionnaires.
11 
4. Participants were direct in completing food recalls and activity logs.
5. Participants in the CC-I and CC-II groups adhered to the nutritional coaching
sessions.
6. Participants in the CC-I, CC-II, and AHA groups followed intensity guidelines for all
workouts.
7. Participants maximally exerted themselves to voluntary exhaustion during strength
and maximal cardiopulmonary testing.
8. Participants adhered to verbal and written instructions and refrained from exercise for
48 hours prior to testing.
9. Participants fasted for at least 10 hours prior to lab collection.
10. Participants reported any adverse events to the study coordinator.
11. All laboratory equipment was calibrated and functioning properly for all testing
sessions.
12. The population from which the sample was drawn from was normally distributed.
13. The inter-individual variance between the groups were approximately equal.
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CHAPTER II 
REVIEW OF THE LITERATURE 
Strategies for Weight Loss 
Non-pharmaceutical techniques have long been evaluated to measure the efficacy of 
weight loss response to a particular stimuli, or response to a combination of interventional 
approaches. To evaluate the efficacy of diet induced protocols, extensive research has been 
conducted examining the acute [57-59] and long-term responses to the macronutrient 
distribution of fats, carbohydrates (CHO) and dietary protein intake [60-66]. To evaluate 
exercise induced physiological adaptations, intervention methods have been implemented to 
measure markers of metabolism (i.e., REE, lipid profile, insulin), fitness and cardiovascular 
functioning (i.e., max strength, VO2max) and body composition (i.e., fat mass, fat-free mass, 
BMD) [67-71]. 
Macronutrient Composition 
The ongoing investigation for optimal macronutrient partitioning of fat, carbohydrate, 
and protein intake remains controversial within the extensive body of literature. Determinant 
responses to energy intake may include mechanistic factors such as levels of insulin 
resistance, thermogenesis [72], and rates of fat oxidation, which are just a few examples of 
how substrate utilization may vary extensively among individuals. For example, Volek et al. 
[65] concluded that a carbohydrate restricted ketogenic diet was superior to a low fat diet in
terms of weight loss and fat mass reduction in overweight men (n=15) and women (n=13). 
Alternatively, Nordmann MD et al. [73] conducted a meta-analysis of 447 weight loss 
subjects from 6 studies and found that although carbohydrate restricted diets are as effective 
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as low fat diets in terms of weight loss, potential favorable changes in triglyceride and HDL 
cholesterol values from a low-fat diet should be considered against potential unfavorable 
changes in LDL cholesterol values from a carbohydrate restricted diet.  
High protein percentage diets have also gained notable interest as a strategy for 
maintenance of fat free mass, while concurrently reducing body weight and fat mass [74-76]. 
Halton et al. [72] conducted a systematic review of randomized studies that intervened 
weight loss with a high protein diet strategy. Indeed, satiety and thermogenesis increased and 
overall energy intake decreased as a result when compared to a lower protein content. 
However, Halton additionally notes that some evidence suggests that diets higher in protein 
result in an increased weight loss and fat mass reduction when compared to diets lower in 
protein, but findings have been inconsistent.  
Dansinger et al. randomly assigned 160 participants to either Atkins (carbohydrate 
restriction, n=40), Zone (macronutrient balance, n=40), Weight Watchers (calorie restriction, 
n=40), or Ornish (fat restriction, n=40) diet groups for 18 months. Participants self-reported 
diet adherence after 2 months [77]. Subjects had known hypertension, dyslipidemia, or 
fasting hyperglycemia and were considered overweight or obese (mean BMI=35). Higher 
compliance was associated with greater weight reduction and lowering cardiac risk factors 
among all diet groups (r = 0.60; p<0.001). Weight loss was not correlated with diet type 
(r = 0.07; p=0.40). For each diet, decreasing levels of HDL cholesterol, C-reactive protein, 
and insulin were significantly associated with weight loss (mean r=0.36, 0.37, and 0.39, 
respectively) with no significant difference between diet groups (p=0.48, p=0.57, p=0.31, 
respectively).  
Despite the conflicting results from these data, we must consider each nutrient does 
contribute a vital role in metabolic efficiency. Additionally, limitations such as participant 
compliance [77], study design, and external behavioral influences (i.e.: physical activity) 
must be regarded when interpreting results.  
Diet and Exercise Intervention 
The contribution of exercise is increasingly revealing its potential as a vital 
component of not only weight loss, but metabolic markers of health in the reduction of 
disease risks such as Type 2 Diabetes and cardiovascular disease. Research from our 
laboratory has extensively exhibited that exercise is a necessary augment to dietary 
intervention for weight loss [64, 78-86]. Although the debate regarding the optimal ratio of 
CHO, fat, and PRO in the diet is ongoing, data from our laboratory suggest that low to 
moderate kcal/day diets partitioned for CHO and PRO preference is equally effective when 
combined with a structured exercise program for reducing the prevalence of metabolic 
syndrome (MetS) in overweight and/or obese women (N=661) [79]. Lockard et al. 
retrospectively examined eight weight loss studies conducted in the Exercise and Sport 
Nutrition Lab over an 11-year period. All studies examined were 10-week weight loss 
intervention trials consisting of exercise sessions that included resistance and aerobic training 
for 30 minutes, 3-4x/week. In addition to exercise, 370 participants were assigned to a high 
protein (HP) (N=370) or high carbohydrate (HC) (N=291) diet for the duration of the 10-
week study. Results concluded that no significant differences were observed between a HC 
or HP intake in regards to serum glucose (-0.07 ± 0.03 vs -0.08 ± 0.04 mM, P=0.87), serum 
triglycerides (-0.16 ± 0.04 vs -0.09 ± 0.04 mM, P=0.20), HDL (-0.21 ± 0.03 vs -
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0.19 ± 0.04 mM, P=0.68). Additionally, reductions in MetS z-score were significantly 
different in both HP and HC groups (49% to 42%, 42% to 36%, P<0.01) respectively.  
However, previous reports from our laboratory contrast Lockard et al.’s recent 
observations. Kreider et al. concluded that obese women assigned to a HP diet experienced 
greater weight loss (-4.4 ± 3.6 kg vs -2.6 ± 2.9 kg), fat loss (-3.4 ± 2.7 kg vs -1.7 ± 2.0 kg), 
decreased serum glucose (-3% vs -2%), and decreases in serum leptin levels (–30.8% vs –
10.8%) when compared to a HC diet with equivalent kcal/day intake after the 10-week 
weight loss trial [78]. 221 subjects were prescribed low-fat (30%) hypocaloric diets that 
consisted of 1200 kcals/day for 1 week (phase 1) and 1600 kcals/day for 9 weeks (phase 2) 
with HP or HC. The exercise intervention was analogous to the method used in the studies 
analyzed by Lockard et al. Participants exercised 3x/week in a circuit-style resistance 
training interspersed with aerobic conditioning for 30 minutes.  
Despite the differences in these observations, exercise remained a key constant 
contribution to improvements in overall health and fitness among all stratified intervention 
groups within the scope of the 10 week studies. The trial methods as reported by Lockard et 
al. and Kreider et al. were consistent with diet and exercise protocols, and were conducted 
and monitored in the Exercise and Sport Nutrition Lab. It is plausible to suggest the results 
from Lockard et al. observations carry a higher statistical power due to the larger N-size and 
the number of studies included in the analysis. However, the opposing efficacy of a HP or 
HC diet in these two findings suggest alterative influences on weight loss, body composition, 
and metabolism. Although diet and exercise have shown to be effective among all weight 
loss intervention groups, differences observed between HP/HC results may be due to genetic 
influences yet to be elucidated. 
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Genetic Influence on Metabolism 
PPARγ2 
The transcriptional factor Peroxisome Proliferator-Activated Receptor gamma 2 
(PPARγ2 [rs1801282]) is a nuclear hormone receptor involved in the expression of adipocyte 
differentiation [87], the storage of lipids in adipocytes, insulin sensitivity [88], decreasing 
inflammation and initiating reverse cholesterol transport [89]. PPARγ2 is expressed primarily 
in adipose tissue, and has an established affinity for polyunsaturated fatty acids (PUFAs). 
Activated PPARγ2 induces LPL and fatty acid transporters (CD36) and enhances adipocyte 
differentiation [88], in addition to inhibiting cytokine and COX2 expression, perhaps by 
modulating NF-κB function. A genetic variant of PPARγ2 results in a substitution of alanine 
for proline at amino acid 12 (Pro12Ala). As a result of increased PPARγ2 transcription 
initiation, carriers of homozygous Pro12 have been considered to possess the ‘thrifty gene’ as 
a protective mechanism in the storage of lipids and induction of adipogenesis [88]. 
Interestingly, the allele variant Ala12 has also been correlated to a higher BMI in obese 
populations and appears to have no effect in non-obese individuals [90], although the Ala12 
variant has a lower frequency than Pro12 carriers.  
An early intervention study conducted by Lindi et al. investigated glucose tolerance 
and the incidence of type 2 diabetes (T2D) in 522 Finnish subjects [91]. Although the Ala12 
allele carriers had a higher risk for development of T2D (95% CI, 1.20, 3.72) at 3-years post 
intervention, the Ala12Ala genotypes lost more weight than those with Pro12Pro or 
Pro12Ala genotypes (p=0.043). Additionally, none of the subjects with the Ala12Ala 
genotype developed T2D in the intervention group versus control. These results thus suggest 
that Ala12 carriers may be predisposed to T2D development in obese populations; however, 
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improvements in dietary intake and physical activity may oppose the diabetic predisposed 
impact due to increased insulin sensitivity. 
Three independent case control studies conducted by Ghoussaini et al. in 2005 
involving 2126 cases and 1124 controls yielded similar results in the French Caucasian 
population [92], in which the Pro12Ala SNP (Pro/Pro) contributed to insulin resistance when 
the type 2 diabetic (T2D) cohort was stratified by obesity classification (p=0.03, OR=1.81). 
The Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) revealed an 
association with the Pro12 allele in glucose tolerant obese adults (p=0.01) and fasting insulin 
levels, and a trend (p=0.06) in normal adults. In normal glucose tolerant children however, 
there was no significant associations with the Pro12Ala polymorphism. 
 Similarly, Regieli et al. conducted a cohort investigating Pro12Ala variances in male 
CAD patients [93] with similar results of the 12Ala carriers for decreased risk of 
cardiovascular morbidity and mortality; therefore, suggesting a protective mechanistic role in 
inherited risk factors and determination of vascular health. As several studies have exhibited 
the protective measurable mechanisms of variant carriers of the PPARγ2, it has become a 
highly regarded target of investigation in the context of dietary and exercise intervention 
research. Table 2.1 highlights weight loss intervention studies on PPARγ2 SNPs. 
FABP2 
Fatty acid binding protein (FABP2) is abundantly distributed in small intestinal 
epithelial cells and has be identified as one of the genes that regulates intracellular 
metabolism [94]. FABP2 is responsible for absorption and intracellular transport of dietary 
long chain fatty acids (LCFA) [95]. A SNP occurs as a result of guanine at codon 54 of 
FABP2 gene is transformed into adenine, alanine encoding allele and-threonine coding allele 
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(Ala54Thr). Agren, J et al. showed that carriers of the Thr54 allele have a 2x higher affinity 
for LCFA than those homozygous for the Ala54 allele [96]. In vitro, allele substitutions that 
increase FABP2 affinity for LCFA (such as Ala54 à Thr54) is associated with an increase in 
triglyceride transport in human intestinal cells [97, 98]. Furthermore, the Thr54 substitution 
has been shown to be associated with insulin resistance, increased fatty acid binding, and 
increased fat oxidation. [99]. Baier et al. reported that among the Pima Indian population of 
non-diabetics, Ala54 homozygotes (40M/28F), heterozygotes (28M/29F) and Thr54 
homozygotes (7M/5F), those who were homozygous or heterozygous for the threonine-
encoding allele were found to have a higher mean fasting plasma insulin concentration 
(p<0.04), a lower mean insulin-stimulated glucose uptake rate (p<0.04), a higher mean 
insulin response to oral glucose and a mixed meal, and a higher mean fat oxidation rate 
(p<0.002) compared with Pimas who were homozygous for the alanine-encoding allele. 
Inconsistent with these findings however; Martinez-Lopez [100] showed within an 8 
week very low calorie diet (VLCD) intervention, Thr54 allele carriers experienced more 
favorable responses to a moderate fat diet among Hispanic (n=109) overweight participants. 
These contradicting results may indicate that genotype does not necessarily differentiate 
changes in weight loss, fitness, or biochemical markers of health when introduced to a 
dietary intervention such as caloric restriction. Table 2.2 highlights weight loss intervention 
studies on FABP2 SNPs. 
ADRB2 and ADRB3 
The ADRB2 and ADRB3 genes code for ß2 and ß3 adrenergic receptors, 
respectively. These receptors are part of the adrenergic system, which stimulates lipid 
mobilization in adipose tissue [101] through the thermogenic effect of catecholamines, 
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specifically epinephrine and norepinephrine [102]. Thus ADRB2 and ADRB3 play a role in 
lipolytic energy expenditure, responsible for activating lipid mobilization from triglyceride 
breakdown to free fatty acid (FFA) and glycerol molecules [88, 103].  
Adrenergic-receptor beta3 (ADRB3) is primarily located on the surface of visceral 
and brown adipose cells, and promotes lipolysis and thermogenesis by releasing 
norepinephrine from the sympathetic nerves when stimulated by the consumption of food or 
exposure to cold temperature [104, 105]. The Trp64Arg variant of ADRB3 has been 
associated with lower resting metabolic rate [106], weight gain [107], visceral obesity [108, 
109], and difficulty losing weight [110]. Adipose cells with ADRB3 of Trp64/Arg64 or 
Arg64/Arg64 showed 0.66 lowered ability to produce intracellular lipolytic glycerol [111] 
and cyclic AMP (cAMP) [112] compared with those with Trp64/Trp64. 
Although ADRB2 and ADRB3 are integral to lipid metabolism, and single nucleotide 
polymorphisms of these genes have been correlated with differences in BMI, body 
composition [113], and energy expenditure [88] in cross-sectional analyses [88,113]; others 
have displayed inconsistency, particularly when lifestyle behavioral modifications have been 
implemented into a research study design [114,115]. For example, Saliba et al. did not find 
any effect of the ADRB2 and ADRB3 polymorphisms in response to a weight loss 
intervention. Tables 2.3 and 2.4 highlight intervention studies investigating ADRB2 and 
ADRB3 variants at selected SNPs. 
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Table 2.1 PPARγ2 Literature Review of SNP (rs1801282 [Pro12Ala]) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
Rosado 
et al., 
Ann 
Nutr 
Metab, 
2010 
[89] 
PPARγ2 rs1801282 
(Pro12Pro 
Pro12Ala 
Ala12Ala) 
Interactions of the 
PPAR gamma 2 
polymorphism with 
fat intake affecting 
energy metabolism 
and nutritional 
outcomes in obese 
women 
37.66 34.59 
(20-49) 
60 F
(50 Pro12Pro + 
10 Pro12Ala/ 
Ala12Ala); 
Obese; Spanish 
~30% 
TEE; 
10weeks 
(70days) 
BW, REE and 
PPEE (indirect 
calorimetry 
and nitrogen 
excretion), 
FM, FFM (bio 
impedance), 
diet 
assessment, 
RMR, WHR, 
leptin, food 
records 
At baseline, MUFA intake 
inversely correlated with 
fat oxidation and BMI in 
Ala allele carriers, while a 
lower PUFA intake (%) in 
the long-term trial was 
associated with an increase 
in RQ only in Ala carriers 
but not in the Pro12Pro 
genotype.  
Fat oxidation and 
energy expenditure 
may be lower in 
Pro12Pro carriers 
compared to 
Pro12Ala/Ala12Ala 
genotypes, while in 
obese women with 
Ala polymorphisms, 
fat oxidation was 
negatively correlated 
with the MUFA and 
PUFA (%) intake.  
Regieli 
JJ, 
Diabetes 
Care, 
2009 
[93] 
PPARγ2 rs1801282 
(Pro/Ala) 
PPARγ Variant 
Influences 
Angiographic 
Outcome and 10-
Year 
Cardiovascular 
Risk in Male 
Symptomatic 
Coronary Artery 
Disease Patients 
25.9 ± 
0.11 
(C/C), 
26.3 ± 
0.26 
(C/G), 
25.8 ± 
0.60 
(G/G) 
55.7 ± 
0.34 
(C/C), 
55.7 ± 
0.74 
(C/G), 
57.0 ± 
1.7 
(G/G) 
679; (540 
Pro12Pro, 126 
Pro/Ala, 13 
Ala/Ala) 
10 yr 
cohort, 
N/A 
Ejection 
fraction, 
NYHA FC, 
Hypertension 
history, Prior 
MI, glucose, 
HDL, LDL, 
TG, CRP 
The 12Ala allele was 
associated with less 
extensive focal (P = 0.001) 
and diffuse (P = 0.002) 
atherosclerosis and lower 
10-year cardiovascular
risk. Hazard ratios were
0.10 (95% CI 0.01–0.70, P
= 0.02) for ischemic heart
disease and 0.24 (0.08–
0.74, P = 0.013) for
vascular death, per each
added copy of 12Ala,
respectively.
Carriers of the 12Ala 
allele have less 
widespread CAD and 
are considerably 
protected against 10-
yr cardiovascular 
morbidity and 
mortality. These long-
term findings in 
patients with manifest 
CAD support an 
important role of 
PPARγ in determining 
vascular risk. 
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Table 2.1 PPARγ2 Literature Review of SNP (rs1801282 [Pro12Ala]) (cont) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
Lindi et 
al., 
Diabetes
, 2002 
[91] 
PPARγ2 Pro12Ala Association of the 
Pro12Ala 
Polymorphism in 
PPARγ2 with 3-
Year Incidence of 
T2DM and Body 
Weight Change in 
the Finnish 
Diabetes 
Prevention Study 
31.1 ± 
4.6 
40-68 490 (161 M, 
329 F), pre-
diabetic; 
Finnish 
7x/yr 
dietary 
consult w 
RD, and 3-
mo FU 
appts. 
Diet Rx: 
<30% 
FAT, 
<10% 
SatF, 15g 
fiber/1k 
kcal. 30 
min/d EX 
suggested 
daily for 
36 months 
BW, BMI, 
WC, HC, 
glucose, 
insulin, 4-day 
food recall logs 
Ala/Ala control group > 
risk for T2DM vs wild-
type (P<0.05). After 36 
months, Ala/Ala genotypes 
sig reduced BW vs wild 
type (P<0.043). Pro/Ala 
also sig reduced BW vs 
wild type @ 36 mo 
(P<0.05) 
Ala allele in codon 12 
of the PPAR-γ2 gene 
was associated with 
the development of 
T2DM in the high-
risk IGT pop. In 
contrast, Ala12Ala 
subjects who followed 
an intensive diet and 
EX protocol lost sig 
more BW vs subjects 
with the Pro12Pro 
genotype, and none of 
subjects with the 
Ala12Ala genotype 
developed T2DM. 
Nicklas 
et al., 
Diabetes
, 2009 
[90] 
PPARγ2 Pro12Ala Genetic variation in 
the peroxisome 
proliferator-
activated receptor-
G2 gene 
(Pro12Ala) affects 
metabolic 
responses to weight 
loss and subsequent 
weight regain 
31.8 
(25-40) 
61 wild 
type; 57 
Ala12 
allele 
carriers 
70 F, post-
menopausal 
(Pro/Pro, 
n=56) (Pro/Ala 
and Ala/Ala, 
n=14); 
Caucasian 
LCD < 
250-350
kcal/day; 
24weeks 
BF%, FM, 
FFM (DXA), 
SWAT and 
VWAT (single 
slice 
tomography 
b/w L-4 and L-
5), VO2max, 
RMR, glucose, 
insulin 
Pro/Pro -8.4 kg, Pro/Ala -
7.6 kg; BMI, BF%, 
visceral and subcutaneous 
FM, RMR, VO2max, 
substrate oxidation, 
glucose and insulin 
responses. No diff b/w 
genotypes. Weight regain 
after 12mo sig greater in 
Ala allele carriers 
Pro12Ala show Ala 
allele, as a result of a 
lower binding affinity 
and reduced ability to 
transactivate 
promotors, is assoc. 
w/ reduced capacity to 
activate transcription 
and mediate 
adipogenesis. It is 
possible that WL may 
have resulted in less 
efficient stimulation 
of PPARγ2 target 
genes w/ Ala causing 
less adipogenesis and 
thus greater insulin 
sensitivity. 
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Table 2.1 PPARγ2 Literature Review of SNP (rs1801282 [Pro12Ala]) (cont) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
Curti et 
al, MetS 
and Rel 
Dis-
orders, 
2013 
[116] 
FTO 
PPARγ2 
ApoA1 
FTO: T/A, 
PPARγ2: 
Pro12Ala, 
ApoA1: -
75G/A 
FTO T/A and 
Peroxisome 
Proliferator-
Activated 
Receptor-G 
Pro12Ala 
Polymorphisms but 
Not ApoA1 -75 Are 
Associated with 
Better Response to 
Lifestyle 
Intervention in 
Brazilians at High 
Cardiometabolic 
Risk 
30.4 ± 
0.48 
56.6 ± 
0.99 
138, CMD 
risk, 90.6% 
MetS; 
Brazilian 
Group 1: 
850mg 
metformin 
2x/d + 
lifestyle 
mod. 
Group 2: 
16 
sessions 
on diet, 
EX, and 
behavior 
mod. 
Meeting 
8x FU. 
All 
treatment 
groups 
<500-1000 
kcal TEE 
per AHA 
rec for WL 
36 weeks 
BW, BMI, 
WC, BP, CRP, 
adipocytokines
, 3-day food 
recall records 
Anthropometric 
measurements, 2-hr plasma 
glucose, insulin, HDL-C, 
and ApoB improved 
significantly for all 
subjects, regardless of 
genotype. 
In Brazilian 
individuals, the FTO 
T/A polymorphism 
induces a favorable 
impact on 
inflammatory status 
and glucose 
metabolism. The 
Pro12Pro PPARγ2 
genotypes correlate 
with a more favorable 
lipid profile, while the 
Ala allele carriers 
exhibited decreased 
BP (P<0.001).  
Goyenechea
et al.,
Br J 
Nutr, 
2006 
[117] 
PPARγ2 
IL-6 
PPARγ2: 
Pro12Ala
IL-6: -
174G>C 
Weight regain after 
slimming induced 
by an energy-
restricted diet 
depends on 
interleukin-6 and 
peroxisome-
proliferator-
activated-receptor-
gamma2 gene 
polymorphisms 
35.8 34.7 67 (45 W, 
22 M); Obese 
BMI = 
35.8±4.8; 
Caucasian 
~500kcal 
< TEE; 
AHA diet 
for WL 
(55% 
CHO, 15% 
PRO, 30% 
FAT) for 
70d; 1yr 
(62wk) FU 
BW, BMI, FM, 
FFM, Blood 
sample (IL-6, 
PPARγ2), 3-
day food 
records 
The C allele of the -
174G>C IL-6 gene was 
more frequently observed 
(P<0.032) in subjects with 
successful WM (<10% 
weight regain). The C 
allele partially protected 
against weight regain (OR 
0.24; P<0.049), while the 
conjoint presence of both 
gene variants
(C+ in IL-6 and Ala+ in 
PPARγ2) further 
augmented WM (OR 0.19; 
P<0.043). 
The C allele of the -
174G/C SNP gives 
protection against 
weight regain. The 
presence of the Ala 
allele of the PPARγ2 
together with the C 
allele strengthens this 
protection. These 
findings support a role 
for these 
polymorphisms on 
weight regulation and 
suggest a synergetic 
effect of both IL-6 
and PPARγ2 variants 
on WM after 
following WL diet. 
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Table 2.1 PPARγ2 Literature Review of SNP (rs1801282 [Pro12Ala]) (cont) 
AHA: American Heart Association, CHO: Carbohydrate, PRO: Protein, RD: Registered Dietitian, CAD: Coronary Artery Disease, CMD: Cardiovascular Metabolic Disease, NYHA-FC: New 
York Heart Association Functional Class, HDL-C: High Density Lipoprotein Cholesterol, LDL: Low Density Lipoprotein, TG: Triglyceride, MI: Myocardial Infarction, TEE: Total Energy 
Expenditure, REE: Resting Energy Expenditure, RMR: Resting Metabolic Rate, WHR: Waist Hip Ratio, BW: Body Weight, BMI: Body Mass Index, BF%: Body Fat Percentage, BP: Blood 
Pressure, SWAT: Subcutaneous White Adipose Tissue, VWAT: Visceral White Adipose Tissue, LCD: Low Calorie Diet, EX: Exercise, MetS: Metabolic Syndrome, T2DM: Type 2 Diabetes 
Mellitus, CRP: C-Reactive Protein, MUFA: Monounsaturated Fatty Acid, PUFA: Polyunsaturated Fatty Acid, FM: Fat mass, FFM: Fat-free mass, WC: Waist Circumference, HC: Hip 
Circumference, WM:Weight Management, WL: Weight Loss, FU: Follow Up, OR: Odds Ratio, M: Male, F: Female 
Table 2.2 FABP2 Literature Review of SNP (rs1799883 [Ala54Thr]) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
Martinez
-Lopez,
Nutritio
n, 2013
[100]
FABP2 Ala54Thr Effect of Ala54Thr 
polymorphism of 
FABP2 on 
anthropometric and 
biochemical 
variables in 
response to a 
moderate-fat diet 
32.7 ± 
6.1 
38.6+/-
11.3 
109 
(20 M+89 F); 
Hispanic 
8 weeks: -
500kcal/d, 
30% FAT, 
(<7% 
SatF, 10–
15%MUF, 
10%PUF), 
15%PRO, 
55% CHO 
BW, BF%, 
WC, HC, 
RMR, BP, 
glucose, 
insulin, lipid 
profile, CRP. 
24-hr recall
dietary records
Thr54 allele carriers 
showed sig decrease in 
WL, BMI, WC, WHR, and 
CRP (P < 0.05). After 
RMR was adjusted, the 
decreases in WC, WHR, 
and CRP remained sig bw 
the 2 genotypes. 
Thr54 allele carriers 
experienced more 
favorable overall 
responses to a 
moderate-fat diet. 
de Luis 
et al., 
Diabetes 
Res Clin 
Pract, 
2008 
[118] 
FABP2 Ala54Thr Influence of 
Ala54thr 
polymorphism of 
FABP2 on weight 
loss and insulin 
levels secondary to 
two hypocaloric 
diets: a randomized 
clinical trial 
34.3 46.5 204(50M+154
F); Non-
diabetic 
outpatient; n/a 
Diet1: LF 
(1500kcal/
d; 
52%CHO/
20%PRO/
27%FAT) 
Diet2:LC 
(1507kcal/
d; 
38%CHO/
26%PRO/
36%FAT) 
+ Aerobic
EX
60min/3x/
wk for
12wks
BW, BP, 
glucose, 
Lipoprotein, 
CRP, Insulin, 
lipid profiles; 
Leptin, 
Adiponectin, 
Resistin, TNF-
a, IL-6 
Diet1+WT: ↓ BMI, FM, 
WC, WHR, SBP, DBP, 
Glucose, TC, TG, Insulin; 
Diet2+WT: ↓ BMI, WT, 
FM, WC, SBP, DBP; 
Both+WT: ↓Leptin 
Similar WL is 
associated with 
different changes, 
depending on the 
FABP2 genotype with 
both diets; WL is 
associated with a 
greater decrease in 
serum leptin 
concentration with LF 
diet 
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Table 2.2 FABP2 Literature Review of SNP (rs1799883 [Ala54Thr]) (cont) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
de Luis, 
Ann 
Nutr 
Metab, 
2006 
[119] 
FABP2 Ala54Thr Influence of 
ALA54THR 
Polymorphism of
Fatty Acid Binding 
Protein 2 on 
Lifestyle
Modification 
Response in Obese 
Subjects 
34.1 ± 
5.1 
45.5+/-
16.7 
69 (14 M, 55 F), 
obese 
BMI>30, non-
diabetic; 
Spanish 
12 weeks: 
Mediterran
ean 
Hypocalor
ic diet 
(1,520 
kcal; 52% 
CHO, 25% 
FAT, and 
23% 
PRO). EX 
consisted 
of aerobic 
exercise at 
least 
60min/3x/
wk 
REE, tetrapolar 
BIA, BP, BW, 
glucose, 
lipoprotein(a), 
CRP, insulin, 
HOMA-IR, 
lipid profiles 
adipocytokines 
(leptin, 
adiponectin, 
resistin, TNF-
a, IL-6), 3 day 
food log 
WL of -3.17+/-3.5 kg 
(3.5%). The % of WL 
responders was similar in 
both groups (89.2 vs. 
90.6%). Carriers of the 
Thr54 allele had a diff 
response in that they had a 
sig ↓ in systolic BP and 
glucose levels, whereas the 
Ala54Ala carriers had a sig 
↓ in FM, LDLc, and leptin 
WL, BC, and 
biomarkers of 
metabolic health are 
associated with 
different correlations, 
depending on FABP2 
genotype. 
Takakura,
Diab 
Res Clin 
Practice, 
2005 
[120] 
FABP2 Ala54Thr Thr54 allele of the 
FABP2 gene 
affects resting 
metabolic rate and 
visceral obesity 
32.9 ± 
5.8 
58.4 ± 
9.6 
80 F treatment 
group (obese); 
146F control 
group 
(healthy); 
Japanese 
28 weeks: 
1200 
kcal/day 
(60% 
CHO, 20% 
fat) 
BW, BMI, 
RMR, VWAT, 
SWAT (via CT 
scan), WHR, 
insulin, 
HOMA-IR, 
HbA1C, 7 day 
food records 
Thr54 carriers, adjusted 
RMR was sig lower than 
the Ala54 wild type. Thr54 
carriers showed sig inc 
WC post diet and EX 
therapy vs subjects with 
Ala/Ala genotype. Thr54 
carriers demonstrated 
greater BW at 20 y/o vs 
Ala/Ala genotypes 
Thr54 allele carriers 
are associated with 
lower adjusted RMR, 
resistance in reducing 
VWAT and early 
onset of obesity in 
Japanese obese 
women 
Weiss 
EP et al., 
Am 
JClin 
Nutr; 
2007 
[121] 
FABP2 Ala54Thr FABP2 Ala54Thr 
genotype is 
associated with 
glucoregulatory 
function and lipid 
oxidation after a 
high-fat meal in 
sedentary 
nondiabetic men 
and women 
29.2 ± 
4.1 
58 ± 6.2 50 M sedentary 
non-smoking; 
72F post-
menopausal; 
n/a 
LF diet, 
RD class 
2x/wk 
6wks pre-
trial 
BW, FM, FFM 
(DXA), BMI, 
VO2max, 
OGTT, insulin, 
lipid profiles, 
TEE, 7 day 
food records 
Thr54 carriers < glucose 
tolerance (P=0.05), ISI 
(P=0.02), and higher 
fasting glucose (P=0.03) 
and OGTT insulin AUC 
(P=0.03) vs Ala/Ala. 
Thr54 carriers have inc 
postprandial lipid OX rates 
(P=0.01) 
Sedentary 
nondiabetics on a LF 
diet, Thr54 carriers 
have lower glucose 
tolerance and insulin 
action, and higher 
lipid oxidation rates 
than Ala54 
homozygotes. This 
may suggest 
glucoregulatory 
dysfunction in Thr54 
allele carriers.  
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Han, J 
Exerc 
Nutr 
Biochem 
2013 
[122] 
FABP2 Ala54Thr Effects Ala54Thr 
polymorphism of 
FABP2 on obesity 
index and 
biochemical 
variable in response 
to a aerobic 
exercise training 
25.6 ± 
5.7 
(AA), 
26.4 ± 
10.6 
(AT/TT) 
45.9 ± 
7.4 
(AA), 
47.3 ± 
7.8 
(AT/TT) 
243W, 
abdominally 
obese, Korean 
12 wk 
Aerobic 
EX (2x/wk 
20 min 
stretch, 60 
min 
walking + 
dance) 
gradual inc 
intensity 
BW, BMI, 
WHR, VWAT 
and SWAT 
(area), LM, 
OGTT, 
HOMA-IR, 
NEFA, HDL, 
LDL, LPL, 
VO2max, 
REE, 24hr 
food recall 
Ala54Ala and 54Thr 
carriers sig decreased BW 
(P<0.001), BMI (P<0.001), 
%BF (P<0.001), WC 
(P<0.001), WHR 
(P<0.001), LM (AA 
p<0.022; AT/TT P<0.001), 
RHR (P<0.001), VWAT 
(AA p<0.005; AT/TT 
p<0.001), SWAT 
(P<0.001), insulin (AA 
p<0.005; AT/TT p<0.001) 
and sig increased VO2max 
(P<0.001). AA sig 
decreased NEFA (P<0.05), 
fasting glucose (P<0.05), 
OGTT (P<0.05) and sig 
increased HDL (P<0.005). 
AT/TT sig decreased SBP 
(P<0.001), DBP (P<0.01), 
LPL (P<0.05), LDL 
(P<0.001), HOMA-IR 
(P<0.01) 
Aerobic EX in 
middle-aged Korean 
women with visceral 
obesity improves BC, 
cardiorespiratory 
fitness, blood lipids, 
fasting glucose and 
HOMA-IR regardless 
of the FABP2 
Ala54Thr SNPs 
TEE: Total Energy Expenditure, REE: Resting Energy Expenditure, DBP: Diastolic Blood Pressure, SBP: Systolic Blood Pressure, TG: Triglyceride, TC: Total Cholesterol, LF: Low Fat, WT: 
Wild Type, BC: Body Composition, BW: Body Weight, BMI: Body Mass Index, %BF: Body Fat Percentage, WC: Waist Circumference, HC: Hip Circumference, CRP: C-Reactive Protein, 
OX: Oxidation, EX: Exercise, MUFA: Monounsaturated Fatty Acid, PUFA: Polyunsaturated Fatty Acid, FM: Fat mass, FFM: Fat-free mass, OGTT: Oral Glucose Tolerance Test, SWAT: 
Subcutaneous White Adipose Tissue, VWAT: Visceral White Adipose Tissue, LM: Lean Mass, WHR: Waist Hip Ratio, HOMA-IR: Homeostatic Model Assessment of Insulin Resistance, 
NEFA: Non Esterified Fatty Acid, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, LPL: Lipoprotein Lipase, RHR: Resting Heart Rate, SNP: Single Nucleotide 
Polymorphism, M: Male, F: Female 
Table 2.3 ADRB3 Literature Review of SNP (rs4994 [Trp64Arg]) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
Shiwaku 
et al., Int 
J Obes 
Relat 
Metab 
Disord, 
2003 
[123] 
ADRB3 Trp64Arg Difficulty in 
losing weight 
by behavioral 
intervention 
for women 
with Trp64Arg 
polymorphism 
of the beta3-
adrenergic 
receptor gene 
24.8 54.3 ± 
7.9 
76 F; Healthy; 
Japanese 
↓ 10% 
dietary 
intake + 
7000 steps / 
day for 
~90days 
BW, BMI, WC, 
HC, REE, HDL, 
LDL, TG, 
insulin, glucose, 
leptin, HOMA-
IR 
At baseline BMI, BW, BF, 
WC, HC, Arm skin fold, 
REE, lipid and glucose 
profile no sig diff by 
genotype; ↓BW 69% 
(Trp/Trp) and 48% 
(Trp64Arg); Sig diff HDL 
and LDL in both 
genotypes 
Trp64Arg mutation of 
ADRB3 > difficulty in 
WL through 
behavioral 
intervention although 
it is not related to 
obesity-related 
phenotypes and REE 
prior to intervention 
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Table 2.3 ADRB3 Literature Review of SNP (rs4994 [Trp64Arg]) (cont) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
de Luis 
et al., 
Ann 
Nutr 
Metab, 
2009 
[124] 
ADRB3 Trp64Arg Influence of 
Trp64Arg 
polymorphism 
of beta 3-
adrenoreceptor 
gene on 
insulin 
resistance, 
adipocytokines 
and weight 
loss secondary 
to two 
hypocaloric 
diets 
34.7 45.8 193 (48 M+145 F)
, (172 Trp/Trp, 
21 Arg64 
carriers); (96 
Diet I, 97 Diet 
II), Obese, Non-
diabetic; n/a 
Diet1: LF 
(1500kcal/d; 
52%CHO/2
0%PRO/27
%FAT) 
Diet2:LC 
(1507kcal/d;
38%CHO/2
6%PRO/36
%FAT) + 
Aerobic EX 
60mins/3x/
wk for 
12wks 
BW, BP, FM, 
FFM, WC, 
WHR, RMR, 
VO2, glucose, 
Lipoprotein (a), 
CRP, Insulin, 
HOMA, LDL, 
HDL, TG; 
Leptin, 
Adiponectin, 
Resistin, TNF-a, 
IL-6 
In Trp/Trp carriers BMI, 
WL, FM, WC, SBP, 
glucose, TG, insulin, 
HOMA and leptin sig 
decreased regardless of the 
diet type. In Arg64 
carriers, this was the case 
for BMI, WL, WC, FM 
and leptin. Only leptin had 
a sig ↓in the wild-type 
group (diet I 13.7%, diet II 
26.3% (P<0.05 for both). 
In Arg64 carriers, leptin 
decreased as well (diet I 
22.5%, diet II 30.1%, 
p<0.05 for both). 
The metabolic effect 
of mild WL by 2 
hypocaloric diets is 
greatest in Trp/Trp 
wild type subjects. 
Improvement in 
glucose, insulin, and 
HOMA-IR is better in 
Arg64 allele carriers. 
Nakamura
et al., 
Nutr 
Res, 
2000 
[125] 
ADRB3 Trp64Arg Association 
between 
ADRB3 
polymorphism 
and a lower 
reduction in 
the ratio of 
visceral fat to 
subcutaneous 
fat area during 
weight loss in 
Japanese 
obese women 
28.7 48.1 90 F (50 
premenopausal, 
40 post); obese; 
Japanese 
12 weeks: 
LCD 
1400kcal/da
y; 1.5g/BW 
(kg) PRO, 
30g FAT, 
20g fiber. 
Ex: walking 
60 min, 3-
7x/week @ 
50% 
VO2max 
VWAT, SWAT 
(MRI), TC, 
HDL, LDL, FM, 
FFM, TG, 
glucose, insulin 
Obese premenopausal 
Arg64 carriers ↓ 
VWAT/SWAT ratio, but 
not Trp64 homozygotes 
(p=0.009). Absolute 
changes in VWAT in 5 
Arg64 homozygotes was 
sig less than those in 50 
obese Trp64 homozygotes 
An AA Arg 
substitution at residue 
64 of ADBR3 may 
play an important role 
in regulation of 
VWAT and SWAT 
distribution in 
Japanese obese 
women. 
Tahara 
et al, 
Obesity 
Research
& Clin 
Practice, 
2011 
[126] 
ADBR3 Trp64Arg Influence of 
ADRB3 
Trp64Arg 
polymorphism 
on the 
improvement 
of MetS by 
exercise in 
Japanese 
middle-aged 
males 
26.7 
(T/T),
25.6 
(T/A) 
48 
(T/T), 
50 
(T/A) 
23 (T/T), 13 
(T/A); MetS; 
Japanese 
3mos, 10k 
step 
pedometer 
WC, TG, HDL, 
SBP/DBP, BW, 
TC, LDL, 
fasting insulin 
MetS improvement 21.7% 
(T/T) and 53.8% (T/A)   
After adjustment for 
age, calorie limitation, 
and 10K+ and 12K+ 
steps/day during trial, 
the OR of Trp/Arg for 
improvement of MetS 
relative to Trp/Trp 
SNP were 5.1 (p = 
0.043), 4.9 (p = 
0.051), 3.7 (p = 
0.074), and 5.0 (p = 
0.045), respectively. 
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Table 2.3 ADRB3 Literature Review of SNP (rs4994 [Trp64Arg]) (cont) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
 Rawson 
et al., 
Metabo-
lism, 
2002 
[127] 
ADRB3 Trp64Arg No effect of 
the Trp64Arg 
beta(3)-
adrenoceptor 
gene variant 
on weight loss, 
body 
composition, 
or energy 
expenditure in 
obese, 
Caucasian 
postmenopaus
al women 
35.6 ± 
6.3 
(>27) 
57.8 ± 
6.6 
34 F (19 carriers, 
15 non 
Trp64Arg 
carriers), obese, 
postmenopausal,
clinically 
healthy 
~13.5±2.6 
mos: 1200 
kcal/d 
55%CHO<3
0%FAT, 
<7%SatF, 
~15%PRO; 
<200mg/d 
CHL) 
BW, FM, FFM, 
REE, TEE, TEF, 
PAEE 
All subjects ↓BW, BMI, 
BF%, FFM and FM 
(P<0.05) post- 
intervention. No sig diff 
detected between 
genotypes 
Changes in body 
composition and 
energy expenditures 
were similar between 
carriers and non-
carriers of the gene 
variant following WL. 
This suggests the 
presence of the 
Trp64Arg variant 
should not hinder 
weight reduction. 
Kim OY 
et al., Int 
Jour 
Obesity, 
2004 
[128] 
ADRB3 
UCP3 
ADRB3: 
Trp64Arg 
UCP3: 
-55CàT
Additive effect 
of the 
mutations in 
the 
b3-
adrenoceptor 
gene and 
UCP3 gene 
promoter 
on body fat 
distribution 
and glycemic 
control 
after weight 
reduction in 
overweight 
subjects with 
CAD or 
metabolic 
syndrome 
25.8 ± 
0.26 
53.6 ± 
1.28 
224 (163 TT, 61 
Arg64 carriers) 
overweight/ 
obese, Korean 
12 wk, -300 
kcal/d TEE 
(60%CHO, 
20%FAT, 
20%PRO) 
BW, BMI, BC 
(CT scan), HDL, 
LDL, VLDL, 
Insulin, TG, 
OGTT 
All subjects lost ~ 5% in 
BW. Highest decreases in 
abdominal adipose tissue 
at L1 and L4 levels were 
observed in the ‘wild-type’ 
(TT-CC) group (P<0.001) 
and the second highest in 
‘only UPC3 promoter 
variant’ (TT-CT) group 
(P<0.001). Both variant-
carriers had the smallest 
reduction only in visceral 
fat area at L4. All subjects 
except both variant-
carriers (TA-CT) had sig 
reductions in fasting 
glucose and FFA. The 
response areas of glucose 
(P<0.01) and insulin 
(P<0.05) were reduced 
largest in the 
‘wild-type’ group (TT-CC) 
and second largest in the 
‘UCP3 promoter variant’ 
(TT-CT) group 
All subjects showed 
similar weight 
reduction after -300 
kcal/d deficit for 12 
wks. However, the 
beneficial effects on 
BF distribution and 
glycemic control 
(OGTT) were greatest 
in the ‘wild-type’ (TT-
CC) group and 
smallest in ‘both 
variants’ (AA-TT) 
group. These effects 
were reduced in 
carriers with ADRB3 
Arg64 allele carriers 
(TA/AA) than with 
UCP3 gene promoter 
variant (TT-CT). 
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Table 2.3 ADRB3 Literature Review of SNP (rs4994 [Trp64Arg]) (cont) 
 BC: Body Composition, BMI: Body Mass Index, BW: Body Weight, FM: Fat Mass, FFM: Fat Free Mass, BF%: Body Fat Percentage, WC: Waist circumference, HC: Hip circumference, 
HDL: High density lipoprotein, LDL: Low density lipoprotein, VLDL: Very Low Density Lipoprotein, TC: Total Cholesterol, TG: Triglycerides, HOMA: Homeostatic Model Assessment of 
Insulin Resistance, LCD: Low Calorie Diet, BP: Blood pressure, SBP: Systolic BP, DBP: Diastolic BP, MetS: Metabolic Syndrome, RMR: Resting metabolic rate, CRP: C-reactive protein, 
FFA: Free Fatty Acid, CAD: Coronary Artery Disease, WL: Weight Loss, VWAT: Visceral white adipose tissue, SWAT: Subcutaneous white adipose tissue, PAEE: Physical activity energy 
expenditure, OGTT: Oral Glucose Tolerance Test, TEE: Total Energy Expenditure, TEF: Thermic Effect of Feeding, CHO: Carbohydrate, PRO: Protein, CHL: Cholesterol, SatF: Saturated Fat, 
M: Male, F: Female 
Table 2.4 ADRB2 Literature Review of SNPs (rs1042713 [Arg16Gly]) and (rs1042714 [Gln27Glu]) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
Ruiz et 
al., 
Obesity, 
2011 
[129] 
ADBR2 rs1042714
(Gln/Glu) 
rs1042713 
(Arg/Gly) 
Role of beta(2)-
adrenergic 
receptor 
polymorphisms 
on body weight 
and body 
composition 
response to 
energy 
restriction in 
obese women: 
preliminary 
results 
34 36.7 78 F, Obese; 
Spanish 
600kcal 
<RMR 
(55% 
CHO / 
30% FAT 
/ 15% 
PRO), RD 
consult 
1x/wk for 
12weeks 
BW, BMI, FM, 
FFM, LM 
(DXA), RMR, 
3-day food
records
ADRB2 Glu27 allele 
carriers ↓ BW (P=0.002) 
and LM (P=0.001) but no 
sig diff in FM, WC, RMR 
in Glu27 allele carriers vs 
Gln/Gln wild type 
subjects. 
The Gln27Glu 
polymorphism has a 
modulating effect on 
diet-induced changes 
on BW and BC, and 
should be considered 
in future treatments of 
obesity. 
Saliba 
LF et al., 
Genetics 
and 
Molecul
Biology, 
2014 
[130] 
ADRB2 
ADRB3 
GHRL 
ADRB2: 
rs1042714 
rs1042713 
ADRB3: 
rs4994 
GHRL: 
rs69621 
(Leu/Met) 
Obesity-related 
gene ADRB2, 
and the response 
to a weight loss 
diet intervention 
in adult women 
>30 20-50
(45%
30-39)
109 F, Obese, 
Brazilian, 
premenopausal, 
clinically healthy 
7 weeks; 
<600kcal 
TEE 
BW, BMI, 
SES 
The WL intervention 
resulted in decreased BMI 
over the 7-week period (P 
< 0.001), for high and low 
SES (p < 0.05) and mainly 
for participants with 30-49 
y 
The intervention did 
not result in a GHRL 
statistically sig diff in 
WL bw WT or mutant 
carriers and although, 
the ADRB3 and 
polymorphisms did not 
moderate WL, the 
ADRB2 Glu27 allele 
carriers demonstrated 
a ↓BMI vs WT in the 
low SES (P=0.018) 
and the 30-39 y (P 
=0.036) groups, 
suggesting a role for 
this polymorphism 
related to BMI control. 
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Table 2.4 ADRB2 Literature Review of SNPs (rs1042713 [Arg16Gly]) and (rs1042714 [Gln27Glu]) (cont) 
Author/ 
Journal/
Year 
Variables Title Population Measured Outcomes Results Conclusion 
Gene SNP BMI Age No./Gender/ Health/Ethnic 
Diet/ 
Duration 
Rauhio 
A., 
Maturitas,
2013 
[131] 
ADRB2 
FTO 
ADBR2: 
rs1042714
(Gln>Glu) 
FTO: 
rs9939609
(T>A) 
Association of 
the FTO and 
ADRB2 genes 
with body 
composition and 
fat distribution 
in obese women 
>30 ~39 75 F; 
Clinically healthy, 
Obese, 
premenopausal 
3mo:wt 
reduction+
9mo: wt 
maintain; 
VLED 
BW, BMI, 
WHR, BC 
(DXA) 
Gln/Gln carriers of the 
ADRB2 gene had smaller 
gynoid fat-% compared 
with both the Gln/Glu and 
Glu/Glu carriers (p = 
0.050 and p = 0.009, 
respectively). The Gln 
homozygotes had smaller 
total BF% and higher total 
LBM% than Glu 
homozygotes (p = 0.018 
and p = 0.019, 
respectively).  
ADRB2 genotype was 
associated with 
android/gynoid fat 
distribution. However, 
all women in the study 
group lost weight 
similarly 
independently of 
genotype. Neither the 
FTO nor ADRB2 
genotype had 
statistically significant 
effect on weight 
reduction or weight 
maintenance.  
Verhoef 
S., 
Physiology
& 
Behavior
, 2014 
[132] 
ADRB2 
PPARγ2 
FTO 
MC4R 
PPARD 
PPARγC1A 
ADRB2: 
rs1042713 
(Arg/Gly) 
PPARγ2: 
rs1801282 
Genetic 
predisposition, 
dietary restraint 
and disinhibition 
in relation to 
short and long-
term weight loss 
32.0 
± 3.1 
20-50 150 (39M + 111F), 
BMI 27-38, 
clinically healthy 
8 wk 
VLED 
(50g CHO, 
52g PRO, 
7g 
FAT/day) 
3 mo WM 
BW, WC, HC, 
BC (Bod Pod) 
All subjects reduced BW, 
BMI, FM, WC, HC after 5 
mo (p<0.001) No 
significant differences in 
BW for ADRB2 
rs1042713 and PPARD 
During long-term WL, 
genetic effects are 
primarily regulated by 
changes in eating 
behavior. 
Bea 
J.,Behav
. Genet., 
2010 
[133] 
ADRB2 
ADRB3 
ADRA2B 
ADRB2: 
rs1042714 
(Gln/Glu) 
ADRB3: 
rs4994 
(Trp/Arg) 
Lifestyle 
modifies the 
relationship 
between BC and 
adrenergic 
receptor genetic 
polymorphisms, 
ADRB2, 
ADRB3 and 
ADRA2B: A 
secondary 
analysis of a 
RCT of PA 
among 
postmenopausal 
women 
25.3 
± 3.8 
55.5 ± 
4.8 
148 normal, 
overweight, and 
obese, clinically 
healthy 
postmenopausal 
women 
320 sedentary 
randomized in EX 
or CTRL group for 
secondary analysis 
12 mo 
high 
intensity 
RE + mod 
impact 
weight 
bearing 
EX 
(75min/3x/
wk) 
BW, BC 
(DXA) 
No main effect of 
individual genes on 
change in BC, although 
interactions were observed 
for ADRB2 
Glu allele carriers w 
increase in lean soft tissue 
(LST) in EX vs CTRL 
(p=0.02). No changes 
observed in Gln/Gln w 
EX. 
ADRB3: All participants 
increase in LST (p<0.05) 
w no sig diff between 
genotypes 
Strong positive effect 
of EX on BC across all 
genotypes. 
Susceptibility to 
adverse BC changes in 
sedentary 
postmenopausal 
women suggest that 
changes with inactivity 
may be more profound 
in certain genetic 
backgrounds. Thus, 
EX may play a 
protective role against 
adverse genetic 
influences on obesity.  
BW: Body weight, BMI: Body mass index, FM: Fat mass, FFM: Fat-free mass, LM: Lean mass, BF%: Body Fat Percentage, LBM%: Lean Body Mass Percentage, PA: Physical Activity, RD: 
Registered Dietitian, RE: Resistance Exercise, RMR: Resting metabolic rate, GHRL: Ghrelin, SES: Socioeconomic status, WC: Waist circumference, HC: Hip circumference, WHR: Waist Hip 
Ratio, BC: Body composition, VLED: Very low energy diet, CHO: Carbohydrate, PRO: Protein, WL: Weight loss, EX: Exercise, CTRL: Control, WT: Wild Type, M: Male, F: Female 
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Rationale for the Study 
Gardner et al. [55] conducted a large scale, 12-month controlled randomized weight 
loss study for women: The A to Z Weight Loss Trial. Briefly, they compared four popular 
weight loss diets: Zone (40% kcal CHO, 30% kcal fat, 30% kcal protein), Atkins (<20 g/d 
CHO x 2-3 months, then ≤50 g/d CHO), LEARN (55-60% kcal CHO, <10% kcal saturated 
fat) and Ornish (≤10% kcal fat).  
Based on the growing body of literature of the SNPs outlined in Tables 1-4, and 
specifically Gardner’s study, Dopler-Nelson et al. [56] conducted a retrospective analysis of 
the A to Z trial data based on allele patterns for these candidate obesity genes and dietary 
group assignment. 101 out of 311 Caucasian participants from the A to Z trial gave consent 
to participate. 31 had been assigned to the Atkins diet, 32 to the Zone diet, 26 in the Ornish 
group, and 34 in the LEARN diet group. The four candidate genes selected for analysis were 
fatty acid binding protein 2 (FABP2 [Ala54Thr]), peroxisome-proliferator activated- receptor 
gamma 2 (PPARγ2 [Pro12Ala]), beta-2 adrenergic receptor (ADRB2 [Arg16Gly] and 
[Gln27Glu]), and beta-3 adrenergic receptor (ADRB3 [Arg64Trp]). Metabolic genotyping 
based on SNP allele variants was determined from buccal cheek swab DNA samples, and 
categorized participants as a “true” match or a “false” match from their A to Z trial diet. 
Participants in the appropriate dietary group (True Match) for their genotype allele pattern 
resulted in 2-3x greater BW reduction over 12 months compared to those in inappropriate 
dietary groups (False Match) for their metabolic profile (p=0.02). Women assigned to a 
genotype appropriate diet lost 5.3% of their initial body weight compared with 2.3% among 
those not matched to genotype. Additional findings were similar for reduced waist 
circumference (p=0.01), decreased triglycerides (p=0.007), and increased HDL (p= 0.01) 
31 
[56]. These findings indicate plausible cause for further investigation of potentially 
influential SNPs in candidate obesity-related genes (i.e. metabolic profiling) as a reliable 
model to predict the efficacy of an individual’s response to a specific diet composition. As a 
result, greater improvements in body composition and biomarkers of health may be based on 
diet type and individual genotypes. 
As a follow-up to replicate the findings of Dopler-Nelson’s investigation of the A to 
Z trial, this study examined the genetic influence of SNP allele patterns in women assigned to 
a specified hypocaloric diet (AHA, CC-I, CC-II) for 24 weeks. Additionally, a structured 
exercise program was included in our study design, whereas an exercise protocol was not 
considered in the A to Z trial investigation. 
32 
 CHAPTER III 
METHODS 
Study Design 
Experimental Approach 
This study was conducted as a randomized comparative effectiveness trial from 
November 2013 to May 2015, with retrospective analysis of genetic influence on weight 
loss. The weight loss intervention included a 6-month diet and exercise program. 
Participants were randomized to a control group, or one of three weight loss treatment 
groups. The treatment groups were assigned to a hypocaloric diet consisting of varying 
nutrient compositions as defined in Table 3.1. All weight loss treatment groups were 
assigned to the same exercise protocol for the duration of the study. 
Table 3.1 Summary of Dietary Assignments 
Diet Kcals Macronutrients % Diet Content g/d Kcals/d 
g/kg/d 
(90kg) 
American Heart Association - High Carbohydrate / Low Fat Diet (AHA) 
1 Week 1,400 kcals/d CHO 
PRO
FAT 
55 
15 
30 
193 
53 
47 
770 
210 
420 
2.14 
0.58 
0.52 
23 Weeks 1,500 kcals/d CHO 
PRO
FAT 
55 
15 
30 
206 
56 
50 
825 
225 
450 
2.28 
0.62 
0.56 
Curves Complete I - Moderate Carbohydrate / High Protein / Low Fat Diet (CC-I) 
1 Week 1,400 kcals/d CHO 
PRO
FAT 
30 
45 
25 
105 
158 
39 
420 
630 
350 
1.17 
1.75 
0.43 
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American Heart Association (AHA) Diet 
Participants in the American Heart Association (AHA) program followed the AHA 
dietary guidelines for weight loss. In concurrence with this plan, subjects followed the phase 
1 hypocaloric kcal intake diet (1,400 kcals/day) for one week, and the phase 2 higher kcal 
intake diet (1,500 kcals/day) for the following 23 weeks. The AHA macronutrient content for 
both phase 1 and 2 diets was 15% protein, 55% carbohydrate, 30% fat. Subjects assigned to 
the AHA group followed a booklet based nutrition plan designed using the Diabetic 
Exchange List (The Exchange Diet) developed by the American Dietetic Association [134].  
Curves Complete I (CC-I) Diet 
Participants in the CC-I group followed the Curves Complete diet administered 
online. CC-I subjects were provided with login and username instructions for the online 
nutrition management program. In concurrence with this plan, subjects followed the phase 1 
hypocaloric kcal intake diet (1,400 kcals/day) for one week, and the phase 2 higher kcal 
Table 3.1 Summary of Dietary Assignments (cont) 
Diet Kcals Macronutrients % Diet Content g/d Kcals/d 
g/kg/d 
(90kg) 
23 Weeks 1,500 kcals/d CHO 
PRO
FAT 
30 
45 
25 
113 
169 
42 
450 
675 
375 
1.25 
1.88 
0.47 
Curves Complete II - Carbohydrate Restricted / High Protein / Moderate Fat Diet (CC-II) 
1 Week 1,400 kcals/d CHO 
PRO
FAT 
20 
45 
35 
70 
158 
54 
280 
630 
490 
0.78 
1.75 
0.60 
23 Weeks 1,500 kcals/d CHO 
PRO
FAT 
20 
45 
35 
75 
169 
58 
300 
675 
525 
0.83 
1.88 
0.65 
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intake diet (1,500 kcals/day) for the following 23 weeks. The CC-I macronutrient 
composition for phase one (1400 kcal/day for 1 week) and phase two (1500 kcal/day for 23 
weeks) of the diet was 45% PRO, 25% CHO, 20% FAT. A registered dietitian reviewed the 
higher protein diet and exercise plan with subjects at baseline. Additionally, CC-I 
participants received nutritional coaching sessions with the study coordinator or RD 1x/week 
for approximately 15 minutes to discuss any dietary challenges or concerns.  
Curves Complete II (CC-II) Diet 
Participants in the CC-II group followed the Curves Complete diet administered via 
a booklet based exchange diet similar to AHA, but with different food options to meet 
respective macronutrient requirements. In concurrence with this plan, subjects followed the 
phase 1 hypocaloric kcal intake diet (1,400 kcals/day) for one week, and the phase 2 higher 
kcal intake diet (1,500 kcals/day) for the following 23 weeks. The CC-II macronutrient 
composition for phase one (1400 kcal/day for 1 week) and phase two (1500 kcal/day for 23 
weeks) of the diet was 45% PRO, 15% CHO, 30% FAT. A registered dietitian reviewed the 
higher protein diet and exercise plan with subjects at baseline. Additionally, CC-II 
participants received nutritional coaching sessions with the study coordinator or RD 
1x/week for approximately 15 minutes. 
Exercise Protocol 
For all treatment groups (AHA, CC-I, and CC-II) the physical training protocol 
included three regular resistance circuit workouts and one circuit combined with Zumba 
workouts each week for 24 weeks, while maintaining a greater than 75% compliance record 
(72 out of 96 workouts). Attendance was recorded at each workout session in order to 
monitor compliance. The circuit equipment was located in the Exercise and Sports Nutrition 
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Laboratory (ESNL) at Texas A&M University. The circuit utilized the computerized 
CurvesSmart system (Curves International, Waco, TX, USA) equipped with software 
designed by MYTRAK (version 4.2.0.0, copyright 2004-2010, MYTRAK Health System, 
Mississauga, Ontario, Canada). The circuit consisted of 13 bi-directional hydraulic 
resistance exercise machines that worked all major muscle groups (i.e., elbow 
flexion/extension, knee flexion/extension, shoulder press/latissimus pull, hip 
abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal 
crunch/back extension, chest flies, oblique, shoulder shrug/dip, hip extension, and side 
bends). During the circuit workouts, subjects were instructed to complete as many 
repetitions as possible during a 30 second interval on each resistance machine. Between 
machines, subjects performed floor-based aerobic exercises or stepping exercise designed to 
maintain an elevated heart rate. Subjects performed the entire circuit twice during the 26-
minute regular circuit workout. During the circuit combined with Zumba workout, subjects 
performed 1 minute of Zumba dance moves in between 1 minute of resistance exercise on 
each machine. All Zumba classes were taught by a certified Zumba instructor. Subjects 
were assisted with self-monitoring of heart rate in order to maintain an aerobic capacity 
between 60-80% of target heart rate by calculating age-predicted maximal heart rate (220-
age). All subjects were provided with Polar FT heart rate monitors for the duration of the 
workout. Subjects were also advised to perform 5 minutes of whole body stretching after all 
circuit workouts. In addition to circuit training, subjects were instructed to walk for 10,000 
steps/day on non-resistance circuit workout days (3x/week). All subjects in the treatment 
groups were provided with a pedometer to monitor and record steps on their physical 
activity log. In the event participants required travel outside the Bryan/College Station area, 
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they were provided with a travel pass valid for 30 days at any Curves franchise location. 
Workouts completed outside the ESNL facility were recorded upon return from travel.  
Independent and Dependent Variables 
The independent variables within the weight loss program were the 1) assigned 
dietary protocol – American Heart Association (AHA), Curves Complete-I (CC-I), or 
Curves Complete-II (CC-II) and 2) genetic match to diet based on metabolic profiles 
defined as a) Fat Trimmer, b) Carbohydrate Reducer, or c) Better Balancer. If a participant 
met the Fat Trimmer genotype profile, the diet is designed to contain ~50-60% CHO, ~30% 
FAT, and 15-20% PRO. This would optimally fit the assignment of the AHA diet, and thus 
a participant would be considered a True (T) genetic match to the AHA diet, and a False (F) 
match to the CC-I or CC-II diet. The Carbohydrate Reducer diet profile is designed to 
contain <30% CHO, ~30-35% FAT, and >40% PRO. This profile optimally fits the 
assigned CC-II diet, and thus a participant would be considered a True genetic match to CC-
II and a False match to AHA or CC-I diet. The Better Balancer profile’s diet is designed to 
contain ~30-40% CHO, ~30% FAT, and ~30% PRO. This nutrient makeup is similar to the 
“Zone diet” and as such, a Better Balancer was determined a True (T) match to the AHA 
and CC-I diets or a False match to the very low CHO CC-II diet.  
Dependent variables included: body weight, hip and waist anthropometric 
measurements, resting energy expenditure (REE), body composition (DEXA), fasting 
clinical blood profiles (cholesterol [HDL and LDL], glucose, triglycerides, insulin), 
maximal cardiopulmonary exercise capacity (VO2max), maximum upper and lower 
extremity strength capacity (1RM) and maximum isotonic strength endurance capacity 
(80% 1RM), standardized quality of life (SF-36), levels of physical activity (METs –
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min/wk), and estimated dietary energy intake (kcal/day). 
Testing Schedule  
The study included a baseline testing session followed by 6 monthly testing sessions. 
Immediately following the baseline testing session, participants were allocated into 
American Heart Association (AHA), Curves Complete-I (CC-I), Curves Complete-II (CC-
II), or the control (CTRL) group. Participants were randomized into one of the four groups: 
3 weight management treatment groups (AHA, CC-I, CC-II) or CTRL based on age, body 
fat percentage, and body mass index (BMI: calculated as kg/m2). Dietary intake and weekly 
physical activity (IPAQ), anthropometric measurements, resting energy expenditure (REE), 
body composition, serum clinical chemistry panels, whole blood counts and hormone 
concentrations, and quality of life were assessed at 0, 4, 8, 12, 16, 20 and 24 weeks to 
determine differences in weight reduction program effects. Maximal cardiopulmonary 
exercise capacity (Peak VO2) and upper and lower body isotonic strength and endurance 
were assessed at 0, 12 and 24 weeks to ascertain chronic program effects on measures of 
fitness. Table 3.2 displays the general research design and time course for the testing 
session assessments. 
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Table 3.2 Overview of Research Design and Testing Schedule 
Familiarization Baseline (T1) 4 Weeks (T2) 8 Weeks (T3) 12 Weeks (T4) 16 Weeks (T5) 20 Weeks (T6) 24 Weeks (T7) 
Familiarization 
Session 
Complete 
Paperwork 
Review Medical 
history 
Physical Exam 
Fasting Blood 
Determination of 
Qualifications to 
Participate 
Group 
Assignment: 
-Control (CTRL)
1. -AHA
2. -CC-I
3. -CC-II
Phase I – 1,
kcals/d for 1 week
Phase II – 1,
kcals/d for
weeks
Diet Record 
Review 
Body Weight 
Hip and Waist 
Measurements 
Resting Energy 
Expenditure 
DEXAa Scan 
Fasting Blood  
DNA Genotyping 
Maximal 
Cardiopulmonary 
Exercise Test 
1RMb and 80% 
1RM Isotonic Leg 
Press and Bench 
Press 
Measures  
Survey 
Completionc 
IPAQd 
Diet Record 
Review 
Body Weight 
Hip and Waist 
Measurements 
Resting Energy 
Expenditure 
DEXAa Scan 
Fasting Blood 
Survey 
Completionc 
IPAQd
Diet Record 
Review 
Body Weight 
Hip and Waist 
Measurements 
Resting Energy 
Expenditure 
DEXAa Scan 
Fasting Blood 
Survey 
Completionc 
IPAQd 
Diet Record 
Review 
Body Weight 
Hip and Waist 
Measurements 
Resting Energy 
Expenditure 
DEXAa Scan 
Fasting Blood 
Maximal 
Cardiopulmonary 
Exercise Test 
1RMb and 80% 
1RM Isotonic Leg 
Press and Bench 
Press 
Measures  
Survey 
Completionc 
IPAQd 
Diet Record 
Review 
Body Weight 
Hip and Waist 
Measurements 
Resting Energy 
Expenditure 
DEXAa Scan 
Fasting Blood 
Survey 
Diet Record 
Review 
Body Weight 
Hip and Waist 
Measurements 
Resting Energy 
Expenditure 
DEXAa Scan 
Fasting Blood 
Survey 
Completionc 
IPAQd 
Diet Record 
Review 
Body Weight 
Hip and Waist 
Measurements 
Resting Energy 
Expenditure 
DEXAa Scan 
Fasting Blood 
Maximal 
Cardiopulmonary 
Exercise Test 
1RMb and 80% 
1RM Isotonic Leg 
Press and Bench 
Press 
Measures  
Survey 
Completionc 
IPAQd 
aDual Energy X-ray Absorptiometry; bRepetition Maximum; cBody Image questionnaires: Standardized quality of life (SF-36), Rosenberg Self Esteem Scale (RSES), 
Social Psychological Anxiety Scale (SPAS); dInternational Physical Assessment Questionnaire 
AHA – American Heart Association Recommended Diet (Phase I 1,400 kcals/d, Phase II 1,500 kcals/d at 55% C, 15% P, 30% F) and Exercise Program 
CC-I – Curves Complete I (Phase I 1,400 kcals/d, Phase II 1,500 kcals/d at 30% C, 45% P, 25% F) and Exercise Program
CC-II – Curves Complete II (Phase I 1,400 kcals/d, Phase II 1,500 kcals/d 20% C, 45% P, 35% F) and Exercise Program
Completionc 
IPAQd 
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Participant Eligibility 
This research protocol was reviewed and approved by the University Institutional 
Review Board before initiation. Participants were recruited through advertisements in local 
newspapers, campus-wide electronic communication, and ESNL webpage advertisement. 
Interested participants were asked to contact the laboratory for an initial telephone 
prescreening interview. General entrance criteria included being an apparently healthy 
woman between ages of 18 and 60 years with a BMI greater than 22.5 and no recent 
participation in a diet or exercise program. Participants were not allowed to participate in 
the study if the subjects reported the following at baseline: a recent weight change of (±3.2 
kg or  ±7 lb) within 3 months; any uncontrolled metabolic or cardiovascular disorder, 
including known electrolyte abnormalities, heart disease, arrhythmias, diabetes, or thyroid 
disease, or a history of hypertension, hepatorenal, musculoskeletal, autoimmune, or 
neurological disease; taking any weight loss supplements and/or ergogenic levels of 
nutritional supplements that affect muscle mass, anaerobic exercise capacity (i.e. creatine, 
ergogenic levels of caffeine, HMB, etc.), anabolic/catabolic hormone levels (i.e. 
androstenedione, DHEA), or weight loss (i.e. ephedra, thermogenics) within 3 months; a 
history of pregnancy or lactation within the past 12 months or intention to become pregnant 
during the next 12 months; participation in a regular exercise program within the past 3 
months; and any condition that is classified as high risk for cardiovascular disease according 
to American College of Sports Medicine criteria [135]. 
Familiarization Session 
Individuals who met initial entrance criteria were invited to attend a familiarization 
session in which the details of the study were explained. During this session, participants 
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received written and verbal explanation of the study protocol, design, equipment, and 
testing procedures that would be required throughout the study. A registered dietitian (RD) 
provided instruction on accurate dietary record completion and estimation of food portion 
sizes. Subjects meeting eligibility criteria were informed of the study requirements and 
signed an informed consent statement in compliance with the Human Subjects Guidelines of 
the Texas A&M University. Potential study participant’s height, weight, heart rate (HR), 
and blood pressure (BP) were attained and recorded on the general screening form upon 
completion of signing the informed consent. 
Medical Monitoring  
Potentially eligible participants filled out personal and medical history information 
at the familiarization session. Based on review of this information recorded on the general 
screening form, the study coordinator and on-site registered nurse (RN) determined whether 
the participant had met entry criteria to participate in the study. Information obtained during 
the familiarization session was reviewed by the research coordinator to determine if all 
requirements were met to participate in the study. Participants with a controlled medical 
condition were required to have their general practitioner approve and sign the physician’s 
consent form prior to participation in the study.  
Participant Selection 
Figure 3.1 outlines the stratification of study participants. A total of 267 individuals 
responded to the study recruitment advertisements. Of these, 241 met the entrance criteria 
and were requested to attend familiarization sessions. During these sessions, 44 eligible 
participants did not consent to participate. 197 women were cleared to participate in the 
study, completed baseline testing and were randomized to one of four groups as further 
explained in the study design below. Eighty-six women completed the 24-week study. The 
primary reasons participants dropped out of the study were due to time constraints, job and 
school related conflicts, transportation difficulties, and relocation. 
Testing Session Requirements 
Participants were instructed to refrain from exercise for 48 hours and fast for at least 
12 hours prior to reporting to the ESNL for testing sessions. The baseline testing session, 12 
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Figure 3.1 Participant Consort Diagram 
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week, and 24 week testing sessions were identical and consisted of dietary inventory 
review, weekly physical activity assessment [International Physical Activity Questionnaire 
(IPAQ)], anthropometric assessments (body mass, waist and hip circumference), resting 
energy expenditure, resting heart rate and systolic and diastolic blood pressure (BP), body 
composition analysis (DEXA), blood collection (metabolic panels, blood lipids, white and 
red blood cells), cardiorespiratory and muscular fitness assessments, psychosocial 
assessments [standardized quality of life (SF-36), Rosenberg Self Esteem Scale (RSES) and 
Social Physique Anxiety Scale (SPAS)]. Additional testing sessions occurred during the 
fourth, eighth, sixteenth, and twentieth weeks, and included all baseline measurements, 
excluding cardiorespiratory and muscular fitness assessments. 
Testing Session Protocols 
Metabolic Genotyping 
Subject’s buccal cheek swab samples were obtained in the ESNL at baseline (T1) to 
determine SNPs in obesity candidate genes FABP2 (rs1799883), PPARγ2 (rs1801282), 
ADRB3 (rs4994), ADRB2, (rs1042713) and (rs1042714), and sent to Interleukin Genetics 
(Waltham, MA) for metabolic profile analysis. Based on the SNPs of these genes, 
participants were matched according to their allelic profile to one of three metabolism 
efficiency categories: Fat Trimmer, Carb Reducer, or Better balancer according to Interleukin 
Genetics profiling algorithm.  
Dietary Inventories 
A registered dietitian instructed all subjects on precise documentation of food intake 
and accurate estimation of food portion size. Participants recorded all food and fluids 
consumed over a four-day period (including one weekend day) prior to each testing session. 
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Dietary inventories were reviewed with participants at each testing session to ensure 
accuracy, completeness, and legibility. Dietary information was then analyzed to determine 
the average caloric intake and macronutrient content using Food Processor 11.1.620 
database Nutrition Analysis Software Version 11.1.0 (ESHA Nutrition Research, Salem, 
OR, USA).  A registered dietitian review all analyzed dietary information. 
Weekly Physical Activity Assessment 
Physical activity patterns were quantified by assessing responses to the 7-day 
version of the International Physical Activity Questionnaire (IPAQ) [136-138]. This 
assessment tool evaluated the frequency and intensity of job-related physical activity; 
transportation physical activity; housework, house maintenance, and caring for family 
related physical activity; and recreation, sports, and leisure-time physical activity based on 
established metabolic equivalent (MET) levels for common activities. The IPAQ defined 
light physical activity as walking level intensities (3.3 METs), moderate physical activity as 
activities at a 4.0 MET level, and vigorous physical activity as activities at an 8.0 MET 
level. The IPAQ has been identified as a valid indicator of general changes in physical 
activity patterns [136-139]. 
Psychometric Assessments 
Psychological self-assessments were administered with Body Image Questionnaires 
comprised of three sections. Participants completed the SF-36 Health-Related Quality of life 
(QOL) inventory [140], Rosenburg Self-Esteem (RSE) [141], and the Social Physique 
Anxiety Scale (SPAS) [142]. The SF-36 quality of life questionnaire has been validated for 
the measurement of psychosocial dimensions that may be influenced by general 
improvement in health and/or weight loss [143, 144]. The SF 36 assessed a number of 
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physical and mental components including physical functioning  (i.e. the ability to perform 
most vigorous physical activities without limitation to health), role physical (i.e., ability to 
work and perform daily activities), bodily pain (i.e., limitations due to pain), general health 
(i.e., assessment of personal health), vitality (i.e., feeling of having energy), social 
functioning (i.e., ability to perform normal social activities), role emotion (i.e., problems 
with work or other daily activities), and mental health (state of feelings of peacefulness, 
happiness, and calm). The RSE measures self-esteem using a four-point Likert scale that 
ranges from one (strongly agree) to four (strongly disagree). Total scores range from 10 to 
40; the higher the score, the greater the correlation with higher self-esteem. The Social 
Physique Anxiety Scale (SPAS) consists of 12 questions that use a five-point Likert scale 
that ranges from one (not at all true) to five (extremely true). Totals range from 12 to 60, 
with an increase in social physique anxiety correlating with an increase in score. This 
portion of the questionnaire is used to evaluate the level of self- anxiety as a result of the 
degree to which she perceives that others are devaluing her body. Several studies have 
shown the internal consistency (r=0.90), predictive validity, and the construct validity [142, 
145-146].
Anthropometrics and Body Composition 
Height and total body weight were determined according to standard procedures 
using a Healthometer (Bridgeview, IL, USA) self-calibrating digital scale with a precision 
of ± 0.02 kg. Hip and waist circumference were measured using a Gulick tension 
standardized measuring tape per guidelines established by the American College of Sports 
Medicine [135].  
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Body Composition 
Bone mineral density (BMD) and body composition including fat mass and fat free 
mass, (excluding cranium) were measured using a Hologic Discovery W QDR series Dual 
Energy X-ray Absorptiometry (DEXA) system (Hologic Inc, Waltham, MA, USA) 
equipped with APEX software (APEX Corporation Software, Pittsburgh, PA, USA). Dual-
Energy X-Ray Absorptiometry has been validated as an accurate method for body 
composition assessment [147-150]. Participants were informed of any inherent risks that 
could present from radiation exposure and completed a radiation exposure questionnaire 
prior to all scans. Quality control (QC) calibration procedures were performed on a spine 
phantom (Discovery W-CALIBER Model DPA/QDR-1 anthropometric spine phantom) 
prior to each testing session. During the DEXA scan, participants lay supine with as 
minimal movement possible. A low dose of radiation scanned their entire body for 
approximately six minutes. The DEXA regions of the body (right arm, left arm, trunk, right 
leg, and left leg) were differentiated by density for determination of fat mass (FM), fat-free 
mass (FFM), lean mass (LM), and bone mineral density (BMD). Radiation exposure from 
DEXA for the whole body scan is approximately 1.5 mR per scan. Mean test-retest 
reliability studies performed with this Hologic system have yielded mean coefficients of 
variation for total bone mineral content and total fat free/soft tissue mass of 0.31% to 0.45% 
with a mean intra-class correlation of 0.985 [151]. 
Resting Energy Expenditure 
Resting energy expenditure assessments were conducted according to standard 
protocols using the Parvo Medics TrueMax 2400 Metabolic Measurement System 
(ParvoMedics, Inc, Sandy, UT, USA). This test was conducted in a fasted state with the 
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participants lying supine on an exam table. A clear metabolic canopy was placed over the 
subject’s head and neck, so that resting inspired oxygen (O2) and carbon dioxide (CO2) 
expired could be determined to predict resting energy expenditure via indirect calorimetry. 
The participants remained motionless yet awake for approximately 20 minutes. Metabolic 
measurements were recorded after the first 15 minutes during a five-minute period in which 
principle variables, such that VO2 mL/min, respiratory quotient (RQ), and kcal/D changed 
less than 5% [152]. Mean test-retest reliability studies on 14 participants from a previous 
study revealed test-retest correlations (r) of collected oxygen uptake range from 0.315 to 
0.901 (mean=0.638) and coefficient of variation range from 8.2% to 12.0% (mean=9.9%) 
with a mean intraclass coefficient of 0.942; p<0.001 [153]. 
Blood Collection and Analysis Procedures 
At least 10-hour fasted and whole blood and serum samples were collected using 
standard phlebotomy techniques. Approximately 20-24 mL venous blood were obtained 
prior to each testing session in BD Vacutainer EDTA and SST tubes for analysis (BD 
Franklin Lakes, NJ, USA). Whole blood samples were analyzed for complete blood counts 
with platelet differentials utilizing an Abbott Cell Dyn 3500 automated hematology analyzer 
(Abbott Laboratories, Abbott Park, IL, USA). Serum samples were obtained by 
centrifugation at 3500 rpm for 10 minutes in a Megafuge 40R (Unity Lab Services Thermo 
Fisher Scientific, Asheville, NC, USA). Samples were then aliquoted under a Class II A2 
Biological Safety Cabinet (Labconco, Kansas City, MO, USA) and stored at -80C in an 
Innova U725 Ultra-Low Temperature Freezer (USA Scientific, Ocala, FL, USA). Serum 
samples were analyzed for a metabolic panel of fasted triglyceride concentrations, CHL 
(total cholesterol, LDL, and HDL), and glucose concentrations using the COBAS® c-111 
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analyzer (Roche Diagnostics, Basel, Switzerland). Fasting insulin was assayed in duplicate 
via a commercially available Enzyme Linked Immunosorbent assay (ELISA) kit (No. 80-
INSHU-E10, ALPCO, Salem, NH) using a BioTek ELX-808 Ultramicroplate reader 
(BioTek Instruments Inc, Winooski, Vermont) at an optical density of 450 nm against a 
known standard curve using standard procedures with BioTek Gen5 Analysis software 
(BioTek Instruments Inc, Winooski, VT). The intra-assay coefficient of variation has been 
shown to range from 2.9% to 6.2%, with an inter-assay coefficient of variation range of 
5.4% to 8.6% (ALPCO, Salem, NH). The homeostasis Model Assessment for insulin 
resistance (HOMA-IR) was calculated as the product of fasting insulin times fasting glucose 
expressed in standard units divided by 405 [154]. 
Cardiopulmonary Efficiency 
Resting heart rate was determined by palpitation of the radial artery and resting 
blood pressure was assessed in the supine position utilizing a mercurial sphygmomanometer 
(American Diagnostic Corporation, model #AD-720, Hauppuage, NY, USA) using standard 
procedures [135].  
Maximal Cardiopulmonary Exercise Test 
Cardiopulmonary exercise tests were performed at baseline, 12 weeks, and 24 weeks 
by ESNL graduate research assistants in accordance to Graded Exercise Test (GXT) standard 
procedures adherent the American College of Sports Medicine (ACSM) Guidelines for 
Exercise Testing and Prescription [135]. Maximal Cardiopulmonary exercise tests (peak 
VO2) were performed utilizing the Bruce treadmill protocol [155]. Standard test termination 
criteria were utilized to assess maximal volitional fatigue [135]. The Nasiff Cardio Card 
electrocardiograph (Nasiff Associates, Inc, Central Square, NY, USA) was used to assess 
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cardiac rhythm and function using a standard 12-lead arrangement [135]. Electrode sites 
were cleansed with a sterile alcohol pad in a circular motion. Once the site was dry, 
electrodes were placed on the 4th intercostal space at the right sternal border (V1), the 4th 
intercostal space at the left sternal border (V2), equidistant between V2 and V4 (V3), the 5th 
intercostal space at the mid- clavicular line (V4), the 5th intercostal space at the anterior 
axillary line (V5), the 5th intercostal space at the midaxillary line (V6), the right 
subclavicular fossa (RA), the left subclavicular fossa (LA), the right abdomen (RL) and left 
abdomen (LL) line. While the subject was in a supine position, resting blood pressure, heart 
rate, and the 12-lead ECG were obtained. The 12-lead ECG was reviewed to ensure that no 
contraindications for exercise testing were present based on the ACSM guidelines [135]. The 
participant was then asked to stand and step onto the treadmill. Standing blood pressure, 
heart rate, and a 12-lead ECG was obtained and reviewed for accuracy and assessment of 
potential abnormalities. A sterile mouthpiece, attached to a head harness, was then secured 
on the participant and a nose clip placed on their nose. Expired gases were collected using a 
ParvoMedics 2400 TrueMax Metabolic Measurement System (ParvoMedics Inc, Sandy, UT, 
USA). Gas and flow sensors were calibrated before testing and were found to be within 3% 
of previous calibration points. Once the participant was ready to begin the GXT protocol, the 
participant was instructed to straddle the treadmill with both legs while the treadmill was 
turned on to a speed of 2.0 mph and at a 0% grade. The participant then stepped onto the 
tread belt while holding the handrails with both hands. Once comfortable walking on the 
treadmill, the participant was instructed to let go of the handrail and begin walking freely. 
49 
Table 3.3 Treadmill Bruce Protocol 
Stage Speed (MPH) Grade (%) Duration (minutes) METS 
Warm-up 2.0 0 2 3.3 
1 1.7 10 3 4.5 
2 2.5 12 3 6.5 
3 3.4 14 3 9.7 
4 4.2 16 3 13.5 
5 5.0 18 3 17 
6 5.5 20 3 20.5 
Participants performed the Bruce treadmill protocol [155] following the speeds and 
grades delineated in Table 3.3. Heart rate (HR), ECG tracings, and expired gases were 
monitored continuously throughout the GXT. Blood pressure (BP) and ratings of perceived 
exertion (RPE) were obtained toward the end of each 3-minute stage. Subjects were 
encouraged to exercise to their maximum aerobic capacity unless they experienced clinical 
signs that required test termination as stated by the ACSM Guidelines for Exercise Testing 
and Prescription [135]. Symptoms may include a decline in systolic blood pressure > 10 
mmHg from baseline, angina, ataxia, dizziness, syncope, cyanosis, nausea, dangerous 
dysrhythmias (ventricular tachycardia, supraventricular tachycardia, new atrial fibrillation, or 
A-V block, increasing or multi-form premature ventricular contractions), an excessive rise in
systolic blood pressure over 250 mmHg or diastolic over 115 mmHg, chronotropic 
impairment, technical difficulties of the ECG or metabolic monitoring systems, or other signs 
or symptoms requiring termination of the test. Voluntary maximal exertion was indicated by 
re-grabbing the treadmill handrails. The test was then immediately terminated and the 
participant continued an active recovery period for three minutes followed by a three-minute 
seated recovery period. Heart rate, blood pressure, and ECG were obtained during both 
recovery stages. Table 3.3 describes the Bruce Protocol for stress test methods. 
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Isotonic Strength Tests 
Absolute strength measured by 1RM was determined using an isotonic Olympic 
bench press (Nebula Fitness, Versailles, OH, USA) and a standard hip sled/leg press (Nebula 
Fitness, Versailles, OH, USA) in accordance with the guidelines provided by the National 
Strength and Conditioning Association (NSCA). Hand positioning on the bench press and 
foot and seat position on the hip sled/leg press were standardized between trials. Muscular 
endurance was determined by performing repetitions to failure at 80% of 1RM load on the 
bench press and leg press using standard lifting techniques and testing criteria [156]. All 
exercise testing sessions were conducted using standardized ACSM guidelines and NSCA 
procedures, and were supervised by certified laboratory assistants experienced in strength 
exercise testing.  
To test for upper body strength and endurance, participants performed a one 
repetition maximum (1 RM) test on the isotonic bench press and the Nebula Fitness 
(Versailles, OH, USA) Olympic Power Station (#1005). Participants performed a warm-up (2 
sets of 10 repetitions at approximately 50% of anticipated 1RM) followed by progressive lifts 
starting at an estimated 70% of the anticipated 1RM. A 2-minute rest interval was required 
between each set. Load was increased by 5-10 lbs until the 1RM was reached. Once the 1RM 
was attained, subjects performed as many repetitions as possible with 80% of their 1 RM 
effort. Following the upper body strength testing, lower body strength testing was performed. 
Participants rested for 5 minutes, then performed a warm up of 10 repetitions at 
approximately 50% of anticipated maximum on the Nebula 45° Leg press. Participants then 
performed 5 successive lifts on the leg press at their estimated 70% of 1RM and increased by 
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25-45 lbs. until 1RM was attained. Once the 1RM was achieved, subjects performed
continuous repetitions to failure 80% of their 1 RM effort. Test-retest reliability of 
performing these strength tests on resistance-trained subjects in the ESNL have yielded low 
mean coefficients of variation and high reliability for the bench press (1.9%, intraclass 
r=0.94) and leg press/hip sled (0.7%, intraclass r=0.91) [157]. 
Statistical Methods 
Only subjects who completed the 24-week trial were included in the T x D (Time x 
Diet) analyses. Subjects who completed T2 but did finish the study were included in the T x 
M (Time x Match) weight loss analysis to ascertain whether N-size may influence results. 
Missing data were replaced using the last observed value method or by replacing missing 
values with the series mean method. Baseline demographic data were analyzed by one-way 
Analysis of Variance (ANOVA). Data were normally distributed. Study data were analyzed 
by Multivariate Analysis of Variance (MANOVA) with repeated measures (IBM SPSS 
Statistics version 22.0.0.0, SPSS Inc, Chicago, IL.). Overall MANOVA effects were 
examined using Wilks’ Lambda time and group x time p-levels as well as MANOVA 
univariate group effects. Greenhouse-Geisser univariate tests of within of within-subjects 
time and group x time effects and between-subjects univariate group effects were reported 
for each variable analyzed within the MANOVA model. In some instances, repeated 
measures ANOVA was run on variables not included in a MANOVA design with univariate 
group, time, and group x time interaction effect reported. Variables with baseline differences 
determined by ANOVA were analyzed using analysis of covariance (ANCOVA). Delta 
values or percent difference were calculated and analyzed on select variables by ANOVA for 
repeated measures to assess changes from baseline values. Delta values were calculated by 
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subtracting the first testing session (T1) from later testing sessions (T7-T1). Percent 
differences were calculated by subtracting T1 from the later testing session, then performing 
division by T1 followed by multiplication by 100 [(T7-T1)/T1•100]. Confidence Intervals 
(CI) were reported for significant differences in group mean deltas. The homeostatic model
assessment of insulin resistance (HOMA-IR) was calculated by (!"#$%&'	)	*+&#",+-./ ) when 
glucose is expressed in mass units (mg/dL) and insulin is expressed in µIU/ml. 
Data were considered statistically significant when the probability of type I error was 
0.05 or less and statistical trends were considered when the probability error ranged between 
>0.05 to <0.10. If a significant group, treatment and/or interaction alpha level was observed,
Tukey’s Least Significant Difference (LSD) post hoc analyses were performed to determine 
where significance was obtained. Power analysis of previous studies using similar designs 
and subject populations indicated that a sample size of 30 subjects per group yielded high 
power (>0.8) for delta values of 0.75 to 1.25 for weight and fat loss. Data are presented as 
means ± standard deviation (SD), and group means ± standard error of the mean (SEM). 
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CHAPTER IV 
RESULTS 
Results 
Eighty-six apparently healthy but sedentary women (age 37.5±13.4 years; height 
163.7±6.9 cm; weight 82.0±16.8 kg; BMI 30.5±5.9 kg/m2; body fat 31.4±9.7 kg) completed 
the 24-week study (CTRL n=20, AHA n=21, CC-I n=21, CC-II n=24) with greater than 
75% compliance. No significant differences were observed among diet groups in baseline 
age, height, weight, BMI, or fat mass as determined by ANOVA in Table 4.1. 
Table 4.1 Baseline Demographics for Control (CTRL), AHA, CC-I, and CC-II 
Diet Group 
(n=86) 
CTRL 
(n=20) 
AHA 
(n=21) 
CC-I
(n=21)
CC-II
(n=24) p-value
Age (years) 37.5±13.4 37.3±14.1 38.7±12.9 38.1±13.2 36.3±14.1 0.94 
Height (cm) 163.7±6.9 165.5±7.6 162.6±6.3 162.9±5.4 163.9±7.9 0.52 
Weight (kg) 82.0±16.8 78.9±17.4 81.2±17.2 82.9±17.5 84.4±15.7 0.75 
BMIa (kg/m²) 30.5±5.9 28.7±5.5 30.6±5.9 31.2±6.3 31.1±6.1 0.51 
31.4±9.7 28.0±9.9 32.0.1±9.8 32.1±10.1 33.2±9.7 0.34 
bAll data is presented as means ± SD atc baseline. Significance level was set at 0.05. 
aBody mass Index, 
Dual Energy X-ray Absorptiometry, Fat Mass 
In the AHA group, 7 were true matches to this diet as fat trimmers or better 
balancers, and 12 were false matches as carb reducers. In the CC-I group, 7 were true 
matches to this diet as fat trimmers or better balancers, and 12 were false matches as carb 
reducers. In the CC-II group, 13 were true matches as carb reducers and better balancers, 
and 8 were false matches as fat trimmers. No significant differences were observed between 
genetic matches in baseline age, height, weight, BMI, or fat mass as determined by 
ANOVA in Table 4.2. 
DXAb FMc 
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Table 4.2 Baseline Demographics for True and False Genetic Matched Participants 
Matched AHA (n=19) CC-I (n=19) CC-II (n=21) p-value
(n=59) 
True 
(n=7) 
False 
(n=12) 
True 
(n=12) 
False 
(n=7) 
True 
(n=13) 
False 
(n=8) 
Age (years) 38.2±13.3 39.0±13.6 40.5±12.9 36.6±11.4 39.3±18.0 37.6±15.2 36.4±12.5 0.79 
Height (cm) 163.3±6.8 161.5±4.9 162.9±7.0 162.1±6.7 164.6±2.4 165.2±6.6 162.8±10.9 0.69 
Weight (kg) 83.6±16.8 82.2±14.8 82.1±19.9 87.9±20.9 75.1±9.8 88.9±15.0 79.5±14.3 0.83 
BMIa (kg/m²) 31.2±6.2 31.4±4.3 30.9±7.1 33.3±7.2 27.7±3.3 31.7±5.6 30.5±7.5 0.99 
DXAb FMc 
kg) 
32.8±9.8 32.9±8.0 32.3±11.5 34.6±11.9 28.0±6.5 35.1±9.0 31.1±9.7 0.88 
All data is presented as means ± SD at baseline. Significance level was set at 0.05. aBody mass Index, bDual Energy X-ray 
Absorptiometry, cFat Mass 
Dietary Intake 
Table 4.3 presents percent changes in nutritional intake at 0, 4, 8, 12, 16, 20, and 24 weeks of 
program participation. Complete food records were measured by a self-reported, four-day 
diet log on all participants completing the study. MANOVA were run on absolute energy 
intake (kcals/d), and macronutrient intake expressed as a percentage of total calories 
consumed per day. MANOVA results of dietary intake data revealed an overall Wilks’ Lambda 
time effect (p<0.001), time by diet (p=0.001) and diet group (D) differences among diet groups 
(p<0.001). MANOVA univariate analysis revealed significant time effects for protein and 
carbohydrate intake and total kilocalories/day consumed (p<0.001), but a time effect did not 
occur in fat intake (p=0.43). Time by diet (T x D) interaction was significant for protein and 
carbohydrate consumption (p<0.001), and T x D did not have an effect on fat intake (p=0.21) 
or total kilocalories/day consumed (p=0.22). However, post hoc tests showed total 
kilocalories/day were significantly higher in the CTRL diet compared to AHA (371.8 kcal/d; 
95% CI, 199.0, 544.6), CC-I (436.3 kcal/d; 95% CI, 263.4, 609.1), and CC-II (345.8 kcal/d; 
95% CI, 178.7, 512.9). There was a greater increase in protein intake as a percentage of 
macronutrient distribution measured at 0 and 24 weeks in the CC-I (+6.22±1.58%, p<0.001)
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Table 4.3 Absolute % of Nutritional Intake at 0, 4, 8, 12, 16, 20, and 24 weeks 
Week 
Variable Diet 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
PRO (%) CTRL 16.6±5.2 17.3±3.9 17.8±4.2  20.5±6.2* 18.5±3.6  19.3±3.4† 18.9±3.7 18.43±1.1 T < 0.001 
AHA 17.7±4.5 17.22±2.7 18.9±5.3 17.9±3.1 18.9±3.6 19.2±3.9 19.0±4.0 18.40±1.1 D <0.001 
CC-I 20.7±6.4ad 26.63±6.9*ab 26.8±6.6*abd 28.5±7.6*abd 26.8±6.3*abd 27.1±6.9*abd 26.9±8.2*ab 26.20±1.1ab TxD < 0.001 
CC-II 17.2±4.0 29.74±11.1*ab 31.4±9.9*abc 33.8±9.3*abc 30.9±9.5*abc 31.5±7.8*abc 30.8±8.3*ab 29.33±1.0ab
Mean 18.0±5.2 23.0±9.0* 24.0±8.9* 25.5±9.5* 24.1±8.3* 24.5±7.9* 24.2±8.3* 
CHO (%) CTRL 42.5±10.1 43.3±8.4bcd 44.4±9.4cd 42.5±9.3bcd 42.4±9.4bcd 43.2±9.2bcd 43.0±11.0d 43.05±1.6bcd T < 0.001 
AHA 46.6±9.5 51.4±7.2*acd 48.3±8.5cd 50.4±7.5acd 50.8±8.5acd 50.3±9.0acd 51.1±9.0†acd 49.83±1.6acd D < 0.001 
CC-I 43.9±10.7 35.8±12.8* 36.3±10.5* 36.0±6.6* 36.5±8.4* 36.1±8.9* 38.2±8.4* 37.5±1.6 TxD < 0.001 
CC-II 46.0±6.5 34.8±10.5* 34.4±10.9* 31.0±11.7* 31.5±9.4* 31.2±8.6* 32.4±10.4* 34.48±1.5 
Mean 44.8±9.2 41.1±11.9* 40.61±11.3* 39.7±11.6* 40.0±11.4* 39.9±11.4* 40.8±11.9*
FAT (%) CTRL 39.9±7.7 38.9±6.1 36.5±7.3 36.9±7.4 37.2±9.2 36.7±8.6 37.5±10.8 37.65±1.3 T = 0.43 
AHA 34.7±7.6 31.1±6.4 32.7±5.5 31.3±7.9 30.3±7.8 30.7±9.0 30.2±10.0 31.58±1.3acd D = 0.013 
CC-I 34.5±8.8 35.4±8.5 35.4±8.3 34.6±8.1 36.4±8.5 36.4±8.9 34.5±7.3 35.32±1.3 TxD = 0.22 
CC-II 36.6±7.4 35.3±8.1 33.5±7.4 35.1±7.6 37.5±7.0 37.3±7.3 39.1±11.2 36.33±1.3 
Mean 36.4±8.0 35.2±7.7 34.5±7.2 34.5±7.9 35.4±8.5 35.4±8.7 35.5±10.4 
Energy 
Intake 
(kcal/d) 
CTRL 2075±558 1988±491 1773±521 1911±623 1755±414 1784±515 1630±387 1845±61bcd T < 0.001 
AHA 1743±571 1431±254 1400±283 1496±584 1386±213 1430±274 1428±368 1474±61 D < 0.001 
CC-I 1480±531 1480±349 1361±213 1324±295 1347±274 1420±278 1450±390 1409±61 TxD = 0.22 
CC-II 1721±485 1410±339 1343±317 1489±334 1466±329 1525±400 1544±518 1500±57 
Mean 1754±566 1571±432* 14645±387* 1553±515* 1488±349* 1539±401* 1514±424* 
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Table 4.3 Absolute % of Nutritional Intake at 0, 4, 8, 12, 16, 20, and 24 weeks (cont) 
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). N=86; CTRL (n=20), AHA (n=21), CC-I (n=21), CC-II 
(n=23). GG= Greenhouse-Geisser. T= Time effect. D= Diet effect. T x D= Time x Diet effect. *= significant time effect from baseline p<0.05 (post hoc LSD). †= a trend 
from baseline p > 0.05 and p < 0.1 (post hoc LSD). All letter superscripts represent significance from post hoc LSD. a= significantly different than CTRL (p < 0.05). b= 
significantly different than AHA (p < 0.05). c= significantly different than CC-I (p < 0.05). d= significantly different than CC-II (p < 0.05).  
Table 4.4 Relative Nutritional Intake (g/kg) at 0, 4, 8, 12, 16, 20, and 24 weeks 
Week 
Variable Diet 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
PRO 
(g/kg/d) CTRL 1.11±0.42d 1.11±0.36 1.0±0.35 1.22±0.4 1.03±0.28 1.09±0.33 0.99±0.3 1.1±0.1 T < 0.001 
AHA 0.97±0.41 0.8±0.23†acd 0.86±0.27 0.86±0.29acd 0.87±0.22 0.92±0.26 0.9±0.29 0.9±0.1cd D < 0.001 
CC-I 0.93±0.32 1.27±0.43* 1.17±0.29*b 1.22±0.4* 1.18±0.33*bd 1.26±0.37*bd 1.27±0.45*b 1.2±0.1 TxD < 0.001 
CC-II 0.86±0.27 1.3±0.61* 1.31±0.56*ab 1.58±0.58*abc 1.43±0.54*abc 1.52±0.6*abc 1.5±0.66*ab 1.4±0.1ab
Mean 0.96±0.36 1.12±0.47* 1.09±0.43* 1.23±0.5* 1.14±0.42* 1.21±0.47* 1.18±0.51* 
CHO 
(g/kg/d) CTRL 2.89±1.07c 2.78±0.81cd 2.53±0.97*cd 2.75±1.44cd 2.42±0.9*cd 2.51±0.99cd 2.34±1.09*cd 2.6±0.2cd T < 0.001 
AHA 2.55±1.02 2.38±0.61cd 2.24±0.76cd 2.42±0.74cd 2.39±0.8cd 2.46±0.83cd 2.52±1.01cd 2.4±0.2cd D < 0.001 
CC-I 2.05±0.87 1.75±0.98†ab 1.64±0.64*ab 1.58±0.51*ab 1.65±0.58*ab 1.7±0.5†ab 1.81±0.55ab 1.7±0.2 TxD = 0.025 
CC-II 2.37±0.81 1.48±0.57*ab 1.43±0.67*ab 1.45±0.62*ab 1.44±0.51*ab 1.49±0.57*ab 1.53±0.6*ab 1.6±0.1 
Mean 2.46±0.97 2.08±0.9* 1.94±0.88* 2.03±1.04* 1.96±0.83* 2.02±0.86* 2.03±0.92* 
FAT 
(g/kg/d) CTRL 1.23±0.52bcd 1.14±0.42bcd 0.93±0.37*bcd 1.05±0.48†bcd 0.94±0.32*bc 0.93±0.29*b 0.86±0.26* 1.0±0.1bcd T = 0.001 
AHA 0.87±0.36 0.65±0.23* 0.69±0.27* 0.7±0.34† 0.63±0.22* 0.69±0.33† 0.68±0.32† 0.7±0.1 D < 0.001 
CC-I 0.74±0.38 0.76±0.27 0.71±0.25 0.67±0.24 0.72±0.22 0.78±0.31 0.75±0.26 0.7±0.1 TxD = 0.015 
CC-II 0.86±0.43 0.68±0.25* 0.63±0.25* 0.73±0.25 0.79±0.27 0.81±0.33 0.85±0.37 0.8±0.1 
Mean 0.92±0.46 0.8±0.35* 0.74±0.31* 0.78±0.36* 0.77±0.28* 0.8±0.32* 0.79±0.31* 
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Table 4.4 Relative Nutritional Intake (g/kg) at 0, 4, 8, 12, 16, 20, and 24 weeks (cont) 
Week 
Variable Diet 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
Energy 
Intake 
(kcal/kg/d) 
CTRL 27.5±9.2bcd 26.0±7.2bcd 22.9±7.5*bcd 25.3±10.3bcd 22.7±6.0*bcd 23.0±6.5*cd 21.2±5.6* 24.1±1.1 bcd T = 0.001 
AHA 22.1±7.6 18.7±4.7* 18.6±5.8* 19.5±6.1 18.7±5.0* 19.7±6.1 19.8±6.9 19.6±1.1 D = 0.001 
CC-I 18.8±6.8 19.3±6.0 17.9±4.5 17.5±4.7 17.8±4.1 19.0±4.6 19.2±4.9 18.5±1.1 TxD = 0.05 
CC-II 20.7±7.2 17.3±4.7* 16.7±4.9* 18.7±4.5 18.6±4.8 19.3±5.8 19.6±6.4 18.7±1.0 
Mean 22.2±8.2 20.2±6.6* 18.9±6.1* 20.2±7.3* 19.4±5.3* 20.2±5.9* 19.9±5.9*
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). N=86; CTRL (n=20), AHA (n=21), CC-I (n=21), CC-II 
(n=23). GG= Greenhouse-Geisser. T= Time effect. D= Diet effect. T x D= Time x Diet effect.). # = significant diet effect p<0.05 (univariate). *= significant time effect 
from baseline p<0.05 (post hoc LSD). †= a trend from baseline p > 0.05 and p < 0.1 (post hoc LSD). All letter superscripts represent significance from post hoc LSD. a= 
significantly different than CTRL (p < 0.05). b= significantly different than AHA (p < 0.05). c= significantly different than CC-I (p < 0.05). d= significantly different than 
CC-II (p < 0.05).
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and CC-II diet groups (+13.6±1.47%, p<0.001). Percentage of protein and carbohydrate 
intake from 0 to 24 weeks did not change among the CTRL and AHA group participants. 
Carbohydrate intake did decrease in CC-I (-5.72±2.65%, p=0.03) and CC-II (-13.6±2.47%, 
p<0.001) as a percentage of total caloric consumption from 0 to 24 weeks. Table 4.4 presents 
relative changes in nutritional intake expressed in grams per kilogram of body weight. As 
consistent with the findings from the percentage distribution MANOVA, an overall time, 
time x diet, and diet group effects were observed (Wilks’ Lambda, p<0.001). Post hoc tests 
reveal an overall increased protein intake in CC-I (0.30 g/kg/d; 95% CI, 0.10, 0.50) and CC-
II (0.47 g/kg/d; 95% CI, 0.28, 0.67) compared to AHA. Concomitantly, an overall decreased 
carbohydrate intake was observed in CC-I vs CTRL (-0.86 g/kg/d; 95% CI, -1.27, -0.45) and 
AHA (-0.68 g/kg/d; 95% CI, -1.09, -0.27). The overall decrease in carbohydrate intake was 
significant in CC-II compared to CTRL (-1.01 g/kg/d; 95% CI, -1.4, -0.61) and AHA (-0.82 
g/kg/d; 95% CI, -1.22, -0.43). 
Physical Activity Level 
Physical activity was assessed at 0, 4, 8, 12, 16, 20, and 24 weeks by the International 
Physical Activity Questionnaire (IPAQ), and validated for consistency with a seven-day 
exercise log report. MANOVA revealed an overall significance for time (Wilks’ Lambda 
p<0.001) and time x diet (Wilks’ Lambda p=0.007) effect for physical activity. An overall 
effect was observed for differences among diet groups (p<0.001). As detailed in Table 4.5 
below, analyses of low level PA (MET=3.3) revealed the CTRL group had no significant 
difference in low PA from baseline (p=0.38) after 24-weeks, whereas all diet groups 
increased PA (AHA 1208±201; CC-I 1203±201; CC-II 899±188 MET-min/wk, p<0.001 
respectively). Analyses of moderate PA (MET=4) revealed no significant difference from 
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baseline for CTRL (p=0.84), and significant increases for the diet groups after 24-weeks 
(AHA 728±136; CC-I 703±136; CC-II 480±128 MET-min/wk, p<0.001 respectively). 
Analyses of vigorous activity (MET=8) from 0 to 24 weeks revealed similar results in terms 
of significant changes from baseline for the diet groups (AHA 2173±212; CC-I 1467±212; 
CC-II 1667±199 MET-min/wk; p<0.001 respectively). CTRL had no deviation from baseline
(p=0.81). AHA was significantly higher than CC-I (783±276 MET-min/wk; p=0.006) and 
CC-II (548±267 MET-min/wk; p=0.043) at 24 weeks. Figure 4.1 demonstrates the delta
changes for total METs 24 weeks. CTRL had no change from baseline (p=0.74), and all diet 
groups significantly increased overall physical activity (AHA 4109±292; CC-I 3373±292; 
CC-II; 3046±273 MET-min/wk, p<0.001 respectively). Additionally, AHA was significantly
higher than CTRL (p<0.001), and higher than CC-I (1046±447 MET-min/wk; 95% CI 156.9, 
1935.7) and CC-II (1095±433 MET-min/wk; 95% CI 233.9, 1956.3). No differences were 
observed in PA due to job-related activity. An overall trend was observed among all groups 
for increased PA as a form of transportation, i.e. walking or bicycling (p=0.07). An increase 
in PA was observed in the CTRL group compared to AHA (p=0.012), CC-I (p=0.007), and 
CC-II (p=0.001) at week 12 due to household based activities; however, no TxD interaction
was observed, as household PA significantly increased for all groups after 24 weeks 
(p=0.02). From 0 through 24-weeks, the diet groups significantly increased recreational 
activity (AHA 928±120, CC-I 931±120, CC-II 1070±112 MET-min/wk; p<0.001 
respectively). All groups were significantly higher than CTRL after 24 weeks (AHA 
524±174 MET-min/wk; 95% CI 178.3, 869.8; CC-I 496±174; 95% CI 150.4, 841.9; CC-II 
624±168; 95% CI 288.5, 958.6). Time spent sitting (MET=1) during vehicle transport, at 
work, or at home was decreased among all four groups (p<0.001). Although an overall diet 
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group difference was observed (p=0.001), no significant interaction occurred, as the CTRL 
had consistently higher mean mins/wk spent seated in comparison to the diet treatment 
groups (AHA, CC-I and CC-II).  
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Figure	4.1	Diet	∆	Physical	Activity	Level	(MET).	Data	present	mean	(95%	CI)	from	baseline	for	total	self-assessed	physical	
activity	levels	over	24	weeks.	Control	(CTRL),	American	Heart	Association	(AHA),	Curves	Complete-I	(CC-I),	and	Curves	
Complete-II	(CC-II);	N=86.	LSD	post	hoc	symbols	p<0.05:	a=	significant	difference	from	CTRL,	b=	significant	difference	from	
AHA,	c=	significant	difference	from	CC-I,	d=	significant	difference	from	CC-II.			CI:	Confidence	Interval.	MET:	Metabolic	
Equivalent	of	Task.	
61 
Table 4.5 Diet Changes in Physical Activity at 0, 4, 8, 12, 16, 20, and 24 weeks 
Week 
Variable Diet 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
Low PA (MET-
min/wk) CTRL 1029±1140c 798±941bcd 732±697bcd 867±1097bcd 986±1016bd 785±980bcd 848±1001bcd 864±130bcd T < 0.001 
AHA 830±707 1944±1027*ac 1799±739*a 2252±1142*ac 1925±876*a 1910±1123*a 2038±891*a 1814±127ac D < 0.001 
CC-I 524±597a 1399±737*ab 1674±826*a 1611±700*ab 1506±739* 1476±750*a 1727±652*a 1417±127ab TxD<0.001 
CC-II 654±359 1779±728*a 1665±860*a 1776±793*a 1702±834*a 1622±898*a 1553±817*a 1536±119a
Mean 753±750 1498±952* 1483±879* 1641±1049* 1542±919* 1462±1013* 1550±935* 
Mod PA (MET-
min/wk) CTRL 884±706 532±713 725±658 1001±1289 851±1407 680±842 913±1097 798±130 T < 0.001 
AHA 349±333 574±651 777±871 872±639 1043±867 736±551 1077±650 775±126 D = 0.89 
CC-I 423±371 744±728 713±654 991±533 1232±955 885±394 1126±730 873±126 TxD = 0.12 
CC-II 534±1136 541±394 669±502 829±438 813±365 805±462 1015±634 744±118 
Mean 543±748 596±623 719±668 919±769* 980±948* 779±574* 1033±780* 
High PA (MET-
min/wk) CTRL 365±983 423±538bcd 342±469bcd 375±476bcd 327±621bcd 310±709bcd 418±683bcd 365±124bcd T < 0.001 
AHA 144±191 1432±956*a 1321±866*a 1945±1041*ad 1964±1012*a 2381±1586*ad 2317±917*acd 1643±121acd D < 0.001  
CC-I 67±162 1088±709*a 1097±527*a 1625±784*a 1490±968*a 1745±1281*a 1533±897*ab 1235±121*ab TxD<0.001 
CC-II 103±203 1233±690*a 1160±697*a 1413±728*ab 1653±1105*a 1589±1254*ab 1769±1015*ab 1274±113ab
Mean 165±505 1058±816* 993±748* 1353±962* 1381±1117* 1523±1434* 1531±1109* 
Total PA 
(MET-min/wk) CTRL 2279±1962bcd 1752±1442bcd 1798±1121bcd 2243±2227bcd 2164±1983bcd 1775±1414bcd 2178±1748bcd 2027±242bcd T < 0.001 
AHA 1323±835a 3949±1571*a 3897±1442*a 5069±1580*ad 4932±1599*a 5027±2239*a 5432±1254*acd 4233±236acd D < 0.001 
CC-I 1013±685a 3231±1309*a 3484±1002*a 4227±1326*a 4228±1689*a 4106±1684*a 4386±1488*ab 3525±236ab TxD<0.001 
CC-II 1291±1297a 3553±850*a 3494±1167*a 4019±935*ab 4169±1448*a 4016±1740*a 4337±1291*ab 3554±221ab
Mean 1461±1345 3152±1520* 3196±1415* 3913±1833* 3903±1934* 3764±2118* 4114±1835* 
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 Table 4.5 Diet Changes in Physical Activity at 0, 4, 8, 12, 16, 20, and 24 weeks (cont) 
Week 
Variable Diet 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
Job PA (MET-
min/wk) CTRL 794±1396 540±746 492±717 589±1104 791±1264 478±825 578±1009 609±204 T = 0.56 
AHA 686±1419 504±1010 669±1202 609±972 593±946 695±1079 633±1231 627±199 D = 0.99 
CC-I 574±694 633±1120 500±648 530±798 528±950 522±741 454±634 534±199 TxD = 0.84 
CC-II 692±1394 562±1200 581±1025 737±1072 501±828 523±927 601±1022 599±187 
Mean 685±1247 560±1026 562±918 621±981 597±989 554±891 567±983 
Transport PA 
(MET-min/wk) CTRL 413±564 247±485 246±260 317±368 433±583 261±327 337±448 322±72 T = 0.068 
AHA 354±352 241±364 305±363 319±399 456±448 312±275 430±456 345±71 D = 0.94 
CC-I 252±340 371±425 306±392 269±435 330±374 245±317 384±486 308±71 TxD = 0.67 
CC-II 232±349 252±421 312±484 221±404 317±412 310±491 350±441 285±66 
Mean 309±407 277±421 294±383 279±398 381±454 283±363 375±451 
House PA 
(MET-min/wk) CTRL 987±1214 971±760 659±548 1410±1809 1278±1629 713±713 817±867 976±91bcd T = 0.02 ‡ 
AHA 687±378 662±317 450±317 665±351 714±362 646±251 612±294 634±89 D = 0.014 # 
CC-I 578±381 586±344 502±367 610±379 819±436 659±339 632±327 627±89 TxD = 0.16 
CC-II 657±393 636±312 617±322 481±312 729±398 635±297 635±348 627±83
Mean 722±680 708±478 558±397* 774±975 875±874* 662±425 671±503 
Rec PA (MET-
min/wk) CTRL 219±276 446±486bcd 451±438bcd 720±581*bcd 413±486 bcd 570±712* bcd 573±516*bcd 485±50bcd T < 0.001 
AHA 168±84 1232±557* 1188±607* 1207±519* 1215±592* 1378±681* 1097±648* 1069±49a D < 0.001 
CC-I 138±95 1198±504* 1196±529* 1198±661* 1126±683* 1159±505* 1069±565* 1012±49a TxD = 0.015 
CC-II 127±87 1358±596* 1124±540* 1228±575* 1267±595* 1171±603* 1196±490* 1067±46
Mean 161±155 1076±638* 1001±606* 1098±612* 1021±676* 1079±684* 996±597* 
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Table 4.6 Diet Changes in Body Composition, Anthropometric Measurements, and REE at 0, 4, 8, 12, 16, 20, and 24 weeks 
Week 
Variable Diet 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
Total 
Mass (kg) CTRL 78.9±17.4 79.2±17.2 79.7±17.8 79.5±18.0 79.7±18.0 79.7±18.2 79.8 ± 18.0 79.5±3.7 T < 0.001 
AHA 81.2±17.2 79.6±16.9* 78.8±16.7* 78.1±16.9* 77.8±16.8* 77.1±16.9* 76.6 ± 17.2* 78.5±3.6 D = 0.94 
CC-I 82.9±17.5 81.3±16.9* 80.4±16.6* 79.5±16.0* 78.9±15.9* 78.4±15.5* 78.3 ± 15.6* 79.9±3.6 TxD < 0.001 
CC-II 84.4±15.8 82.7±15.4* 81.8±15.5* 80.8±15.6* 80.5±16.6* 80.4±15.9* 80.1 ± 16.1* 81.5±3.4 
Mean 82.0±16.7 80.8±16.3*  80.3±16.3*  79.5±16.3*  79.3±16.6*  78.9±16.4*  78.73 ± 16.5*  
Fat mass 
(kg) CTRL 28.1±9.9 28.2±9.4 28.1±9.8 28.8±10.1 28.5±10.4 28.6±10.3 28.6±10.2 28.4±2.2 T < 0.001 
AHA 32.0±9.8 30.6±9.5* 29.7±9.3* 29.1±9.7* 28.7±9.9* 28.2±10.2* 27.8±9.9* 29.5±2.1 D = 0.928 
CC-I 32.1±10.1 31.0±9.4* 30.2±9.8* 29.4±9.4* 28.7±9.6* 28.2±9.6* 27.9±9.7* 29.6±2.1 TxD < 0.001 
CC-II 33.2±9.2 31.9±9.2* 30.7±9.1* 29.7±9.4* 29.1±9.6* 29.2±10.1* 28.7±9.8* 30.4±1.9 
Mean 31.4±9.8 30.5±9.3*  29.8±9.4*  29.2±9.5*  28.8±9.7*  28.56±9.9*  28.3±9.7*  
 Table 4.5 Diet Changes in Physical Activity at 0, 4, 8, 12, 16, 20, and 24 weeks (cont) 
Week 
Variable Diet 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
Seated min/wk: 
(MET-min/wk) CTRL 3469±1126 3425±1071 3136±650 3249±842 3214±773 3093±995 3433±1152 3288±76 T < 0.001 
AHA 3236±506 2670±583 2819±514 2863±558 2851±568 2857±526 2872±480 2881±74 D = 0.001 
CC-I 3308±406 2925±552 2661±510 3051±594 2815±546 2999±425 3030±536 2970±74 TxD=0.16 
CC-II 3453±314 2984±572 2723±576 2679±497 3101±574 3018±504 2684±568 2949±69
Mean 3368±647 2995±753* 2827±583* 2947±654* 2996±630* 2991±636* 2989±763* 
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). N=86; CTRL (n=20), AHA (n=21), CC-I (n=21), CC-II 
(n=23). GG= Greenhouse-Geisser. T= Time effect. D= Diet effect. T x D= Time x Diet effect. *= significant time effect from baseline p<0.05 (post hoc LSD). †= a trend 
from baseline p > 0.05 and p < 0.1 (post hoc LSD). All letter superscripts represent significance from post hoc LSD. a= significantly different than CTRL (p < 0.05). b= 
significantly different than AHA (p < 0.05). c= significantly different than CC-I (p < 0.05). d= significantly different than CC-II (p < 0.05). PA: Physical Activity. MET: 
Metabolic Equivalent of Task.  
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Table 4.6 Diet Changes in Body Composition, Anthropometric Measurements, and REE at 0, 4, 8, 12, 16, 20, and 24 weeks (cont) 
Week 
Variable Diet 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
Fat free 
mass (kg) CTRL 44.8±8.1 44.8±8.5 45.2±8.6 44.9±8.4 44.9±8.3 44.9±8.6 44.7±8.6 44.9±1.6 T = 0.61 
AHA 43.0±7.3 43.0±7.4 42.9±7.4 42.8±7.3 43.0±6.9 42.9±6.9 42.9±7.1 42.9±1.6 D = 0.771 
CC-I 44.4±7.6 44.1±7.9 44.6±7.7 44.3±7.7 43.8±7.1 44.0±6.7 44.3±6.7 44.2±1.6 TxD = 0.89 
CC-II 44.9±7.0 44.8±6.3 45.1±6.6 45.2±6.4 44.9±6.4 45.0±6.2 45.3±6.3 45.0±1.5 
Mean 44.3±7.4 44.2±7.4 44.5±7.5 44.3±7.4 44.2±7.1 44.2±7.0 44.3±7.1 
BF % CTRL 37.8±6.0bd 37.9±5.8bc 37.8±6.0 37.7±6.4 38.1±6.4 38.0±6.2 38.1±6.7 37.9±1.2 T < 0.001 
AHA 42.2±4.3a 41.2±4.3*a 40.5±4.1* 39.8±4.6* 39.2±5.3* 38.9±5.6* 38.7±5.2* 40.1±1.2 D = 0.57 
CC-I 40.7±5.1 40.3±5.2 38.8±5.5* 38.3±5.9* 37.6±5.9* 37.1±6.4* 36.6±6.2* 38.5±1.2 TxD < 0.001 
CC-II 42.0±4.0a 40.9±4.6*a 39.8±4.5* 38.7±5.3* 38.2±5.5* 38.1±6.2* 37.6±5.9* 39.3±1.1 
Mean 40.8±5.1 40.1±5.1* 39.3±5.1* 38.6±5.5* 38.3±5.7* 38.0±6.0* 37.7±5.9* 
Waist 
(cm) CTRL 85.9±12.3 85.7±11.2 85.7±12.3 87.0±11.1 87.0±11.6 85.7±12.3 85.9±12.3 86.1±2.8 T < 0.001 
AHA 88.7±16.2 87.2±14.9† 87.1±16.0 † 86.2±14.0* 85.2±15.1* 86.3±15.4* 84.3±14.7* 86.4±2.7 D = 0.91 
CC-I 91.4±14.0 89.0±13.9* 88.4±12.3* 88.4±11.7* 88.2±10.1* 86.9±11.8* 87.3±12.1* 88.5±2.7 TxD = 0.006 
CC-II 88.7±11.7 87.3±11.0† 86.2±10.9* 85.5±11.0* 84.7±11.2* 85.3±11.9* 85.1±12.1* 86.1±2.5 
Mean 88.7±13.5 87.3±12.6* 86.9±12.7* 86.7±11.8* 86.2±12.0* 86.0±12.7* 85.7±12.6* 
Hip (cm) CTRL 109.6±12.3 110.1±11.5 110.7±12.0 110.9±11.5 110.7±12.1 110.2±12.2 110.8±12.4 110.4±2.5 T < 0.001 
AHA 112.4±13.9 110.7±12.5* 110.1±13.6* 110.3±12.5* 109.2±11.8* 109.5±13.3* 108.1±13.2* 110.0±2.5 D = 0.92 
CC-I 114.1±10.6 112.1±10.7* 110.5±11.1* 109.1±10.6* 110.1±10.4* 109.7±10.3* 109.2±10.8* 110.7±2.5 TxD < 0.001 
CC-II 115.3±10.0 113.5±10.4* 111.2±11.3* 111.5±9.7* 111.2±10.4* 111.2±10.8* 111.3±11.5* 112.2±2.3 
Mean 113.0±11.7 111.7±11.1* 110.7±11.8* 110.5±10.9* 110.3±11.0* 110.2±11.5* 109.9±11.8* 
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Table 4.6 Diet Changes in Body Composition, Anthropometric Measurements, and REE at 0, 4, 8, 12, 16, 20, and 24 weeks (cont) 
Week 
Variable Diet 0 4 8 12 16 20 24 Group (SEM) GG p-value 
REE 
(kcal/d) CTRL 1375±243 1369±266 1411±253 1423±273 1438±259 1361±311 1388±272 1395±55 T = 0.43 
AHA 1394±321 1410±260 1323±294† 1351±285 1338±254 1398±258 1329±323 1364±53 D = 0.90 
CC-I 1418±286 1371±227 1417±269 1407±302 1378±288 1315±325 1361±323 1381±53 TxD = 0.16 
CC-II 1476±219 1445±259 1426±238 1383±282 1399±288 1387±316 1406±224 1418±50 
Mean 1419±267 1401±251 1395±263 1390±282 1388±271 1366±300 1372±283 
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). N=86; CTRL (n=20), AHA (n=21), CC-I (n=21), CC-II 
(n=23). GG= Greenhouse-Geisser. T= Time effect. D= Diet effect. T x D= Time x Diet effect. *= significant time effect from baseline p<0.05 (post hoc LSD). †= a trend 
from baseline p > 0.05 and p < 0.1 (post hoc LSD). All letter superscripts represent significance from post hoc LSD. a= significantly different than CTRL (p < 0.05). b= 
significantly different than AHA (p < 0.05). c= significantly different than CC-I (p < 0.05). d= significantly different than CC-II (p < 0.05).BF%= Body Fat Percentage, 
REE= Resting Energy Expenditure. 
Body Composition, Anthropometry and Resting Energy Expenditure 
Table 4.6 presents changes in body composition, anthropometry, and resting 
energy expenditure data observed at 0, 4, 8, 12, 16, 20, and 24 weeks of program 
participation. MANOVA of body composition data revealed overall time (Wilks’ Lambda 
p<0.001) and time by diet interaction (p=0.05) with no differences observed among groups 
(p=0.86). Univariate analysis revealed a significant time by diet interaction for differences in 
total body weight (CTRL 0.77±00.98, AHA -4.60±0.96, CC-I -4.59±0.96, CC-II -4.34±0.89 
kg; p<0.001) fat mass (CTRL 0.53±0.79, AHA -4.23±0.78, CC-I -4.16±0.78, CC-II -4.51
±0.73 kg; p<0.001), and body fat percentage (CTRL 0.33±0.78, AHA -3.55±0.76, CC-I -4.15
±0.76, CC-II -4.44±0.72; p<0.001), as all diet treatment groups experienced a decrease in 
these variables, while the control group had no deviation from baseline. Post hoc comparisons 
of weight loss from 0 to 24 weeks show the diet treatment groups AHA, CC-I, and CC-II 
demonstrated a significant decrease from CTRL. At 24 weeks, total differences in weight loss 
compared to the control group was AHA (-5.38kg; 95% CI, -8.10, -2.65), CC-I (-5.37kg; 95% 
CI, -8.09, -2.65), and CC-II (-5.11kg; 95% CI, -7.75, -2.47). No differences in weight loss 
among the diet treatment groups were observed at any time point as demonstrated in Figure 
4.2. 
Time by diet changes in fat mass are parallel with total weight loss results as shown 
in Figure 4.3. At 24 weeks, fat mass decreased in the diets AHA (-4.76kg; 95% CI, -2.54, -
6.97), CC-I (-4.69kg; 95% CI, -2.47, -6.9), and CC-II (-5.04kg; 95% CI, -2.89, -7.12) as 
compared to participants assigned to CTRL. Figure 4.4 demonstrates no significant 
differences in fat-free mass were observed within or among diet groups.  
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Figure	4.2	Diet	∆	Body	Weight.	Data	present	mean	(95%	CI)	from	baseline	for	total	body	weight	over	24	weeks.	Control	
(CTRL),	American	Heart	Association	(AHA),	Curves	Complete-I	(CC-I),	and	Curves	Complete-II	(CC-II);	N=86.	CI:	Confidence	
Interval.	LSD	post	hoc	symbols	p<0.05:	b=	significant	difference	from	AHA,	c=	significant	difference	from	CC-I,	d=	significant	
difference	from	CC-II.	
Figure	4.3	Diet	∆	Fat	Mass.	Data	present	mean	(95%	CI)	from	baseline	for	fat	mass	over	24	weeks.	Control	(CTRL),	
American	Heart	Association	(AHA),	Curves	Complete-I	(CC-I),	and	Curves	Complete-II	(CC-II);	N=86.	CI:	Confidence	Interval.	LSD	
post	hoc	symbols	p<0.05:	b=	significant	difference	from	AHA,	c=	significant	difference	from	CC-I,	d=	significant	difference	from	
CC-II.
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Figure	4.5	Diet	∆	Body	Fat	Percentage.	Data	present	mean	(95%	CI)	from	baseline	for	body	fat	percentage	over	24	
weeks.	Control	(CTRL),	American	Heart	Association	(AHA),	Curves	Complete-I	(CC-I),	and	Curves	Complete-II	(CC-II);	N=86.	CI:	
Confidence	Interval.	LSD	post	hoc	symbols	p<0.05:	b=	significant	difference	from	AHA,	c=	significant	difference	from	CC-I,	
d=	significant	difference	from	CC-II.	
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Figure	4.4	Diet	∆	Fat	Free	Mass.	Data	present	mean	(95%	CI)	from	baseline	for	fat-free	mass	over	24	weeks.	Control	
(CTRL),	American	Heart	Association	(AHA),	Curves	Complete-I	(CC-I),	and	Curves	Complete-II	(CC-II);	N=86.	CI:	Confidence	
Interval.		
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At 24 weeks, total differences in body fat percentage compared to the control group was 
AHA (-4. 5%; 95% CI, -7.5, -1.4), CC-I (-5.37; 95% CI, -2.65, -8.09), and CC-II (-5.11; 95% 
CI, -2.47, -7.75) (p<0.001) as seen in Figure 4.5. 
MANOVA of anthropometric data revealed overall time (Wilks’ Lambda p<0.001) 
and time by diet effects (Wilks’ Lambda p=0.01). Univariate analysis revealed significant 
time x diet group effects for waist and hip measurements. After 24 weeks, all diet 
treatment groups had decreased waist circumference (CTRL 0.00±0.43; AHA -1.72±0.42, 
CC-I -1.58±0.42, CC-II -1.43±0.39 cm; p=0.006) and hip circumference (CTRL
0.50±0.40; AHA -1.69±0.39, CC-I -1.94±0.39, CC-II -1.58±0.36 cm; p<0.001), whereas 
the CTRL experienced no change from baseline. No differences were observed among diet 
groups for waist (p=0.908) and hip (p=0.922) measurements. Although all diet groups 
reduced both waist and hip circumference, the waist-hip ratio (WHR) remained consistent 
among all four diet groups as seen in Figure 4.6.  
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Figure	4.6	Diet	∆	Waist-Hip	Ratio.	Data	present	mean	(95%	CI)	from	baseline	for	waist-hip	ratio	over	24	weeks.	Control	
(CTRL),	American	Heart	Association	(AHA),	Curves	Complete-I	(CC-I),	and	Curves	Complete-II	(CC-II);	N=86.	CI:	Confidence	
Interval.		
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Table 4.7 Diet Changes in Fitness Measurements at 0, 12, and 24 weeks 
Week 
Variable Diet 0 12 24 
Group 
(SEM) GG p-value 
GXT Time 
(secs) CTRL 547.2±111.5 545.6±98.1 555±93.5 549.3±21.3 T < 0.001 
AHA 521.5±90.7 554.7±88.6* 569.3±97.2* 548.5±20.8 D = 0.96 
CC-I 514.6±106.3 547.0±124.2* 574.2±114.9* 545.3±20.8 TxD = 0.02 
CC-II 524.4±85.9 573.5±79.1* 580.1±104.5* 559.3±19.4 
Mean 526.6±97.5 555.9±97.2* 570.2±101.7* 
VO2max 
(ml/kg) CTRL 26.0±6.1 25.4±5.9 25.92±6.1 25.8±1.3 T < 0.001 
AHA 23.6±4.3 27.2±5.0* 27.7±4.9* 26.2±1.2 D = 0.996 
CC-I 24.1±6.0 26.4±7.1* 27.6±7.7* 26.0±1.2 TxD < 0.001 
CC-II 23.5±4.7 26.4±5.9* 27.9±5.7* 25.9±1.1 
Mean 24.3±5.3 26.4±6.0* 27.3±6.1* 
Bench Press 
1RM (kg) CTRL 32.3±9 34.3±9.9 33.8±10 33.4±1.9 T < 0.001 
AHA 33.1±7.9 34.7±8.8 35.7±7.9 34.5±1.9 D = 0.86 
CC-I 32.1±10.7 35.4±11.2 36.8±10.4 34.8±1.9 TxD = 0.24 
CC-II 33.2±7.8 35.7±8.1 38.2±7.7 35.7±1.8 
Mean 32.7±8.7 35.1±9.4* 36.2±9* 
Bench Press 
Reps*kg 
(80%) CTRL 210.2±101.1 184.1±73.4 203.8±77.8 199.4±17.0 T =0.078 
AHA 211.3±83.6 221.1±92.6 249.2±110.5 227.2±16.6 D = 0.42 
CC-I 222.5±90.1 229.7±98.2 248.3±125.5 233.5±16.6 TxD = 0.36 
CC-II 196.4±98.6 253.4±127.6 252.5±111.6 234.1±15.5 
Mean 209.6±92.5 223.6±102.6 237.2±110.6* 
Leg Press 
1RM (kg) CTRL 188.0±61.4 212.3±68.6 225.3±79.2 208.5±14.9 T < 0.001 
AHA 201.9±7 218.1±71.9 227.3±75.1 215.7±14.6 D = 0.32 
CC-I 187.6±62.7 207.3±72.2 224.2±73.5 206.3±14.6 TxD = 0.96 
CC-II 221±68.0 239.5±68.5 258.0±78.9 239.5±13.6 
Mean 200.5±67.1 220.1±70.2* 234.6±76.8* 
Leg Press 
Reps*kg 
(80%) CTRL 2237.4±1072.3 2520.7±1211.0 2279.6±905.3 2345.9±277.8 T =0.011 
AHA 2309.2±1361.7 2893.5±1972.5 2888.1±2220.4 2696.9±271.1 D = 0.156 
CC-I 1970.8±1239.5 2155.8±1015.7 2561.2±1736.0 2229.3±271.1 TxD = 0.58 
CC-II 2720.9±1315.8 2909.8±1702.7 3383.1±1535.3 3004.6±253.6 
Mean 2324.8±1265.1 2631.2±1538.9* 2804.9±1692.9* 
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). N=86; 
CTRL (n=20), AHA (n=21), CC-I (n=21), CC-II (n=23). GG= Greenhouse-Geisser. T= Time effect. D= Diet effect. T x 
D= Time x Diet effect. # = significant diet effect p<0.05 (univariate). *= significant time effect from baseline p<0.05 
(post hoc LSD). †= a trend from baseline p > 0.05 and p < 0.1 (post hoc LSD). GXT: Graded Exercise Test. Series 
mean was used to replace 0.9% missing values (n=5) for 516 data points. 
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Repeated Measures ANOVA revealed no significant time (Wilks’ Lambda p=0.43) or time 
x diet group interaction (p=0.16) in resting energy expenditure (REE), and no differences 
were observed among diet groups (p=0.90).  
Cardiorespiratory Fitness, Muscular Strength and Endurance 
Table 4.7 presents changes in fitness variables data observed at 0, 12, and 24 weeks 
of program participation. MANOVA of cardiovascular fitness reveals an overall time effect 
and time x diet interaction (Wilks’ Lambda p<0.001) with no difference among diet groups 
(p=0.78). Univariate analysis showed a significant time x diet interaction for peak oxygen 
uptake (VO2max) in ml/kg/min (CTRL -0.035±0.77; AHA 4.17±0.72; CC-I 3.48±0.72; CC-II 
4.40±0.67, p<0.001) and maximal time to exhaustion in seconds (CTRL 7.80±12.99; AHA 
47.86±12.67; CC-I 59.59±12.68; CC-II 55.69±11.86, p=0.02), as all diet treatment groups 
experienced a significant increase in VO2max and treadmill time to voluntary exhaustion in 
comparison to the control group.  
MANOVA of isotonic maximal strength and endurance measurements reveal an 
overall time effect but no time x diet interaction (Wilks’ Lambda p<0.001 and p=0.54, 
respectively). No differences among diet groups were observed (p=0.56). Although all 
treatment diet groups (AHA, CC-I, CC-II) significantly improved bench press 1RM at 24 
weeks and the CTRL did not, a lack of time x diet interaction (p=0.24) was observed as the 
CTRL demonstrated a slight increase in strength from baseline for a significant time effect 
(CTRL 3.25±2.77; AHA 5.71±2.70; CC-I 10.24±2.70; CC-II 10.83±2.52 kg, p<0.001). A 
similar pattern was observed in leg press 1RM. All diet treatment and control subjects 
significantly improved strength from baseline (CTRL 82.25±21.45; AHA 55.81±20.94; CC-I  
80.71±20.94; CC-II 81.25±19.59 kg, p<0.001) without a time x diet interaction (p=0.96).  
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Table 4.8 Diet Changes in Fasting Blood Lipids at 0, 12, and 24 weeks 
  Week   
Variable Diet 0 12 24 
Group 
(SEM) GG p-value 
Total CHL 
(mg/dl) CTRL 200±53.5 193.5±40.1 202.4±47.1 198.6±8.3 T < 0.001  
  AHA 203.4±39.9 181.5±41.1* 198.7±38.8 194.5±8.1 D = 0.55 
  CC-I 202.9±50.4 190.0±48.0† 179.2±34.2* 190.7±8.1 TxD = 0.08 
  CC-II 195.2±41.6 174.7±32.7* 178.9±36.4* 182.9±7.6   
  Mean 200.2±45.8 184.5±40.6* 189.3±40.0*    
LDL-c 
(mg/dl) CTRL 125.1±51.1 115.2±41.5 129.1±43.9 123.1±10.7 T < 0.001  
  AHA 136.14±43.7 142.34±51.3 129.3±41.1 135.94±10.4 D = 0.034  
  CC-I 185.2±71.7ab 190.1±72.9abd 124.9±59.1* 166.8±10.4ab TxD < 0.001 
  CC-II 159.32±67.6 142.44±59.4* 120.5±41.8* 140.76±9.8   
  Mean 152.0±63.2 147.7±62.6 125.7±46.2*    
HDL-c 
(mg/dl) CTRL 56.4±19.9 52.0±15.8 58.2±17.8 55.5±3.6 T =0.001  
  AHA 63.42±18.9 54.16±16.9 61.0±17.6 59.5±3.5 D = 0.87 
  CC-I 61.43±19.4 56.75±18.9 57.7±16.6 58.6±3.5 TxD = 0.45 
  CC-II 58.02±18.5 55.46±14.8 60.8±18.5 58.11±3.3   
  Mean 59.78±19.0 54.65±16.4* 59.52±17.4    
Triglycerides 
(mg/dl) CTRL 123.9±64.4 129.6±64.9 117.5±56.9 123.7±11.6 T = 0.001  
  AHA 107.8±52.3 96.1±45.9 98.8±47.4 100.9±11.3 D = 0.21 
  CC-I 151.1±75.2 138.1±62.7† 107.8±50.6* 132.3±11.3 TxD = 0.023 
  CC-II 119.9±59.2 103.6±48.7* 107.3±52.1 110.3±10.6   
  Mean 125.5±64.0 116.2±57.5* 107.7±51.3*    
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). N=86; 
CTRL (n=20), AHA (n=21), CC-I (n=21), CC-II (n=23). CHL= Cholesterol. LDL-c= Low density lipoprotein 
cholesterol. HDL-c= High density lipoprotein cholesterol. GG= Greenhouse-Geisser. T= Time effect. D= Diet effect. T x 
D= Time x Diet effect. # = significant diet effect p<0.05 (univariate). *= significant time effect from baseline p<0.05 
(post hoc LSD). †= a trend from baseline p > 0.05 and p < 0.1 (post hoc LSD). All letter superscripts represent 
significance from post hoc LSD. a= significantly different than CTRL (p < 0.05). b= significantly different than AHA (p 
< 0.05). c= significantly different than CC-I (p < 0.05). d= significantly different than CC-II (p < 0.05). To convert 
mg/dL cholesterol to mmol/L, multiply mg/dL by 0.026. To convert mmol/L cholesterol to mg/dL, multiply mmol/L by 
38.6. Cholesterol of 194 mg/dl=5.04 mmol/L. To convert mg/dL triglyceride to mmol/L, multiply mg/dL by 0.0113. To 
convert mmol/L triglyceride to mg/dL, multiply mmol/L by 88.6. Triglyceride of 137 mg/dl=1.55 mmol/L.  
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Biochemical Markers of Health by Diet 
Table 4.8 presents changes in blood lipid biomarkers of health observed at 0, 12, 
and 24 weeks. MANOVA of these measurements reveal an overall time effect (Wilks’ 
Lambda p<0.001) and time x diet interaction (Wilks’ Lambda p<0.001). Univariate 
analysis showed a significant interaction for low density lipoproteins (CTRL 3.92±12.21; 
AHA -6.80±11.92; CC-I -60.25±11.92; CC-II -38.80±11.15 mg/dL, p<0.001), as all diet 
treatment groups lowered LDL concentration, while the control group experienced a slight 
increase. A significant time x diet interaction was observed in triglyceride concentration 
(CTRL -6.41±10.58; AHA -8.99±10.32; CC-I -43.26±10.32; CC-II -12.64±9.66 mg/dL, 
p=0.023). All diet treatment groups experienced a greater decrease in serum triglycerides 
versus the CTRL. A time x diet trend was observed in total cholesterol (CTRL 2.37±7.28; 
AHA -4.63±7.11; CC-I -23.85±7.11; CC-II -16.18±6.65 mg/dL, p=0.081), as all diet 
treatment groups experienced a decrease in total cholesterol concentration in comparison 
to the CTRL. 
 Table 4.9 presents changes in fasting glucose concentration observed at 0,12, and 
24 weeks, and insulin and HOMA-IR at 0 and 24 weeks of program participation. No 
overall Wilks’ Lambda significant time effects were observed for glucose (p=0.70); 
however, time by diet analysis revealed significant differences (p=0.001) as only CC-I 
reduced glucose concentration (p=0.001), and the CTRL saw an increase in glucose 
(p=0.041) from baseline to 24 weeks (CTRL 8.78±4.24; AHA 5.53±4.14; CC-I -
14.85±4.14; CC-II -3.58±3.87 mg/dL, p<0.001). A time effect was observed for insulin 
concentrations in µIU/ml at 24 weeks (p<0.001) without a significant time x diet 
interaction (p=0.224). Although all diet groups (including CTRL) reduced insulin levels 
from baseline to 24 weeks (CTRL -0.87±0.79; AHA -2.09±0.77; CC-I -1.11±0.77; CC-II -
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2.84±0.72 p<0.001), only AHA and CC-II observed a significant decrease (p=0.008 and 
p<0.001, respectively) so no time x diet interaction occurred. A significant overall Wilks’ 
Lambda time effect was observed (p=0.037), with no time x diet effect (p=0.18) nor 
differences among groups (p=0.58). Although all diet treatment groups reduced HOMA-
IR, only CC-II had a significant decrease from baseline (-0.78±0.31, p=0.02). These 
observations partially accept Hypothesis 1. 
Table 4.9 Diet Changes in Fasting Glucose, Insulin and HOMA-IR at 0, 12, and 24 weeks 
Week 
Variable Diet 0 12 24 
Group 
(SEM) GG p-value 
Fasted Glucose 
(mg/dl) CTRL 95.4±17.9 100.1±34.3b 104.2±44.5*c 99.9±3.8 T =0.70 
AHA 87.7±9.8cd 86.2±12.2 93.2±9.1 89.0±3.7 D = 0.24 
CC-I 102.0±15.4 98.4±17.6 † 87.2±7.6* 95.3±3.7 TxD < 0.001 
CC-II 96.6±8.0 93.38±9.3 93.0±12.7 94.3±3.5 
Mean 95.5±13.9 94.4±20.5 94.2±23.6 
Fasted Insulin 
(µIU/ml) CTRL 11.7±7.3 - 10.9±6.9 11.3±1.4 T < 0.001 
AHA 10.6±5.8 - 8.5±6.8 9.5±1.4 D = 0.85 
CC-I 10.8±8.1 - 9.7±7.2 10.3±1.4 TxD = 0.22 
CC-II 11.6±5.9 - 8.7±4.7 10.2±1.3 
Mean 11.2±6.7 - 9.4±6.4*
HOMA - IR CTRL 2.9±2.5 - 3.2±4.5 3.1±0.5 T = 0.037 
AHA 2.4±1.5 - 2.02±1.8 2.2±0.5 D = 0.58 
CC-I 2.6±2.1 - 2.1±1.5 2.4±0.5 TxD = 0.18 
CC-II 2.8±1.4 - 2.01±1.1 2.4±0.4 
Mean 2.7±1.9 - 2.3±2.6*
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). 
N=86; CTRL (n=20), AHA (n=21), CC-I (n=21), CC-II (n=23). GG= Greenhouse-Geisser. T= Time effect. D= Diet 
effect. T x D= Time x Diet effect. *= significant time effect from baseline p<0.05 (post hoc LSD). †= a trend from 
baseline p > 0.05 and p < 0.1 (post hoc LSD). All letter superscripts represent significance from post hoc LSD. a= 
significantly different than CTRL (p < 0.05). b= significantly different than AHA (p < 0.05). c= significantly different 
than CC-I (p < 0.05). d= significantly different than CC-II (p < 0.05). To convert mg/dL glucose to mmol/L, multiply 
mg/dL by 0.0555. To convert mmol/L to mg/dL, multiply mmol/L by 18.0. Glucose of 99 mg/dl=5.5 mmol/L To 
convert µIU/ml insulin to pmol/L, multiply µIU/ml by 6.945. To convert pmol/L to µIU/ml, multiply pmol/L by 
0.144.  Insulin of 13.8 µIU/ml=95.8 pmol/L. Homeostatic Model Assessment of Insulin Resistance. T=time alpha 
level. D=diet group alpha level. T x D=time by diet group interaction alpha level. 
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Table 4.10 Changes in Psychological Self-assessments at 0, 4, 8, 12, 16, 20, and 24 weeks 
Week 
Variable Diet 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
Quality of 
Life (SF36) CTRL 125.6±13.2 130.5±13.4 133.1±1.8 134.4±11.2 132.9±13.6 133.2±13.9 134.7±13.1 132.1±2.1 T < 0.001 
AHA 125.9±12.4 132.9±9.6 135.9±8.4 136.1±7.9 136.8±8.8 137.05±10.3 136.4±13.5 134.4±2.0 D = 0.17 
CC-I 129.5±11.0 138.2±7.8 136.0±14.3 139.1±9.0 139.3±8.1 141.5±6.8 141.5±7.3 137.9±2.0 TxD = 0.79 
CC-II 131.0±16.1 136.4±9.9 139.1±7.4 135.4±23.6 140.2±9.0 138.6±10.9 139.8±11.8 137.2±1.9 
Mean 128.1±13.4 134.6±10.6* 136.2±11.2* 136.3±14.7* 137.5±10.2* 137.7±10.9* 138.2±11.8* 
Social 
Anxiety CTRL 33.5±8.6 34.9±7.4 36.0±8.0 36.5±8.5 34.2±9.2 36.6±9.9 36.0±8.8 35.4±1.9 T < 0.001 
AHA 30.3±8.1 32.3±8.5 34.4±8.5 34.0±9.3 34.8±9.6 34.9±8.6 35.1±9.0 33.7±1.9 D = 0.86 
CC-I 31.4±8.7 32.7±9.1 35.7±7.6 35.4±7.6 37.7±8.4 37.3±8.7 37.7±8.2 35.4±1.9 TxD = 0.20 
CC-II 33.0±9.5 34.3±10.1 35.3±10.9 36.3±11.7 36.7±10.9 36.9±11.3 37.8±12.4 35.8±1.8 
Mean 32.1±8.7 33.6±8.8* 35.4±8.8* 35.6±9.4* 35.9±9.5* 36.4±9.6* 36.7±9.8* 
Self-esteem 
(Rosenberg) CTRL 30.9±3.5 31.1±3.8 31.3±3.5 30.9±4.1 32.2±4.4 31.6±4.4 32.1±4.2 31.4±0.7 T =0.003  
AHA 29.6±3.6 29.8±2.8 29.7±3.2 31.0±3.5 30.2±3.8 31.1±3.5 31.1±3.0 30.4±0.7cd D = 0.031 
CC-I 32.8±3.5 32.7±2.9 33.1±3.2 32.8±3.7 33.2±3.5 33.4±3.4 33.9±3.4 33.1±0.7 TxD = 0.41 
CC-II 31.8±4.1 32.8±3.4 32.5±3.6 32.2±3.8 31.7±5.5 33.6±3.4 32.8±3.9 32.5±0.7 
Mean 31.3±3.8 31.6±3.4 31.7±3.6 31.7±3.8 31.8±4.5 32.5±3.8* 32.4±3.9* 
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). N=86; CTRL (n=20), AHA (n=21), CC-I (n=21), CC-II 
(n=23). GG= Greenhouse-Geisser. T= Time effect. D= Diet effect. T x D= Time x Diet effect. †= a trend from baseline p > 0.05 and p < 0.1 (post hoc LSD). All letter 
superscripts represent significance from post hoc LSD. a= significantly different than CTRL (p < 0.05). b= significantly different than AHA (p < 0.05). c= significantly 
different than CC-I (p < 0.05). d= significantly different than CC-II (p < 0.05). 
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Psychosocial 
Table 4.10 presents changes in psychosocial assessments observed at 0, 4, 8, 12, 
16, 20, and 24 weeks of program participation as determined by the SF36 Quality of Life 
(QOL), Social Physique Anxiety Scale (SPAS), and Rosenberg Self-Esteem Scale (RSES) 
Questionnaire inventories. MANOVA of SF36 QOL indices revealed an overall time 
effect (Wilks’ Lambda, p<0.001), and no significant time x diet interaction (p=0.34). All 
diet groups, including CTRL, reported an improvement in QOL (CTRL 9.1±2.69; AHA 
10.57±2.63; CC-I 12.03±2.63; CC-II 8.75±2.46, p=0.798). Univariate ANOVA of 
physique dependent social anxiety, measured by the Social Physique Anxiety Scale 
(SPAS), demonstrated that all four diet groups improved feelings of self-confidence and 
reduced social anxiety, although no time by diet interaction was observed (CTRL 
2.5±1.36; AHA 4.81±1.33; CC-I6.24±1.33; CC-II 4.75±1.24, p=0.20). No time by diet 
interaction were observed in measures of self-esteem as reported by the Rosenberg Self-
Esteem Scale (RSES) (CTRL 1.12 ±0.72; AHA 1.42±0.70; CC-I 1.05±0.70; CC-II 
1.08±0.66, p=0.41). However, all diet groups, including CTRL, improved perceptions of 
self-esteem as an overall time effect was observed (p<0.001). 
Genetic Match Results 
Body Composition 
Table 4.11 demonstrates changes in body composition variables as dependent on 
genetically matched to diet (M) only in the treatment groups (N=59), excluding CTRL. 
Participants were retrospectively analyzed as a true or false match to their assigned diet 
group based on their metabolic profile variants of FABP2 (Ala54Thr), ADRB-2 
(Gln27Glu and Arg16Gly), ADRB-3 (Trp64Arg), and PPARγ2 (Pro12Ala). MANOVA of 
body composition variables measured by DEXA (body weight, fat mass, fat-free mass, and 
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body fat percentage) revealed an overall time effect (Wilks’ Lambda p<0.001), but not a 
time x match interaction (p=0.99). Figure 4.7 shows that both false and true matches 
reduced a significant amount of body weight (kg) over 24 weeks, with no time by match 
interaction (F -4.25±0.93; T -4.63±0.85 kg, p=0.61). A trend was observed in true and 
false match differences in absolute values (kg) of body weight (p=0.099) and fat-free mass 
(p=0.07), as the true matches tended to be consistently higher than false matches. 
However, the relative percentage of body fat remained unchanged (p=0.97) between both 
groups. Figure 4.8 shows that both false and true matches lost a significant amount of fat 
mass (F -4.26±0.78; T -4.18±0.72 kg, p<0.001). Neither false or true genetic matches 
experienced a change from baseline in fat free mass (p=0.79) at 24-weeks. However, 
Figure 4.9 demonstrates a significant difference in delta values (p=0.032) between 
matches at 16 weeks. The falsely matched participants slightly gained FFM (0.28 kg; 95% 
CI, -0.35, 0.91) whereas the true matched participants lost FFM (-0.62 kg; 95% CI, -1.19, 
-0.06). Figure 4.10 illustrates the decrease in body fat percentage (F -4.45±0.75; T -
4.24±0.69%, p<0.001) with no time x match interactions (p=0.86 and p=0.79, 
respectively). 
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Table 4.11 Genetic Changes in Body Composition and Anthropometric Measurements at 0, 4, 8, 12, 16, 20, and 24 weeks 
Week 
Variable 
Genetic 
Match 0 4 8 12 16 20 24 
Group 
(SEM) GG p-value 
Total Mass 
(kg) FALSE 79.5±15.9 77.9±15.7 77.5±15.4 76.6±15.2 76.3±15.1 75.6±15.1 75.3±15.2 77.0±3.1 T < 0.001 
TRUE 87.1±17.1 85.4±16.5 84.2±16.8 83.3±16.9 83.2±17.3 82.7±16.8 82.4±17.0 84.0±2.8 M = 0.099 
Mean 83.6±16.8 82.0±16.4* 81.2±16.4* 80.3±16.3* 80.0±16.6* 79.4±16.3* 79.2±16.5* TxM = 0.61 
Fat mass 
(kg) FALSE 30.8±9.7 29.6±9.4 28.7±8.9 27.9±9.2 27.3±9.2 27.0±9.6 26.5±8.8 28.3±1.8 T < 0.001 
TRUE 34.4±9.8 33.2±9.4 31.9±9.6 31.3±9.9 30.8±10.3 30.6±10.4 30.3±10.7 31.8±1.7 M = 0.16 
Mean 32.8±9.9 31.6±9.5* 30.4±9.4* 29.8±9.6* 29.2±9.9* 28.9±10.1* 28.6±9.9* TxM = 0.86 
Fat free 
mass (kg) FALSE 42.5±6.3 42.5±6.5 42.8±6.8 42.79±6.4 42.8±6.3 42.63±6.02 42.8±6.5 41.1±1.3 T = 0.79 
TRUE 46.2±7.5 46.0±7.5 46.1±7.4 45.97±7.6 45.62±7.1* 45.8±6.85 46.0±6.7 44.3±1.2 M = 0.072 
Mean 44.5±7.2 44.41±7.2 44.58±7.3 44.52±7.2 44.33±6.83 44.35±6.62 44.5±6.7 TxM = 0.43 
BF % FALSE 41.6±4.1 40.5±4.2 39.3±4.6 38.9±5.4 38.0±5.4 37.5±6.1 37.1±6.1 39.0±0.9 T < 0.001 
TRUE 41.4±4.5 40.6±5.0 39.6±4.7 38.5±5.3 37.9±5.5 37.6±5.8 37.2±5.5 39.0±0.9 M = 0.97 
Mean 41.5±4.3 40.6±4.6* 39.5±4.6* 38.7±5.3* 37.9±5.4* 37.6±5.9* 37.1±5.7* TxM = 0.79 
Waist (cm) FALSE 86.3±14.1 84.8±13.6 84.7±13.9 84.2±12.5 84.1±13.3 84.1±13.8 83.1±13.0 84.5±2.4 T < 0.001 
TRUE 93.0±12.9 91.1±12.3 89.7±12.4 89.6±11.4 88.3±10.8 88.7±11.7 88.3±12.5 89.8±2.2 M = 0.106 
Mean 89.9±13.8 88.2±13.2* 87.4±13.2* 87.1±12.1* 86.4±12.1* 86.6±12.8* 86.0±12.9* TxM =0.22 
Hip (cm) FALSE 112.6±12.3 110.5±12.3 109.9±12.9 109.1±11.8 109.3±11.5 108.9±12.3 108.2±12.5 109.8±2.2 T < 0.001 
TRUE 115.9±11.2 113.9±10.8 112.4±11.1 112.0±10.9 111.8±10.7 111.9±11.4 111.4±12.1 112.8±2.0 M = 0.33 
Mean 114.4±11.8 112.4±11.5* 111.3±11.9* 110.7±11.3* 110.7±11.1* 110.5±11.8* 109.9±12.3* TxM = 0.91 
REE 
(kcal/D) FALSE 1362±260 1395±263 1336±252 1324±273 1333±237 1321±286 1303±316 1339±47 T = 0.41 
TRUE 1503±290 1435±233 1463±274 1461±292 1422±297 1434±323 1426±283 1449±43 M = 0.09 
Mean 1439±283 1416±246 1405±269 1398±289 1382±273 1382±309 1370±302 TxM = 0.54 
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). N=59; FALSE (n=27), TRUE (n=32). GG= 
Greenhouse-Geisser. T= Time effect. M= Match effect. T x M= Time x Match effect. # = significant match effect p<0.05 (univariate). *= significant time effect from 
baseline p<0.05 (post hoc LSD). †= a trend from baseline p > 0.05 and p < 0.1 (post hoc LSD). 
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Figure	4.7	Genetic	∆	Total	Body	Weight.	Data	present	mean	change	(95%	CI)	from	baseline	for	total	body	weight	in	
False	and	True	genetic	matches	over	24	weeks;	N=59.	CI:	Confidence	Interval.		
Figure	4.8	Genetic	∆	Fat	Mass.	Data	present	mean	change	(95%	CI)	from	baseline	for	body	fat	mass	in	False	and	True	
genetic	matches	over	24	weeks;	N=59.	CI:	Confidence	Interval.		
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Figure	4.9	Genetic	∆	Fat	Free	Mass.	Data	present	mean	change	(95%	CI)	from	baseline	for	fat	free	mass	in	False	and	True	
genetic	matches	over	24	weeks;	N=59.	LSD	post	hoc	analysis	is	indicated	by	the	following	superscripts:	^	represents	p	<	0.05	
difference	between	matches	(groups).	CI:	Confidence	Interval.		
	
Figure	4.10	Genetic	∆	Body	Fat	Percentage.	Data	present	mean	change	(95%	CI)	from	baseline	for	body	fat	percentage	
in	False	and	True	genetic	matches	over	24	weeks;	N=59.	CI:	Confidence	Interval.		
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MANOVA of anthropometric measurements revealed an overall time effect 
(Wilks’ Lambda p<0.001) but no time x match interaction (p=0.20). Univariate analysis of 
waist measurement reveals a significant reduction in waist circumference for both false 
and true matches (F -3.16±1.02; T -4.64±0.93 cm, p<0.001) with no time by match 
interaction (p=0.23). Univariate analysis of hip measurement reveals a significant 
reduction in hip circumference for both false and true matches (F -4.45±0.93; T -
4.54±0.86 cm, p<0.001) with no time by match interaction (p=0.91). No significant 
differences between or within genetically matched participants were observed in terms of 
waist-hip ratio as demonstrated in Figure 4.11. 
 Repeated Measures ANOVA revealed no significant time (Wilks’ Lambda 
p=0.41) or time x diet group interaction (p=0.54) in resting energy expenditure (REE), 
although a trend was observed between T and F matches (p=0.09), as true matches tended 
to intake higher kcals/day at each time point. These observations reject Hypothesis 2.  
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Figure	4.11	Genetic	∆	Waist-Hip	Ratio.	Data	present	mean	change	(95%	CI)	from	baseline	for	Waist-Hip	Ratio	in	False	
and	True	genetic	matches	over	24	weeks;	N=59.	CI:	Confidence	Interval.	 
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To determine if N-size may have influenced overall genetic match results, delta 
changes from baseline in body composition (body weight, fat mass, and body fat 
percentage) were analyzed that included dropped participants who did not complete the 
study as shown in Table 4.12. Although N-size was larger between weeks 0-20, no 
differences in relative measures of body composition were observed between T and F 
matches to diet by genetic profile. 
Table 4.12 Relative Changes in Body Composition at 0, 4, 8, 12, 16, 20, and 24 weeks 
Week (N-size) 
Variable 
Diet 
Match 
0 4 
(N=83) 
8 
(N=73) 
12 
(N=64) 
16 
(N=66) 
20 
(N=62) 
24 
(N=59) 
Body 
Weight 
(kg) FALSE 0±0 -1.78±1.5 -2.18±2.2 -3.35±3 -3.71±3.7 -4.29±4 -4.25±4.8
TRUE 0±0 -1.35±1.7 -2.44±2.5 -3.61±3.2 -3.64±4.2 -4.48±4.2 -4.63±4.8
Mean 0±0 -1.52±1.6 -2.33±2.4 -3.48±3.1 -3.67±4 -4.39±4.1 -4.46±4.8
TxM p=0.24 p=0.65 p=0.74 p=0.95 p=0.86 p-0.86
Fat mass 
(kg) FALSE 0±0 -1.31±1.7 -2.03±1.8 -3.04±2.5 -3.69±3 -3.95±3.3 -4.26±4
TRUE 0±0 -1.12±1.7 -2.38±2 -3.07±2.6 -3.52±3.1 -4.01±3.6 -4.17±4.1
Mean 0±0 -1.2±1.7 -2.23±1.9 -3.06±2.5 -3.6±3 -3.98±3.4 -4.21±4
TxM p=0.63 p=0.44 p=0.97 p=0.82 p=0.95 p=0.93 
Fat free 
mass (kg) FALSE 0±0 -0.05±1.5 0.17±1.5 0.07±1.7 0.07±1.7 -0.06±1.7 0.28±1.8
TRUE 0±0 -0.17±1.6 -0.09±1.3 -0.18±1.8 -0.42±1.8 -0.38±1.7 -0.27±1.7
Mean 0±0 -0.12±1.5 0.02±1.4 -0.06±1.7 -0.19±1.7 -0.23±1.7 -0.02±1.7
TxM p=0.72 p=0.43 p=0.57 p=0.26 p=0.46 p=0.23 
BF % FALSE 0±0 -0.97±1.9 -2.04±1.9 -2.59±2.6 -3.54±2.8 -3.99±3.3 -4.45±3.8
TRUE 0±0 -0.77±1.8 -1.72±1.6 -2.84±2.8 -3.44±3.4 -3.85±3.7 -4.24±4
Mean 0±0 -0.85±1.8 -1.85±1.7 -2.73±2.7 -3.49±3.1 -3.92±3.5 -4.33±3.8
TxM p=0.63 p=0.45 p=0.72 p=0.89 p=0.87 p=0.84 
Delta values are represented as means ± standard deviation (SD) difference from baseline (0 week) through 
24 weeks. T x M= Time x Match Interaction effect as determined by one-way ANOVA. P-levels represent 
TxM interaction of participants who completed the study up to that testing session. BF%: Body fat 
percentage. 
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Figure	4.12	Genetic	∆	Total	Body	Weight	[N=83	à59].	Data	present	mean	change	(95%	CI)	from	baseline	for	total	body	
weight	in	False	and	True	genetic	matches	over	24	weeks,	including	dropped	participants.	0	weeks	N=83,	4	weeks	N=83,	8	
weeks	N=73,	12	weeks	N=66,	16	weeks	N=64,	20	weeks	N=62,	24	weeks	N=59.		CI:	Confidence	Interval.		
Figure	4.13	Genetic	∆	Fat	Mass	[N=83	à59].	Data	present	mean	change	(95%	CI)	from	baseline	for	fat	mass	in	False	and	
True	genetic	matches	over	24	weeks,	including	dropped	participants.	0	weeks	N=83,	4	weeks	N=83,	8	weeks	N=73,	12	
weeks	N=66,	16	weeks	N=64,	20	weeks	N=62,	24	weeks	N=59.		CI:	Confidence	Interval.		
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Biochemical Markers of Health by Genetics 
Table 4.13 demonstrates the changes in blood lipid variables as dependent on 
metabolic match to diet type in the treatment groups. MANOVA of blood lipids revealed  
an overall time effect (Wilks’ Lambda p<0.001) but not a time x genetic match interaction 
(Wilks’ Lambda p=0.30). Univariate analysis of total cholesterol concentration revealed 
both false and true matches reduced CHL (F -14.11±6.88; T -15.20±6.32 mg/dL, p<0.001) 
without a significant time x match interaction (p=0.16). However, a match interaction was 
observed (p=0.01), as false matches had higher values relative to the true matches 
throughout the 24-week trial. Univariate analysis of LDL concentrations revealed an 
overall time effect (p<0.001) as both false and true matches had significantly reduced LDL 
levels measured at 24 weeks. A time x genetic interaction was observed, as the true diet 
matches experienced a significantly greater loss in LDL concentration from baseline (F – 
31.29±12.94; T -44.41±11.89 mg/dL, p=0.04). Univariate analysis of HDL concentrations  
showed an overall time effect (p=0.003), although the only difference from baseline was 
observed in the false matched group at 12 weeks. A match group difference was observed 
as the false matches had significantly higher mean HDL levels (F 64.36±2.84; T 
54.72±2.61, p=0.015) than the true matched group. No significant time x match interaction 
was observed (p=0.16). Figures 4.14-4.17 demonstrate relative changes in the blood lipid 
concentrations for True and False genetic matches at 0, 12, and 24 weeks. 
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Table 4.13 Genetic Changes in Fasting Blood Lipids at 0, 12, and 24 weeks 
Week 
Variable 
Genetic 
Match 0 12 24 
Group 
(SEM) GG p-value 
aTotal CHL 
(mg/dl) FALSE 214.98±42.92 186.15±46.9 200.86±37.56 200.66±6.2 # T < 0.001 
TRUE 188.73±37.42 175.14±31.37 173.53±33.02 179.13±5.7 M = 0.013 
Mean 200.74±41.81 180.18±39.28* 186.04±37.47* TxM = 0.16 
bLDL-c 
(mg/dl) FALSE 159.53±57.94 # 153.32±57.36 # 128.24±41.02* 147.03±9.9 T < 0.001 
TRUE 168.02±72.27 167.78±73.88 123.62±55.03* 153.14±9.1 M = 0.65 
Mean 164.13±65.68 161.17±66.67 125.73±48.76* TxM = 0.04 
cHDL-c 
(mg/dl) FALSE 68.94±19.44 58.48±16.74 65.68±18.5 64.36±2.8 # T = 0.003 
TRUE 55.56±16.42 52.67±16.26 55.94±15.56 54.72±2.6 M = 0.015 
Mean 61.68±18.94 55.33±16.6* 60.4±17.52 TxM = 0.16 
dTAG 
(mg/dl) FALSE 122.16±61.63 110.95±57.07 104.58±50.18 112.57±9.9 T = 0.001 
TRUE 131.12±63.37 114.76±55.27 107.7±52.03 117.86±9.2 M = 0.698 
Mean 127.02±62.2 113.02±55.65† 106.27±50.77* TxM = 0.81 
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean (SEM). N=59; 
FALSE (n=27), TRUE (n=32). GG= Greenhouse-Geisser. T= Time effect. M= Match effect. T x M= Time x Match 
effect. # = significant match effect p<0.05 (univariate). *= significant time effect from baseline p<0.05 (post hoc LSD). 
†= a trend from baseline p > 0.05 and p < 0.1 (post hoc LSD). aCHL: Cholesterol, bLDL-c: Low Density Lipoprotein 
concentration, cHDL-c: High Density Lipoprotein concentration, dTAG: Tri(acyl)glycerides. To convert mg/dL 
cholesterol to mmol/L, multiply mg/dL by 0.026. To convert mmol/L cholesterol to mg/dL, multiply mmol/L by 38.6.  
Cholesterol of 194 mg/dl=5.04 mmol/L bTo convert mg/dL triglyceride to mmol/L, multiply mg/dL by 0.0113. To 
convert mmol/L triglyceride to mg/dL, multiply mmol/L by 88.6.  Triglyceride of 137 mg/dl=1.55 mmol/L. 
Figure	4.14	Genetic	∆	Total	Cholesterol.	Data	present	mean	change	(95%	CI)	from	baseline	for	total	cholesterol	
concentration	in	False	and	True	genetic	matches	over	24	weeks;	N=59.	LSD	post	hoc	analysis	is	indicated	by	the	following	
superscripts:	^	represents	p	<	0.05	difference	between	matches	(groups).	CI:	Confidence	Interval.	
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Figure	4.15	Genetic	∆	Low	Density	Lipoprotein.	Data	present	mean	change	(95%	CI)	from	baseline	for	low	density	
lipoprotein	concentration	in	False	and	True	genetic	matches	over	24	weeks;	N=59.	CI:	Confidence	Interval.		
Figure	4.16	Genetic	∆	High	Density	Lipoprotein.	Data	present	mean	change	(95%	CI)	from	baseline	for	high	density	
lipoprotein	concentration	in	False	and	True	genetic	matches	over	24	weeks;	N=59.	CI:	Confidence	Interval.		
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Table 4.14 demonstrates the changes in fasting glucose and insulin concentrations 
at baseline through 24 weeks. MANOVA of glucose concentrations at 0, 12, and 24 weeks 
revealed an overall time effect (Wilks’ Lambda p=0.05) but not time x match interaction  
(Wilks’ Lambda p=0.32). Falsely matched participants had a significant decrease in 
glucose levels at 12 weeks from baseline (-4.59±2.12 mg/dL, p=0.034); however, the 
levels increased back to a non-significant change from baseline at 24 weeks (-1.57±3.03 
mg/dL, p=0.61). True matched participants demonstrated a trend in decreased glucose 
levels at 24 weeks (-5.44±2.79 mg/dL, p=0.056). MANOVA of insulin concentrations at 
baseline and 24 weeks revealed an overall time effect (Wilks’ Lambda p<0.001) but no 
time x match interaction (p=0.64). Both false and true matches decreased insulin levels in 
at 24 weeks (F -1.71±0.70; T -2.16±0.65 µIU/ml, p<0.001). An overall match trend 
demonstrated that true matches tended to have higher concentrations at 0 and 24 weeks 
Figure	4.17	Genetic	∆	Triglycerides.	Data	present	mean	change	(95%	CI)	from	baseline	for	triglyceride	concentration	in	False	
and	True	genetic	matches	over	24	weeks;	N=59.	CI:	Confidence	Interval.		
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compared to false matched participants (p=0.098). An overall Wilks’ Lambda time effect 
was observed for HOMA-IR (p<0.001), as both false and true matches reduced measures 
of insulin resistance from 0 to 24 weeks (F -0.48±0.20; T -0.59±0.19, p<0.001). No 
significant time x match interaction was observed (p=0.68) and there was no significant 
difference between T or F matches (p=0.23). These observations reject Hypothesis 3. 
Table 4.14 Genetic Changes in Fasting Glucose and Insulin at 0, 12, and 24 weeks 
Week 
Variable 
Genetic 
Match 0 12 24 
Group 
(SEM) GG p-value 
aFasted 
glucose (mg/dl) FALSE 95.1±14.5 90.5±16.7* 93.5±10.1 93.0±1.8 T = 0.037 
TRUE 95.2±10.9 93.1±10.9 89.7±10.6 † 92.7±1.6 M = 0.87 
Mean 95.1±12.6 91.9±13.8* 91.5±10.5 † TxM = 0.024 
bFasted Insulin 
(µIU/ml) FALSE 9.5±6.7 8.7±1.2 T < 0.001 
TRUE 12.4±6.4 11.3±1.1 M = 0.098 
Mean 11.1±6.6 TxM = 0.64 
HOMA - IR FALSE 2.3±1.8 2.1±0.3 T < 0.001 
TRUE 2.9±1.5 
- 9.1±6.1*
2.6±0.3 M = 0.23 
Mean 2.6±1.7 - 2.1±1.5* TxM = 0.68 
Values are represented as means ± standard deviation (SD) except group means are ±standard error mean 
(SEM). N=59; FALSE (n=27), TRUE (n=32). GG= Greenhouse-Geisser. T= Time effect. M= Match effect. 
T x M= Time x Match effect. # = significant match effect p<0.05 (univariate). *= significant time effect from 
baseline p<0.05 (post hoc LSD). †= a trend from baseline p > 0.05 and p < 0.1 (post hoc LSD). aTo convert 
mg/dL glucose to mmol/L, multiply mg/dL by 0.0555. To convert mmol/L glucose to mg/dL, multiply 
mmol/L by 18.0. Glucose of 99 mg/dl=5.5 mmol/L. bTo convert µIU/ml insulin to pmol/L, multiply µIU/ml 
by 6.945. To convert pmol/L to µIU/ml, multiply pmol/L by 0.144. Insulin of 13.8 µIU/ml=95.8pmol/L. 
Homeostatic Model Assessment of Insulin Resistance. 
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
Summary 
Obesity and its subsequent consequences of developing concerning medical 
conditions has been a focal point of health practitioners and researchers, as this condition 
has not appeared to subside despite the increased awareness of diet and exercise benefits. 
Although interventions such as increased physical activity and a reduction in caloric intake 
renders weight loss for most, variability in response to an identical stimulus still exists 
among individuals. Inherited genetic variability attributes to these differences, and may 
influence metabolic responses depending on SNPs of candidate genes responsible for 
nutrient absorption, tissue delivery, and the efficient utilization of stored energy. As such, 
it may be possible to predict outcomes such as weight loss, body composition, lipid 
biomarkers, and markers of insulin resistance when intervened with a specific diet and 
exercise protocol. This study first examined the efficacy of a standardized exercise 
protocol with participants assigned dietary protocols, and then examined the genetic 
influence of the results.  
Reported inventories of dietary intake demonstrated participants in the dietary 
intervention groups were adherent to the total 1500 kcal/day requirements throughout 
weeks 4-24 as reported by group means (AHA 1474±61, CC-I 1409±61, CC-II 1500±57 
kcal/day); however, CC-I and CC-II assigned to 45% PRO intake/day came short of this 
requirement as reported by the group means (CC-I 26.2±1.1, CC-II 29.3±1.0% PRO). 
Participants in AHA were better able to meet their assigned nutrient distribution 
requirements (15% PRO, 55% CHO, 30% FAT) as reported by group means (18.4±1.1% 
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PRO, 49.8±1.6% CHO, 31.6±1.3% FAT). Although the percentage of PRO distribution 
fell short in CC-I and CC-II, the relative intake (g/kg/day) had a considerable increase 
from baseline (CC-I 0.30 g/kg/d; 95% CI, 0.10, 0.50) and (CC-II 0.47 g/kg/d; 95% CI, 
0.28, 0.67) when compared to the AHA diet group.  
Self-reported levels of physical activity demonstrated the significant increase in 
METs-min/week in all diet intervention groups. Low levels of physical activity (PA) were 
calculated from the amount of walking related activity when at work, in transit, or during 
leisure time. As described in the methods, all participants in the diet treatment groups were 
recommended to walk 10k steps/day on non-resistance circuit exercise days, and 
participants were provided a pedometer to record and monitor their progress. The time, 
time by diet, and diet group effects were significant (p<0.001), as the interaction is clearly 
due to the significant increase in low PA among all the diet treatment groups (AHA, CC-I, 
CC-II) relative to the control group. This increase is likely due to the increase in walking
during recreational activity. As expected, recreational activity had the most prominent 
increase in regards to METs-min/wk from baseline to week 24 in the intervention groups 
(AHA 928±120, CC-I 931±120, CC-II 1070±112 MET-min/wk; p<0.001) which may be 
attributed the exercise protocol of 30 min/day, 4x/week of resistance and Zumba exercise, 
in addition to the recommended steps/day. 
All participants in this study included in the diet and exercise treatment groups 
(AHA, CC-I, CC-II) had significant reductions in body weight (p<0.001), fat mass 
(p<0.001), body fat percent (p<0.001), waist (p=0.006) and hip circumference (p<0.001), 
while maintaining fat-free mass (p=0.90) after 24 weeks. Additionally, all participants in 
the diet treatment groups experienced a significant increase in relative VO2max (p<0.001) 
and GXT time (secs) to exhaustion (p=0.02) as measured by the Bruce Protocol 
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cardiopulmonary stress test. These initial findings suggest adherence to a hypocaloric 
structured diet that includes supervised resistance training interspersed with low-impact 
callisthenic exercise is effective in promoting positive body composition changes, 
cardiovascular capacity and muscular strength. Additionally, the results from this study 
support recent findings from our laboratory that indicate diet induced weight loss, when 
combined with a structured exercise program, reduces symptoms of metabolic syndrome 
(MetS) despite differences in PRO:CHO distribution [158].  
A central hypothesis of this study was to determine the efficacy of a six-month diet 
and exercise weight loss intervention based on the influence of single nucleotide 
polymorphisms (SNPs) in metabolic regulatory genes ADRB2, ADRB3, FABP2, and 
PPARγ2 in previously sedentary women. The allele patterns comprised of different 
genotypes potentially attribute to biological functions responsible in nutrient and energy 
metabolism, and can be classified into three different categories of pre-determined 
metabolic efficiencies loosely referred to as “carb reducer,” “fat trimmer,” or “better 
balancer” defined by Interleukin GeneticsÒ. The subsets of pre-determined metabolic 
efficiency were categorized by a low CHO diet responsive genotype (carb reducer), a low-
fat diet responsive genotype (fat trimmer), and a balanced diet responsive genotype (better 
balancer). These categorical stratifications were used to retrospectively predict 
participants’ response to their randomized dietary protocol by assigning them as a true 
match (T) or false match (F) to AHA, CC-I or CC-II. 
Although all diets in our study were hypocaloric in daily intake (1500 kcal/day), 
the macronutrient composition varied in PRO:CHO:FAT as discussed previously. In 
contrast, the diets analyzed by Dopler-Nelson [54] from genetic samples in the 12-month, 
cohort A to Z trial [55] included the Atkins (CHO restricted) [159], Zone (low CHO) 
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[160], LEARN (Lifestyle, Exercise, Attitudes, Relationships, and Nutrition; low FAT, 
high CHO) [161], and Ornish diet (very high CHO) [162]. In Gardner’s A to Z trial, the 
primary objective was to examine the degrees of CHO intake on weight loss and related 
metabolic variables in overweight, premenopausal women. In contrast, our study 
examined two high PRO diets (CC-I and CC-II) in comparison to one low PRO, high 
CHO American Heart Association (AHA) diet. High PRO was not a primary consideration 
in Gardner’s initial study prior to Dopler-Nelson’s retrospective analysis. Dopler-Nelson 
sought to examine the obesity candidate SNPs in ADRB2-79, ADRB2-46, ADRB3, 
FABP2, and PPAR γ2. The analysis [56] suggested a genetically influenced response to 
diet type in terms of weight loss and waist circumference reduction; however, few studies 
have replicated the design with the addition of exercise. Our study was designed to 
replicate the findings of Dopler-Nelson by categorically distributing SNP allele patterns 
and diet type; however, our results did not show the same statistical significance. 
Specifically, Dopler-Nelson reported that 101 overweight women in a dietary intervention 
study (A to Z trial) who were on a diet appropriate to their genotype (T) lost a mean of 5.2 
kg body weight, whereas those who were not on a genotype appropriate diet (F) lost only 
1.65 kg (p=0.013). In contrast, our study demonstrated that all participants in a diet and 
exercise intervention had similar weight reduction outcomes (F -4.25±0.93; T -4.63±0.85 
kg, p=0.61) regardless of genetic match to diet. Additionally, women who were matched 
to a genotype appropriate diet in Dopler-Nelson’s analysis reduced waist circumference by 
6.6 cm, and those who did not match their genotype to diet reduced waist circumference 
by 3.0 cm (p=0.01). In our study, all participants reduced waist circumference without a 
significant difference between T or F genetic match to diet (F -3.16±1.02; T -4.64±0.93 
cm, p=0.23). Additional data from Dopler-Nelson included differences in decreased 
93 
triglycerides (p=0.007) and increased HDL-c (p=0.01) in T matches compared to F 
matches to diet; however, the exact values were not reported.  
According to Stanford’s Dopler-Nelson report [56], identifying candidate genes 
influencing metabolism were shown to affect outcomes based on macronutrient 
distribution; however, these results have not been easily replicated in further 
investigations, especially with required exercise training as an additional component. 
Exercise was only a suggestion in the A to Z trial analyses [55], and can be determined as 
irrelevant to Dopler-Nelson’s diet x genetic influence on weight loss and related metabolic 
factors. Because each of these obesity-related gene SNPs have differentiating effects on 
nutrient and exercising metabolism, this flux adds to the convolution of possible 
individual results. 
In our study, overall changes in body weight, fat-mass, fat free mass, body fat 
percentage, waist and hip circumference were not dependent on participants’ genetic false 
or true match to their specified diet. MANOVA of body composition variables (body 
weight, fat mass, lean mass, fat-free mass, and body fat percentage) revealed an overall 
time effect (Wilks’ Lambda p<0.001), but not a time x match interaction (p=0.99), as all 
participants significantly reduced body weight in kg (p=0.61) independent of false or true 
genetic match to diet type. Both false and true matched participants lost a significant 
amount of fat mass (p<0.001) and body fat percentage (p<0.001) with no time x match 
interactions (p=0.86 and p=0.79, respectively). Neither false or true matches to diet 
experienced a change in fat free mass (p=0.79) from 0 to 24 weeks. However, a significant 
difference in FFM was observed at week 16, in which the false matches had maintained 
FFM, and the true matches slightly decreased FFM (p=0.03). This may be possibly due to 
the higher relative body composition of FFM in the true matches. As such, a slight loss of 
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FFM was parallel with overall weight loss. Consistent with this observation, a trend in T/F 
group differences in absolute values of body weight (p=0.099), fat-free mass (p=0.07), and 
notably fat mass (p=0.16) was present throughout the duration of the study, as the true 
matches tended to be higher than false matches. However, the relative percentage of body 
fat remained unchanged (p=0.97) between both groups. Anthropometric measurements 
revealed an overall time effect (p<0.001) but as with the measures of body composition, 
no time x match interaction was observed (p=0.20). As with body composition, true 
matches tended to have larger waist and hip measurements than false measurements for an 
overall Match trend; however, the reduction in anthropometrics were relative throughout 
the duration of the study. Both false and true matches significantly reduced waist 
circumference (p<0.001) with no time and a significant reduction in hip circumference 
was also observed for both false and true matches (p<0.001) with no time by match 
interaction (p=0.91). 
In regards to lipid biomarkers and markers of insulin resistance, analysis of total 
cholesterol concentrations revealed both false and true matches reduced values (p<0.001) 
without a significant time x match interaction (p=0.16). However, a group effect was 
observed (p=0.01), as false matches had higher values relative to the true matches 
throughout the 24-week trial. This may be attributed to the higher HDL-c in F matches 
relative to the T matches. The analysis of HDL concentrations showed an overall time 
effect (p=0.003), although the only difference from baseline was observed in the false 
matched group at 12 weeks. A group difference was observed (p=0.015) as the false 
matches had significantly higher mean HDL concentrations than the true matched group. 
No significant time x match interaction was observed (p=0.16). Analysis of LDL 
concentrations revealed an overall time effect (p<0.001) as both false and true matches 
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had significantly reduced LDL levels by the end of the trial. A time x match interaction 
was observed, as the true diet matches experienced a significantly greater loss in LDL 
from baseline (p=0.04). The attribution to this interaction is due to differences at baseline 
(F 159.5±57.9; T 168.0±72.3 mg/dL, p=0.05) as true matches were higher in LDL-c; 
however, at week 24 both groups were significantly lower in absolute LDL-c (F -
31.29±12.94; T -44.41±11.89 mg/dL, p=0.04) without a mean group difference (p=0.65).  
Falsely matched participants had a significant decrease in glucose levels at 12 weeks from 
baseline (-4.59±2.12 mg/dL, p=0.034); however, the levels increased back to a non-
significant change from baseline at 24 weeks (p=0.61). True matched participants 
demonstrated a trend in decreased glucose levels at 24 weeks (p=0.056), and the overall 
time effect reveals false and true matches decreased insulin levels in at 24 weeks 
(p<0.001). Both false and true groups reduced measures of insulin resistance from 0 to 24 
weeks, as an overall time effect was observed in HOMA-IR (p<0.001).  
Discussion 
This investigation clearly demonstrates the efficacy of a controlled diet and 
exercise induced weight loss protocol among all diet and exercise intervention groups 
(AHA, CC-I, CC-II) when compared to CTRL. However, the lack of differentiation 
between true and false genetic matches to diet type on most outcomes may be attributed to 
the substantial increase in physical activity among all intervention participants. The same 
five genetic variants (SNPs) in Dopler-Nelson’s analysis [56] were matched to determine 
individual metabolic profiles as predictors of response to diet type. However, each SNP 
has been shown to differ in its potential contribution in response to exercise.  
For example, several studies have investigated the role of ADRB 2 and 3 
polymorphisms on the risk of developing obesity and assessed the effect of physical 
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activity on this risk. In a case-control study it was observed that the effect of the ADRB3 
variant on obesity changes depending on the recreational physical activity levels. 
According to a study conducted on 313 Spanish subjects [163], carriers of Arg64 alleles in 
the ADRB3 gene could reduce the risk of developing obesity if their physical activity level 
was ≥ 20 MET hours/week. Additionally, in the HERITAGE Family Study, it was 
observed that carriers of Arg16 and Arg64 alleles, respectively, for ß2- and ß3- adrenergic 
receptors showed a greater decrease in fat mass in response to endurance training (METs > 
6) than subjects with other allelic combinations [164]. Alternatively, results of other
studies found no differences in weight loss in participants with various polymorphismsof 
the ADRB3 gene [127, 165-166]. However, these discordances could be due to a lack of 
homogeneity of the study groups (obese versus non-obese subjects, diabetics versus non-
diabetics) or to ethnic differences.  
SNPs in FABP2 have been shown to result in greater binding of the fatty acids 
released in the intestine from dietary fat, which in turn results in higher absorption of fat 
[99, 167]. The Ala54Thr polymorphism has been linked with obesity in multiple clinical 
research studies that indicate individuals with the Thr54 form of the protein demonstrate 
increased absorption and/or processing of dietary fatty acids by the intestine. The Thr54 
variant has also been associated with elevated BMI and body fat [168], increased 
abdominal fat [169] and obesity and higher plasma leptin levels [170]. Multiple dietary 
intervention clinical research studies show that the Ala54Thr polymorphism affects the 
response to changes in dietary fat in test meals. It has been reported that individuals with 
54Thr/Thr homozygous variant show increased levels of postprandial triglycerides [171, 
172] and increased levels of 14-18-carbon fatty acids [96, 173] compared with the
54Ala/Ala form of the protein. A group of obese, non-diabetic patients analyzed before 
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and three months after a lifestyle modification program, consisting of hypocaloric diet 
(1,520 kcal/day) and aerobic exercise three times per week [119], showed that carriers of 
the Thr54 allele failed to have a significant reduction in fat mass, plasma LDL-c, and 
leptin levels when compared to the wild-type 54Ala/Ala homozygotes. Similarly, although 
the evidence of gene-diet interaction is strong involving the Pro12Ala polymorphism of 
PPARγ [174-177], few studies have examined the level of influence on exercising 
metabolism. As such, including PPARγ genotype as a predictor of response to diet and 
exercise has yet to be elucidated. 
Limitations 
Understanding how genetic polymorphisms contribute to metabolic processes can 
be valuable in evaluating human response to dietary intake, absorption, and the efficacy of 
energy expenditure. However, metabolic adaptions to exercise and diet can influence, and 
may override hereditary genetic dispositions (such as SNPs) in identified obesity related 
genes. A primary consideration is the specific metabolic function of each SNP. For 
example, FABP2 plays a significant role in nutrient absorption, whereas the adrenergic 
receptors (ADRB2 and ADRB3) have regulatory roles in exercising metabolism. As in 
Dopler-Nelson’s study [56], analyzing ADRB2 and ARDB3 SNPs to match a true or false 
diet may be inaccurate without previously considering the effects of physical activity. The 
addition of exercise to a weight loss intervention requires a more analytical and replicable 
investigation of each SNPs influence on nutrient absorption and utilization before 
determining a metabolic profile to a diet designed to optimize results. Furthermore, the 
exercise intensity and frequency among participants in the treatment groups may interact 
with the polymorphisms (SNPs) of the genes analyzed (ADRB2, ADRB3, FABP2, and 
PPARγ) to influence DNA expression, and as such result in homogeneous means among 
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all treatment groups. Finally, Dopler-Nelson’s analysis based genetically assigned match 
to diet on carbohydrate metabolism; whereas in our study, genetic matches were 
determined on very high protein diets without primary consideration of carbohydrate 
distribution. Interleukin Genetics did not match participants in AHA; therefore, these 
participants were matched based on previously similar categorical data with high 
carbohydrate distributions. 
Conclusion 
Future research should continue to evaluate the influence of exercise on metabolic 
regulatory genes when assigned a specified diet protocol. In addition to assessing SNPs, 
examining the expression of proposed candidate genes has potential to augment the 
understanding of physical activity induced changes in metabolic mechanisms, and 
subsequent weight loss results. Secondarily, monitoring the success of weight maintenance 
following a structured program may be beneficial in correlating SNPs to hereditary 
disposition to either regain weight, or successfully uphold the results from the initial weight 
loss intervention. Although this study did not provide evidence of genetic influence based on 
diet intervention, it does maintain that women adhering to a hypocaloric diet plan, regardless 
of macronutrient distribution, while participating in a supervised resistance-exercise based 
program, is effective in successful weight loss, body composition changes, cardiovascular 
capacity, muscular strength and endurance, and improvements of biochemical markers of 
health. 
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APPENDIX A 
 
TEXAS A&M UNIVERSITY HUMAN SUBJECTS PROTECTION PROGRAM 
CONSENT FORM 
 
Project Title: Effects of a Carbohydrate Restricted, High Protein, High Fat Diet on 
Weight Loss and Health Outcomes in Women Participating in the Curves Fitness & 
Weight Loss Program 
 
You are invited to take part in a research study being conducted by Dr. Richard 
Kreider, a researcher from Texas A&M University and funded by Curves 
International. The information in this form is provided to help you decide 
whether or not to take part. If you decide to take part in the study, you will be 
asked to sign this consent form. If you decide you do not want to participate, there 
will be no penalty to you, and you will not lose any benefits you normally would 
have. 
 
Why Is This Study Being Done? 
The purpose of this study is to determine if a carbohydrate restricted, high protein, high 
fat diet (20% carbohydrate, 45% protein, 35% fat; CC-II) promotes more favorable 
changes in weight loss and health outcomes compared to a traditional high carbohydrate, 
low protein, low fat diet (55% carbohydrate, 15% protein, 30% fat; AHA) and the Curves 
moderate carbohydrate restricted, high protein, and low fat diet (30% carbohydrate, 45% 
protein, 25% fat; CC-I). 
 
Why Am I Being Asked To Be In This Study? 
You are being asked to be in this study because you are a female between the ages of 18 
and 60 years of age with a Body Mass Index (BMI) > 22 and a body fat percentage > 
30%. You will not be allowed to participate in this study if you report a recent weight 
change of plus or minus 7 lbs. within the past 3 months. In addition you will not be 
allowed to participate in this study if you report any uncontrolled metabolic or 
cardiovascular disorder; including known electrolyte abnormalities, heart disease, 
arrhythmias, diabetes, thyroid disease, or a history of hypertension, hepatorenal, 
musculoskeletal, autoimmune, or neurological disease; if you are taking any weight loss 
supplements and/or ergogenic levels of nutritional supplements within the last 3 months 
that may affect body composition and/or anabolic/catabolic hormone levels; a history of 
pregnancy or lactation within the past 12 months or intentions to become pregnant during 
the next 12 months; participation in a regular exercise program within the past 3 months; 
or, the presence of any absolute or relative contraindications for exercise testing or 
prescription as outlined by the American College of Sports Medicine unless your 
personal physician feels the condition is controlled, would not be a limitation for you to 
participate in the study, and clears you for participation. If you do not qualify for this 
study we will keep your contact information (phone number and/or e-mail) and contact 
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you at a later date for potential entry into a similar study. 
How Many People Will Be Asked To Be In This Study? 
Approximately 400 people will be invited to participate in this study locally. 
 
What Are the Alternatives to being in this study? 
The alternative to being in the study is not to participate. 
 
What Will I Be Asked To Do In This Study? 
You will be asked to not exercise for 48 hours nor eat or drink calorie containing drinks 
for 12 hours before each testing session/visit. You will also be asked to record all food 
and drinks you eat and drink on food record forms for four days (including one weekend 
day) prior to all of the testing sessions/visits. Your participation in this study will last up 
to approximately six months and include eight visits (visit 1 ~ 1 hour/visit 2,5 and 8 ~ 3 
hours/visit 3,4,6 and 7 ~ 1.5 hours).  These visits are detailed below and in Table 1. 
 
Visit 1 (week one) - Familiarization 
This visit will last about one hour. During this visit the details of the study will be 
explained, human subject consent forms will be signed, personal and medical history 
information will be completed, and you will have a general physical that will include 
measurement of fasting blood to determine if you can participate in the study. You will 
donate approximately 5 ml (about 1 teaspoon) of fasting blood from a vein in your arm 
according to standard procedures.  You will also be weighed and have your height 
measured. 
 
Visit 2, 5 and 8 (week 0, 12 and 24) – (T1,T4 and T7) 
These visits will last about three hours. During these visits you will first be asked to 
complete a physical activity questionnaire, a quality of life inventory, a social physique 
anxiety scale, a self-esteem scale, a body image questionnaire and an eating satisfaction 
inventory. These items will take about 30 minutes to complete. Two cheek swabs will 
then be taken from the inner cheek during visit 2 (baseline, T1) only. Interleukin Genetics 
will only be evaluating DNA to assess which diet may be more effective from a 
metabolism viewpoint. The samples will be destroyed after analysis. You will then have 
your resting energy expenditure determined. This will take about 30 minutes. You will 
then donate approximately 20 milliliters (4 teaspoons) of blood from a vein in your arm. 
Blood samples will be obtained by standard/sterile procedures using a needle inserted 
into a vein in your arm. This will take about 15 minutes. You will then have your total 
body composition measured, total body water determined, hip/waist measurements 
determined, resting blood pressure determined and heart rate measured. Collectively 
these tests will take about 30 minutes. You will then be prepared to perform a maximal 
treadmill test.  This test will take about 30 minutes to complete. You will then perform 
a one repetition maximum and 80% of 1 repetition maximum endurance repetition test 
on the bench press and hip/leg sled using standard procedures. These tests will take about 
30 minutes to complete. In the event of an emergency during an exercise test proper 
emergency response protocols (calling 9-911 for serious injury or a medical emergency, 
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calling Biosafety/EHS for cleanup assistance or spill team response, calling UPD for 
incidents in public areas, retrieving AED located in the lab, performing CPR or other 
First Aid techniques, etc.) will be followed by the Exercise & Sport Nutrition Laboratory 
(ESNL) staff depending on the severity of the emergency. 
 
Visit 3,4,6 and 7 (week 4,8,16 and 20) – (T2, T3, T5 and T6) 
These visits will last about one and a half hours. The same tests will be performed at 
visits 3, 4, 6 and 7 minus the exercise tests (maximal treadmill test, bench press test and 
hip/leg press test). 
After baseline testing you will be matched according to BMI, age and body fat 
percentage and randomly assigned to one of four groups including: 1.) a no exercise, no 
diet intervention control group (C); 2.) an American Heart Association recommended 
high carbohydrate, low protein, and low fat diet (55% carbohydrate, 15% protein and 
30% fat) group (AHA); 3.) the Curves Complete moderate carbohydrate, high protein, 
low fat diet (30% carbohydrate, 45% protein and 25% fat) group (CC-I); or, 4.) the 
Curves Complete carbohydrate restricted, high protein, high fat diet (20% carbohydrate, 
45% protein, 35% fat) group (CC-II). If you are in groups 2, 3 or 4 you will consume 
1,400 kcals/day for 1 week and 1,500 kcals/day at the prescribed macronutrient intakes 
for 23 weeks. Meal plans on the Curves Complete diets will be provided with limited 
food options for the first two weeks.  
Thereafter, more variety in food choices will be provided to meet macronutrient goals. 
Additionally, the Curves Complete diets will be designed by a dietitian with a goal of 
providing foods with low amounts of saturated fat. In addition, if you are in groups 2, 3 
or 4 you will be expected to exercise four days per week using the Curves 30 minute 
circuit training program.  Each circuit style workout consists of 14 resistance exercises 
that work all major muscle groups. These are set up with floor-based calisthenics 
exercises (e.g., running/skipping in place, arm circles, Zumba dance, etc.) designed to 
maintain an elevated heart rate.  You may also be asked to wear a heart rate monitor.  All 
exercise sessions will be held in the Exercise and Sport Nutrition Laboratory. Research 
Assistants will monitor your exercise sessions and record your attendance. You will also 
be encouraged to walk for 30 minutes at a brisk pace and/or accumulate 10,000 steps per 
day on non-circuit training days. The International Physical Activity Questionnaire 
(IPAQ), daily physical activity logs and daily steps recorded from a pedometer will be 
used to assess physical activity patterns. 
	
You may be removed from the study by the investigator for these reasons: 
• You do not show up for your scheduled testing sessions/visits and the 
investigators are unable to contact you to reschedule. 
• You do not follow your assigned diet protocol. 
• You do not follow your assigned exercise protocol. 
	
Are There Any Risks To Me? 
The things that you will be doing are greater than risks that you would come across in 
everyday life. Although the researchers have tried to avoid risks, you may feel that some 
questions/procedures that are asked of you will be stressful or upsetting.  You do not 
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have to answer anything you do not want to.  You will be exposed to a low level of 
radiation during the body composition test, which is similar to the amount  of natural 
background radiation you would receive in one month while living in College Station 
Texas. In addition, a very low level of electrical current will be passed through your body 
during the body water test. This analyzer is commercially available and has been used in 
the health care/fitness industry as a means to assess body composition and body water 
for over 20 years. The use of these analyzers have been shown to be a safe method of 
measuring body composition and total body water and are approved by the FDA. You 
will donate approximately 4 teaspoons (20 milliliters) of blood during the initial 
familiarization/screening visit and then again at each of the seven testing sessions 
throughout the study using standard procedures. These procedures may cause a small 
amount of pain when the needle is inserted into the vein as well as some bleeding and 
bruising. You may also experience some dizziness and/or faint if you are unaccustomed 
to having blood drawn. The exercise tests that will be performed may cause symptoms 
of fatigue, shortness of breath, and/or muscular fatigue/discomfort. The exercise tests 
may also cause short-term muscle soreness and moderate fatigue for several days 
following the tests. You may also experience muscle strains/pulls during the exercise 
testing and/or training program. However, exercise sessions will be conducted by trained 
personnel and monitored to ensure you follow appropriate exercise guidelines. You will 
follow a prescribed dietary regimen involving consuming 1,400 or 1,500 calories per day 
during various phases of the program. In addition, one group will eat a high percentage 
of calories in the form of protein. Although the total amount of total protein is not 
excessive (169 grams/day) it may be higher than you are accustomed to eating and may 
exceed recommended protein intake for active individuals. As a result, you may 
experience weight loss or gain, feelings of hunger or fullness, and/or changes in appetite 
and/or mood during various phases of the dietary intervention. In addition your risk to 
participation in this study may be greater if you have medical clearance to participate 
with a controlled medical condition. The likelihood of any of these occurring is slim. 
 
Are There Any Benefits To Me? 
The direct benefit to you being in this study is to know more about your health and fitness 
status from the tests to be performed. However, even if no individual benefit is obtained, 
you will be paid for your participation. 
 
Will There Be Any Costs To Me? 
Other than your time, there are no costs for taking part in the study. 
 
Will I Have To Pay Anything If I Get Hurt In This Study? 
If you suffer any injury as a result of taking part in this research study, please understand 
that nothing has been arranged to provide free treatment of the injury or any other type 
of payment. However, all needed facilities, emergency treatment and professional 
services will be available to you, just as they are to the community in general. You should 
report any injury to Dr. Richard Kreider at 979-845-1333. You will not give up any of 
your legal rights by signing this consent form. 
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Side effects (injury) can happen in any research study. These effects may not be your 
fault or the fault of the researcher involved. Known side effects have been described in 
the “Are there any risks to me?” section of this consent form. However, side effects that 
are not currently known may happen and require care. You do not give up any of your 
legal rights by signing this form. 
 
Will I Be Paid To Be In This Study? 
You will receive a total of $300 ($20 for the Familiarization and $40 for each additional 
testing session T1 – T7) in one check at the end of the study. Payment will occur after 
finishing all eight sessions and after all study materials (food records, etc.) have been 
turned in to the study staff. You will be paid on a prorated basis if you are unable to 
complete the entire study. 
 
Will Information From This Study Be Kept Private? 
The records of this study will be kept private. No identifiers linking you to this study 
will be included in any sort of report that might be published. Research records will be 
stored securely and only Exercise & Sport Nutrition Laboratory staff will have access to 
the records. 
 
Information about you will be stored in locked file cabinets in a locked file room in an 
ID card swipe access controlled laboratory. Computer files will be protected with a 
password. This consent form will be filed securely in an official area. 
 
People who have access to your information include the Principal Investigator and 
research study personnel. Representatives of regulatory agencies such as the Office of 
Human Research Protections (OHRP) and entities such as the Texas A&M University 
Human Subjects Protection Program (HSPP) may access your records to make sure the 
study is being run correctly and that information is collected properly. 
 
The agency that is funding this study (Curves International) and the institutions(s) where 
study procedures are being performed (Texas A&M University) may also see your 
information. However, any information that is sent to them will be coded with a number 
so that they cannot tell who you are. Representatives from these entities can see 
information that has your name on it if they come to the study site to view records. If 
there are any reports about this study, your name will not be in them. 
 
Information about and related to this study will be kept confidential to the extent 
permitted or required by law. 
 
Who may I Contact for More Information? 
You may contact the Principal Investigator, Richard Kreider, PhD, to tell him about a 
concern or complaint about this research at 979-845-1333 or rkreider@hlkn.tamu.edu. 
You may also contact the Co- Investigator/Laboratory Research Associate, Chris 
Rasmussen, at 979-458-1741 or crasmussen@hlkn.tamu.edu. 
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For questions about your rights as a research participant; or if you have questions, 
complaints, or concerns about the research, you may call the Texas A&M University 
Human Subjects Protection Program office at (979) 458-4067 or irb@tamu.edu. 
 
What if I Change My Mind About Participating? 
This research is voluntary and you have the choice whether or not to be in this research 
study. You may decide to not begin or to stop participating at any time. If you choose 
not to be in this study or stop being in the study, there will be no effect on your student 
status, medical care, employment, evaluation, relationship with Texas A&M University, 
etc. Any new information discovered about the research will be provided to you.  This 
information could affect your willingness to continue your participation. 
 
STATEMENT OF CONSENT 
I agree to be in this study and know that I am not giving up any legal rights by 
signing this form. The procedures, risks, and benefits have been explained to me, 
and my questions have been answered. I know that new information about this 
research study will be provided to me as it becomes available and that the 
researcher will tell me if I must be removed from the study. I can ask more 
questions if I want.  A copy of this entire consent form will be given to me. 
 
 
 
Participant’s Signature Date 
 
 
 
Printed Name Date 
 
 
 
INVESTIGATOR'S AFFIDAVIT: 
Either I have or my agent has carefully explained to the participant the nature of the 
above project. I hereby certify that to the best of my knowledge the person who signed 
this consent form was informed of the nature, demands, benefits, and risks involved in 
his/her participation. 
 
 
   Signature of Presenter Date 
 
 
Printed Name       Date
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